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1 Introduction 
1.1 Somatic tumor genetics 
Over the last decades a lot of research has been done to understand and unravel the mechanisms 
underlying tumor development. It has been found that tumor development is a complex process 
involving several factors, e.g. accumulation of genetic alterations and evasion of apoptosis. Generally 
speaking, cancer is essentially a genetic disease. Tumor development is driven by alterations in three 
types of genes: oncogenes, tumor suppressor genes and stability genes (Vogelstein and Kinzler, 
2004). In the case of oncogenes (e.g. RAS, MYC), the genetic alterations usually activate genes 
involved in cellular processes such as cell proliferation, cell differentiation and survival (Alberts, 
2008). The activating genetic alteration causes abnormal cell proliferation via increased gene 
expression or uncontrolled activity of the oncogene encoded protein (Alberts, 2008). The underlying 
aberration can be a chromosomal translocation, gene amplification or an intragenic mutation 
affecting a major domain of the gene product and therefore its activity (Vogelstein and Kinzler, 2004). 
In contrast, genetic alterations in tumor suppressor genes (e.g. TP53, PTEN) reduce the activity of the 
gene product. Causes of these inactivations are missense mutations in domains essential for the 
activity of the gene product, mutations causing truncated proteins, and any kind of deletions or 
insertions disturbing the gene as well as loss of complete chromosomes (Vogelstein and Kinzler, 
2004). For tumor suppressor genes a two‐hit hypothesis has been postulated, in 1971 by Knudson, 
stating that a tumor suppressor needs two inactivating mutations in order to turn a normal cell into a 
tumor precursor and trigger tumorigenesis (Knudsen, 1971; Strachan and Read, 2011). The third class 
of genes involved in tumorigenesis consists of the so called stability genes. Their function is to 
monitor basic cellular processes, such as mismatch repair, nucleotide‐excision repair and base 
excision repair, replication of mistakes or DNA damage after exposure to mutagens (Vogelstein and 
Kinzler, 2004).  
A single mutation is not sufficient to cause cancer. In contrast, several alterations in different 
genes, indicating a multistep process, are needed for a cell to become cancerous (Hanahan and 
Weinberg, 2000; Vogelstein and Kinzler, 2004). Since a high number of somatic mutations are found 
in any kind of cancer, which can now be readily identified because of reduced costs in sequencing 
technologies, a clear differentiation between driver and passenger mutations has to be made. In 
general, it is difficult to identify which somatic mutations are driver and which are passenger 
mutations. All mutations that confer a selective growth advantage to a cell are classified as driver 
mutations. On the other hand, mutations that have no effect on the malignant transformation are 
called passenger mutations (Vogelstein et al., 2013). 
Not only single base‐pair substitutions can render a gene into an active oncogene or an inactive 
tumor suppressor gene. Also larger chromosomal aberrations such as changes in chromosome 
number (aneuploidy), translocations, deletions or insertions of various sizes play an important role in 
the malignant transformation of a normal cell into a tumor cell. When larger parts of a chromosome 
are affected, it is rather challenging to identify the specific target gene (Vogelstein et al., 2013). 
INTRODUCTION 
 
- 11 - 
By chromosomal translocations, fusion genes can be generated (Vogelstein et al., 2013). One 
prominent example is the so called Philadelphia chromosome that is often found in patients with 
chronic myeloid leukemia. Here, the BCR (breakpoint cluster region) gene located on chromosome 9 
is fused to the ABL (Abelson murine leukemia viral oncogene homolog) gene located on chromosome 
22 (Rowley, 1973), resulting in a constitutively activated Abl kinase. 
 
 
1.2 Genetics of tumor predisposition 
Tumor predisposition syndromes may account for up to 5% – 10% of adult cancers (Garber and 
Offit, 2005). A characteristic of hereditary cancer syndromes is the early onset of disease as well as 
childhood tumors. Moreover, several first‐degree or second‐degree family members in the same 
family line are usually affected. The cause of tumor predisposition syndromes is most frequently a 
germline mutation, which can be found in a variety of genes and can be passed on to the offspring, if 
not the individual’s ability to have offspring is seriously impaired (Strachan and Read, 2011). 
One prominent tumor predisposition syndrome is the so called Li‐Fraumeni syndrome (LFS) 
already described in 1969 by Li and Fraumeni (Li and Fraumeni, 1969). It is a clinically and genetically 
a heterogeneous tumor syndrome with autosomal dominant inheritance. It is characterized by the 
early onset of tumors, multiple tumors in an individual and several affected family members. The 
tumors usually involved are soft tissue sarcomas and osteosarcomas, breast cancer, brain tumors, 
adrenal cortical carcinoma, and leukemias (Li et al., 1988). In 1990 the underlying cause was identified 
to be a germline mutation in the TP53 (tumor protein 53) gene, which maps to chromosome 17p13.1 
(Malkin et al., 1990). Further studies have shown that mutations in the TP53 gene are found in 70% of 
families with the classic LFS (Varley, 2003a). Additionally, mutations in the CHEK2 (checkpoint kinase 
2) gene have been described to be causative for LFS (Bell et al., 1999; Varley 2003b). 
Another prominent hereditary cancer syndrome is familial adenomatous polyposis (FAP). It is also 
inherited in an autosomal dominant manner, and is caused by a germline mutation in the APC 
(adenomatous polyposis coli) gene located on chromosome 5q22.2 (Kinzler et al., 1991). A 
characteristic of this disorder is the development of hundreds of adenomatous polyps of the colon 
and rectum in affected patients. If not treated surgically, these polyps can progress to colorectal 
carcinoma (Rustgi, 2007). Importantly, the penetrance of developing polyps is 100% at the age of 35 
years. Furthermore, the risk of developing colon cancer is also approximately 100% with an average 
age of diagnosis at 39 years (Garber and Offit, 2005). 
Strategies in these tumor predisposition syndromes are early genetic testing for all family 
members, if the causative mutation is known. If tested positive, tight surveillance is advisable. If an 
APC gene mutation and adenomas have been found in a patient suffering from FAP, prophylactic 
colectomy is performed regularly (Hampel and Peltomaki, 2000). 
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1.3 Genome‐wide screening methods 
The development of genome‐wide screening methods such as array‐based comparative genomic 
hybridization (array‐CGH) or next generation sequencing (NGS) made high throughput studies 
feasible. Nowadays, genome‐wide screening methods are applied not only to screen different cancer 
entities, but also in clinical genetics to identify the underlying cause, such as copy number changes or 
disease causing mutations, of various syndromes. With reduced costs for sequencing whole genomes 
or exomes as well as for microarray analyses, large numbers of samples can be examined in a timely 
manner (Vogelstein et al., 2013). In the study described here, different genome‐wide screening 
methods were used. Firstly, bacterial artificial chromosome (BAC)‐arrays have been used for the 
analysis of more than 300 glioma DNA samples, as well as oligonucleotide arrays for the analysis of a 
patient presenting with a highly complex syndromal phenotype including cancer predisposition. 
Secondly, whole exome sequencing (WES) was used to unravel and explain the complete phenotype 
of the same patient. 
 
 
1.3.1 Array‐CGH: BAC versus oligonucleotide arrays 
In 1997, array‐CGH was described for the first time (Solinas‐Toldo et al., 1997; Pinkel et al., 1998). 
It is a molecular cytogenetic method that can be used to reveal copy number gains or losses across 
the whole genome, while comparing the copy number of a test and a reference DNA. The copy 
number changes can range from aberrations of whole chromosomes (aneuploidy) e.g. trisomy 21 in 
Down syndrome, to microdeletions or duplications e.g. in the 22q11.2 region (Miller et al., 2012). A 
disadvantage of this method is that balanced chromosomal rearrangements including balanced fusion 
chromosomes are generally not detected. The overall resolution of an array is determined by the 
number and size of the probes spotted on the microarray (Strachan and Read, 2011). 
In this study, two types of arrays were used, a BAC array (10.6k) with an average resolution of 
better than 0.5 Mb as well as chromosome specific tiling oligonucleotide arrays (385k). Initially in 
array‐CGH, the DNA microarrays used were glass slides spotted with bacterial artificial chromosomes 
(BAC) or P1 artificial chromosomes (PAC). These BACs and PACs contained large inserts with a size of 
about 100 – 150 kb (Fiegler et al., 2007). As an improvement in this technology, oligonucleotide 
arrays were developed (Lucito et al., 2003). Today, different kinds of oligonucleotide arrays are 
available. Some manufacturers produce arrays containing oligomers with a size of 50 – 70 bp in order 
to focus on high quality copy number detection. Other arrays with shorter oligomers size of 25 bp can 
also be used for genome‐wide single nucleotide polymorphism (SNP) genotyping (Shen and Wu, 
2009).  
There are several advantages of oligonucleotide arrays. Therefore, they have mainly replaced BAC 
arrays. First of all, the reproducibility of oligonucleotide arrays is better. Additionally, the 
oligonucleotide probe sequences lack repetitive sequences. Oligonucleotide arrays also have a higher 
resolution, which results from smaller interprobe spacing leading to a much higher probe density. 
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Therefore, smaller genomic imbalances can be detected and the breakpoint mapping is more precise. 
Whereas oligonucleotide probes are designed after the reference human genome sequence, BAC 
clones need to be selected from existing libraries, and their location needs to be mapped and 
validated (Shen et al., 2007; Shen and Wu, 2009). Oligonucleotide arrays are also easier to customize, 
so manufacturers can offer a wide range of microarray types, while the update of BAC arrays and 
their production is more time consuming. Lastly, with increasing probe numbers in oligonucleotide 
arrays, a multiprobe confirmation is achieved (Ylstra et al., 2006; Shen et al., 2007; Ou et al., 2008). 
The principle of array‐CGH is similar when using large insert clone or oligonucleotide arrays. Firstly, 
the test and reference DNA are labeled with different fluorescent dyes, usually Cy3 and Cy5. 
Secondly, the samples are co‐hybridized to the microarray. Thirdly, the array is scanned and the 
different fluorescent intensities are measured, finally the data is analyzed (Miller et al., 2012). 
However, when using large insert clone arrays, a suppression of repetitive DNA sequences using 
human Cot‐1‐DNA is required.  
 
 
1.3.2 Next generation sequencing – exome sequencing 
In the last few years, next generation sequencing (NGS) became more and more popular, and 
started to push aside Sanger sequencing, also called the ‘first‐generation’ technology, as a first‐line 
sequencing technique particularly in research. Improvements were needed to cover the demand of a 
high throughput method to sequence whole human genomes or to identify all variants located in the 
coding region of genes in an individual human genome, the so called exome (whole exome 
sequencing, WES) (Metzker, 2010; Bamshad et al., 2011). Identifying all the variants in a human 
genome might influence the understanding of how genetic differences affect health and disease.  
NGS is based on the combination of different strategies for template preparation, massive parallel 
sequencing, imaging, sequence alignment to a reference genome and assembly of aligned sequences 
(Metzker, 2010). Currently, different technologies for the enrichment of DNA to be sequenced using 
NGS are available. They are based on the same principle and differ only slightly in their target choice, 
bait density and capture molecule. These baits are employed to capture the fragmented genomic 
DNA by hybridization enabling the generation of libraries. For exome sequencing, for example, 
biotinylated oligonucleotide baits covering the human exome regions are usually used to capture the 
human exome prior it exome sequencing. Enrichment of the bound libraries takes place by a pull 
down with magnetic streptavidin beads, followed by NGS sequencing technologies (Wheeler et al., 
2008; Clark et al., 2011). One disadvantage of WES is currently that depending on the used 
enrichment kit, 5% – 10% of the exome is poorly enriched and therefore poorly covered by 
sequencing. For this reason, some exons are missed completely, and have to be analyzed by 
conventional Sanger sequencing. Besides that, the detection of small insertion and deletions, so 
called INDELs has to be improved (Alkan et al., 2011; Bamshad et al., 2011). The huge advantage of 
NGS is that large genomes, such as the human genome, can be sequenced easily and cost effectively. 
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But the handling of the enormous amounts of data generated and the interpretation of the detected 
variants is very challenging. 
Depending on the technologies used for sequence enrichment and analysis of sequencing data 
approximately 40,000 single nucleotide variants are found in each whole human exome sequencing 
analysis on DNA from peripheral blood. When performing WES in clinical genetics. The challenge is to 
find the causative variants among the many variants identified. In rare diseases, the causative 
variants can be enriched by excluding variants with a high minor allele frequency (MAF). But not all 
rare variants are disease causing. Therefore, stringent filter strategies are needed to reduce the 
number of these variants, in order to find the causative variant of the investigated disease.  
 
 
1.3.3 Data analysis and filtering strategies in NGS 
NGS analysis of a human exome or genome results in an enormous number of identified variants. 
In order to reduce these numbers and the number of individuals which have to be sequenced, 
different data analysis and filtering strategies have been developed to single out the causative 
mutation or gene for the investigated disorder. In the following, some of these strategies are 
described. One analysis approach is that DNA from a few unrelated individuals with the same disorder 
are sequenced and subsequently compared, in order to find a gene commonly affected by pathogenic 
variants in several of these individuals (Figure 1A, page 15). In addition, these genomes are also 
compared to controls, e.g. healthy individuals or data from dbSNP and the 1000 Genomes Project to 
identify causative mutations. In this case, large sample sizes are of advantage (Bamshad et al., 2011). 
A second approach is a family based procedure of trio sequencing in order to identify de novo 
mutations. Here, the unaffected parents as well as the affected offspring are sequenced, and all the 
variants inherited from the parents are subtracted from the patient’s variants (Figure 1B). Among the 
few remaining de novo variants occurring only in the index patient, it is often possible to pick out the 
variant probably causative for the disease (Figure 1B). This approach has been found to be quite 
effective and has identified new candidate genes in several genetic disorders (Vissers et al., 2010; 
O’Roak et al., 2011; de Ligt et al., 2012). 
In the case of the candidate gene strategy, only variants in genes already known to be associated 
with the analyzed disease are retained. Further in silico prediction of pathogenicity of the identified 
variants is important. Usually only the variants predicted to be pathogenic by two or three different 
prediction programs are retained and considered to be causative (Figure 1C) (Neveling and Hoischen, 
2012). 
De Ligt et al. developed a workflow of filtering variants detected in DNA from peripheral blood by 
exome sequencing in patients with intellectual disability. This workflow was shown to be quite 
effective in identifying the causative mutations in patients with severe intellectual disability, in which 
all conventional genetic tests were negative (de Ligt et al., 2012). Firstly, variants were separated on 
the basis of being synonymous or non‐synonymous coding. In the case of synonymous coding 
variants, it was checked if a splice site was affected. If this was not the case, the variant was excluded 
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from further analysis and was considered not causative. In the case of non‐synonymous coding 
variants, in silico prediction was performed and if the variants were classified as pathogenic, they 
were retained. De Ligt et al. further considered the found variants to be causative if the same gene 
was mutated in other patients with overlapping phenotypes. This gene was then considered a novel 
intellectual disability gene (de Ligt et al., 2012). If no additional patients were found to carry variants 
in the same gene, this gene was classified as a candidate intellectual disability gene. With this 
strategy, the authors were able to identify candidate genes as well as novel genes associated with 
intellectual disability (de Ligt et al., 2012). 
 
 
 
Figure 1: Schematic drawing of data analysis strategies in NGS.  
Shown are different pedigrees, persons surrounded by the dotted line are sequenced. The circles beneath the 
pedigrees represent the identified variants. The circles with solid lines represent variants from affected 
patients; circles with dotted lines represent variants from unaffected individuals (modified from Neveling and 
Hoischen, 2012). 
 
 
1.4 Classification of glial tumors according to the World Health Organization 
The World Health Organization (WHO) has graded the tumors of the central nervous system based 
on their histological features in order to establish a classification and grading system that is accepted 
worldwide and facilitates e.g. epidemiological studies and clinical trials. The grading system provides 
information about the malignant potential of the tumor and can give indications about the response 
to certain therapies. In addition to the histological features, the grading system is increasingly 
complemented by genetic characterization details of the neoplasms (Louis et al., 2007a). For 
clinicians, the grading system helps to predict the biological behavior of the tumor and may influence 
the choice of therapy, e.g. the use of an adjuvant radiation and specific chemotherapy protocol (Louis 
et al., 2007b). 
Gliomas are brain tumors derived from glial cells, which are subdivided into WHO grade I to WHO 
grade IV tumors. WHO grade I is assigned to tumors displaying low proliferative potential which can 
be cured by surgical resection. WHO grade II tumors show an infiltrative behavior, although a low 
proliferative activity is often present. Some tumor types of WHO grade II have been found to progress 
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to higher grades of malignancy, e.g. low grade diffuse astrocytomas may transform to anaplastic 
astrocytomas of WHO grade III or even to glioblastomas of WHO grade IV, also known as secondary 
glioblastomas (Figure 2). In the case of WHO grade III tumors, evidence of malignancy can be found 
histologically with tumor cells showing nuclear atypia and brisk mitotic activity. WHO grade IV is 
assigned to the most aggressive tumors, which are typically associated with a rapid pre‐ and 
postoperative disease progression and with a fatal outcome. These tumors are cytologically 
malignant, mitotically active and necrosis prone. Also, widespread infiltration into surrounding tissues 
is one of the features that makes WHO grade IV glioblastomas so unfavorable (Louis et al., 2007a).  
 
 
 
Figure 2: Malignant progression of glioma (modified from Ohgaki and Kleihues, 2005a). 
 
 
In total, six distinct histological entities of astrocytic neoplasms are recognized by the WHO 
classification, which can be separated into two major groups. The first group comprises the diffuse 
infiltrating astrocytic tumors, including diffuse astrocytoma, anaplastic astrocytoma and glioblastoma 
multiforme. The second group contains the less frequent tumors with a more circumscribed growth 
behavior such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant 
cell astrocytoma (Riemenschneider and Reifenberger, 2009). In addition, the WHO grading system 
recognizes two malignancy grades for oligodendroglial tumors, namely the oligodendrogliomas of 
WHO grade II, which are well differentiated, and the WHO grade III anaplastic oligodendrogliomas. 
Furthermore, there are oligoastrocytic tumors of WHO grade II and anaplastic oligoastrocytomas of 
WHO grade III, which are composed of a mixture of two distinct neoplastic cell types. From the 
morphologic point of view, these tumors display oligodendroglial and astrocytic tumor cells 
(Reifenberger et al., 2007). 
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1.4.1 Gliomas of WHO grade II and WHO grade III 
Low grade gliomas are subdivided into three types: astrocytomas, oligodendrogliomas, and mixed 
oligoastrocytomas and are classified as WHO grade II (Louis et al., 2007a). The classification is done 
according to the morphologies of the tumor cells and their origin. Of all astrocytic brain tumors, 10% 
– 15% are classified as diffuse astrocytomas (von Deimling et al., 2007). They exhibit a high degree of 
cellular differentiation and are, therefore, classified as WHO grade II. Even though they have a better 
disease prognosis than malignant gliomas, they tend to recur and progress to higher grade tumors 
such as anaplastic astrocytoma of WHO grade III and secondary glioblastomas of WHO grade IV 
(Figure 2, page 16) (Riemenschneider and Reifenberger, 2009). Diffuse astrocytomas usually develop 
in the frontal and temporal cerebral lobes, while they are uncommon in the cerebellum. These 
tumors often occur in younger adults with an age between 30 and 40 years (von Deimling et al., 
2007). Mutations in the tumor suppressor gene TP53 are detected in about 60% of diffuse 
astrocytomas (Ichimura et al., 2000). It seems that TP53 mutations are an early event in astrocytoma 
progression (Figure 3, page 18), because the frequency of TP53 mutations does not increase in 
recurrent tumors. Moreover, MGMT promoter methylation is also found in up to 50% of 
astrocytomas (Watanabe et al., 2007). Apart from chromosomal imbalances such as losses on 
chromosomes 6, 10p, 13q, 19q and 22q, array‐CGH analysis showed a frequent gain on chromosomal 
arm 7q, which has been detected in up to 50% of cases. Combined loss of chromosomal arms 1p and 
19q is rarely found in astrocytomas (Reifenberger and Collins, 2004). 
In contrast to the above mentioned diffuse astrocytomas, anaplastic astrocytomas of WHO grade 
III are characterized by a more infiltrative behavior and display nuclear atypia, increased cellularity 
and significant proliferative activity. They might develop from WHO grade II lesions or de novo. The 
mean age at diagnosis is approximately 45 years (Kleihues et al., 2007). Anaplastic astrocytomas 
represent an intermediate state of progression between low grade tumors and secondary 
glioblastomas of WHO grade IV. TP53 mutations are quite common (in 50% – 60% of tumors), as well 
as loss of chromosomal arm 10q that can be found in about 35% – 60% (Ichimura et al., 1998; 
Balesaria et al., 1999; Louis et al., 2007b). About 20% – 30% of anaplastic astrocytomas also exhibit a 
loss of chromosomal arm 22q (Hartmann et al., 2004). 
Anaplastic oligoastrocytomas (WHO grade III) also display increased cellularity and mitotic activity 
as well as nuclear atypia, and infiltrate surrounding tissues. Patients are diagnosed with a mean age 
of 44 years (Miller et al., 2006; Reifenberger et al., 2007). Anaplastic oligoastrocytomas often 
demonstrate genetic alterations characteristic for astrocytomas and oligodendrogliomas, showing 
TP53 mutations as well as the combined loss of chromosomal arms 1p and 19q (Mueller et al., 2002; 
Louis et al., 2007b). Moreover, they often share other genetic alterations commonly found in 
astrocytomas such as loss of chromosomal arm 9p, including deletions of the CDKN2A gene, as well as 
losses of chromosomes 10 and 11p (Louis et al., 2007b). 
Anaplastic oligodendrogliomas are classified as WHO grade III tumors and have by definition focal 
or diffuse histological features of malignancy and are associated with a less favorable prognosis 
(Reifenberger et al., 2007). They display a high cellularity, marked cytological atypia, high mitotic 
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activity, and necrosis. Patients are usually diagnosed between 45 and 50 years of age (Ohgaki and 
Kleihues, 2005a). Chromosomal and array‐CGH analysis showed a combined loss of chromosomal 
arms 1p and 19q in about two thirds of tumors. But also additional chromosomal aberrations such as 
gains on chromosomes 7 and 15q as well as losses on chromosomes 4q, 6, 9p, 10q, 11, 13q, 18 and 22 
have been found (Jeuken et al., 2004; Reifenberger et al, 2007). 
 
 
 
Figure 3: Frequent genetic changes in diffuse astrocytomas in association with the tumor grade.  
(modified from Ohgaki and Kleihues, 2005a; Riemenschneider and Reifenberger, 2009) 
 
 
1.4.2  Glioblastoma multiforme 
Glioblastoma multiforme is a distinct glioma entity classified as WHO grade IV. Glioblastomas are 
the most frequent gliomas and usually develop in a sporadic fashion without any known genetic 
predisposition. However, a few cases are associated with a hereditary tumor syndrome, e.g. Li‐
Fraumeni syndrome (Kleihues et al., 1997). So far, no exogenous factors have been identified that are 
associated with the development of this tumor entity. Glioblastomas mainly develop in the cerebral 
hemispheres (Kleihues et al., 2007). 
On the basis of their clinical presentation, glioblastomas are differentiated into primary and 
secondary glioblastomas (Figure 2 (page 16) and Figure 3 (page 18)). Primary glioblastomas are 
characterized by a de novo development without any history of a low grade precursor lesion. They 
often occur in older patients, with a median age of diagnosis of 55 to 60 years. Secondary 
glioblastomas on the other side may arise from diffuse astrocytoma of WHO grade II and anaplastic 
astrocytoma of WHO grade III through malignant progression and are usually diagnosed in younger 
patients with an age at diagnosis of younger than 45 years (Riemenschneider and Reifenberger, 
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2009). Primary and secondary glioblastoma cannot be separated morphologically (Weller et al., 2012), 
but on the basis of genetic alterations. With the aid of high throughput methods such as microarray 
based technologies, vast numbers of tumors could be analyzed. Based on expression analysis, Phillips 
et al. described three distinct molecular subclasses of high‐grade astrocytoma, which they proposed 
to be of prognostic value. They used clustering of 35 signature genes for the identification of the 
subtypes and named the subclasses after the characteristic dominant features of the genes. The 
subclasses they identified are named proneural, proliferative and mesenchymal (Phillips et al., 2006). 
In an independent study from Verhaak et al., similar groups were proposed on the basis of detected 
genetic aberrations and gene expression analysis. Based on their molecular classification, they 
described proneural, neural, classical, and mesenchymal subtypes and could show that genetic 
aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH define the classical, mesenchymal, 
and proneural subtypes, respectively. Importantly, they could show that the response to aggressive 
therapy differs between the subtypes (Verhaak et al., 2010). 
Glioblastoma patients can also be classified by their clinical characteristics. The age of the patient 
and the Karnofsky Performance Scale (KPS) score, are important prognostic parameters (Weller et al., 
2012). Age is one of the most powerful prognostic factors for glioblastoma patients, since higher age 
is associated with a poor prognosis (Ohgaki and Kleihues, 2005b). The KPS score has been commonly 
used since its development in 1948 to assess the general performance of cancer patients. Patients 
with a KPS from 60 to 100 are considered fit enough to receive standard cancer treatment or 
participate in clinical trials (Terret et al., 2011). Patients with a value below 60 need more and more 
assistance, a KPS of 10 describes that the fatal process is progressing rapidly (Terret et al., 2011).  
Glioblastoma multiforme is usually associated with poor survival. Despite multimodal aggressive 
treatment, the median survival time after diagnosis is still in the range of 12 months (Smith and 
Jenkins, 2000). Nevertheless, 3% – 5% of patients survive longer than 36 months after diagnosis. This 
group of patients is referred to as long‐term survivors. Young age and a good KPS performance score 
are characteristic in these patients as well as the presence of MGMT promoter methylation in the 
tumors. No environmental or socio‐economic factors were associated with the better survival 
outcome (Krex et al., 2007). The typical genetic aberrations of primary and secondary glioblastoma 
are described below (1.5, page 20).  
The current standard glioblastoma therapy consists of surgical resection followed by local 
radiotherapy and adjuvant chemotherapy with DNA methylating agents such as temozolomide (TMZ). 
Importantly, it has been shown that the combined therapy of TMZ administration and radiotherapy 
results in a significantly increased survival for the glioblastoma patient of 2.5 months versus surgery 
plus radiotherapy only, without additional toxicity. The two year survival rate of patients treated only 
with radiotherapy and those treated with radiotherapy and TMZ increased from 10.4% to 26.5% 
(Stupp et al., 2005). However, the treatment depends strongly on the age and performance score of 
the patients. Older patients are less often treated by surgical resection, but generally patients 
operated on showed a better survival (Ohgaki and Kleihues, 2005a). Nevertheless, there is a need for 
better therapeutic strategies. 
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1.5 Important molecular markers in gliomas 
Various molecular markers e.g. MGMT, IDH1 and IDH2 (IDH1/2), EGFR and loss of chromosomal 
arms 1p and 19q, play also a prognostic or predictive role in gliomas (Figure 3, page 18). Nevertheless, 
further biological markers are needed as a basis for effective therapies, because most treatment 
approaches are still based on age and performance status of the patient (Weller et al., 2012). It is 
important to identify molecular signatures in order to devise personalized treatment strategies. In 
addition, none of the known molecular markers is completely specific for primary versus secondary 
glioblastoma, although some alterations such as EGFR amplification or TP53 mutations occur more 
frequent in either primary or secondary glioblastomas, respectively (Parsons et al., 2008). The most 
important molecular markers for glioma are described in more detail in the following sections. 
 
 
1.5.1 MGMT (O6‐methylguanine‐DNA methyltransferase) gene 
MGMT was mapped to chromosomal band 10q26.3 (Nataranjan et al., 1992). The MGMT gene 
encodes a DNA repair protein that removes alkyl groups from DNA, more precisely the O6 position of 
guanine, which is an important site of DNA alkylation (Hegi et al., 2005). If the MGMT promoter is 
methylated, the gene is silenced and the cells no longer express MGMT (Esteller et al., 2000). Various 
studies have shown that MGMT promoter methylation in glioma is related to responsiveness of a 
tumor to therapeutic alkylating agents e.g. temozolomide. For this reason, MGMT became an 
important biomarker for glioblastoma. Hegi et al. showed that glioblastoma patients with a 
methylated MGMT promoter responded better thus benefited more from temozolomide treatment, 
while patients displaying no methylated MGMT promoter had less benefit. Therefore, they postulated 
that MGMT promoter methylation is an independent predictive factor in glioblastoma patients (Hegi 
et al., 2005). It has been proposed, that resistance of cancer cells to alkylating agents such as 
temozolomide can occur due to high levels of MGMT activity. Hence, missing MGMT promoter 
methylation might explain treatment failures (Hotta et al., 1994; Silber et al., 1999; Gerson, 2004). 
 
 
1.5.2 IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2) gene 
The IDH1 gene was mapped to chromosomal band 2q33. Somatic mutations in the IDH1 gene in 
gliomas were originally described in 2008 (Parsons et al., 2008). Gliomas lacking an IDH1 mutation can 
display a mutation in the IDH2 gene, mapped to chromosomal band 15q26.1. Compared to gliomas, 
IDH mutations in other tumor types are less common (Bleeker et al., 2009). The IDH1 gene encodes 
the cytosolic NADP(+)‐dependent isocitrate dehydrogenase, an enzyme that is involved in the citric 
acid cycle. IDH1 and IDH2 mutations are early events in the development of gliomas (Figure 3, page 
18), meaning that they are frequently found already in WHO grade II and WHO grade III gliomas and 
also in secondary glioblastomas of WHO grade IV, but only in approximately 10% of primary 
glioblastomas (Balss et al., 2008; Hartmann et al., 2009; Yan et al., 2009). It has been shown that 
INTRODUCTION 
 
- 21 - 
gliomas with an IDH mutation are clinically and genetically distinct from gliomas displaying no IDH 
mutations (IDHwt tumors). It was even proposed that IDH1 mutations should be used as a marker to 
distinguish primary from secondary glioblastoma (Nobusawa et al., 2009). All IDH1 mutations are 
located in the conserved residue R132. This residue is part of the substrate binding site of the IDH 
protein (Parsons et al., 2008, Riemenschneider et al., 2010). The most common variant results in an 
amino acid change from arginine to histidine at position 132 (Horbinski, 2013).  
IDH mutations are further associated with better survival of patients and can, therefore, be used 
for prognosis predictions (Parsons et al., 2008; Sanson et al., 2009; Weller et al., 2009). In order to 
diagnose IDH mutations as a diagnostic factor, an antibody was developed detecting the R132H‐
mutated IDH1 by Western blot analysis and immunohistochemistry of human brain tumor samples 
(Capper et al., 2010). In cases displaying an IDH2 mutation, the amino acid R172 of the IDH2 gene is 
affected (Yan et al., 2009). 
 
 
1.5.3 TP53 (tumor protein 53) gene 
Molecular aberrations in the TP53 gene located in chromosomal band 17q13.1 or in TP53 
downstream as well as upstream effector genes are frequently found in many cancers, including 
gliomas (Parsons et al., 2008; Cancer Genome Atlas Research Network, 2008). It has been found that 
TP53 mutations are frequent in WHO grade II and WHO grade III gliomas and secondary glioblastomas 
with up to 60% of these tumors being mutated (Ichimura et al., 2000). While, in primary 
glioblastomas, TP53 mutations are only found in up to 30% of cases (Riemenschneider and 
Reifenberger, 2009). TP53 mutations are seen as an early event in glioma development (Figure 3, 
page 18), due to the fact that their frequency does not increase in tumors with higher WHO grade or 
in recurrent tumors. Alterations of this tumor suppressor gene were recently shown to be associated 
with the IDH mutation status (Weller et al., 2012). 
 
 
1.5.4 EGFR (epidermal growth factor receptor) gene 
EGFR has effects on motility, adhesion, invasion and proliferation of tumor cells, it additionally 
favors the inhibition of apoptosis and induction of angiogenesis (Nicholson et al., 2001; Marie et al., 
2005). Increased EGFR activity is also associated with resistance to irradiation and chemotherapy 
(Weller et al., 2012). In primary glioblastomas, an amplification of the EGFR gene, located in 
chromosomal band 7p11.2, can be found in about 40% – 50% of cases (Gan et al., 2009; 
Riemenschneider and Reifenberger 2009). In contrast, in anaplastic astrocytomas (WHO grade III) an 
EGFR amplification is only found in about 10% of tumors (Riemenschneider and Reifenberger, 2009). 
Increased expression of the EGFR gene may result from amplification of the EGFR gene or from 
mutational activation (Weller et al., 2012). Deletions of the EGFR exons 2 to 7 result in a mutant 
receptor termed EGFRvIII. This mutant receptor is constitutively active in the absence of ligand 
INTRODUCTION 
 
- 22 - 
binding (Gan et al., 2009). Various studies aimed at targeting EGFR in glioblastoma patients, but the 
tested molecules did not demonstrate significant anti‐tumor activity. Nevertheless, the EGFRvIII 
remains under investigation as a target for immunotherapy (Weller et al., 2012). 
 
 
1.5.5 Combined loss of chromosomal arms 1p and 19q 
Combined loss of chromosomal arms 1p and 19q can be frequently found in gliomas. However, 
this genetic aberration is more frequent in oligodendrogliomas or tumors with an oligodendroglial 
component. In primary glioblastomas it is rare and only found in about 10% of cases (Reifenberger et 
al., 1994; Riemenschneider and Reifenberger, 2009). The combined loss of chromosomal arms 1p and 
19q was shown to result from a balanced whole chromosome arm translocation between 
chromosomes 1 and 19. As a consequence, two derivative chromosomes are formed; a 1q;19p 
translocation, and a 1p;19q translocation. The subsequent loss of the 1p;19q derivative results in the 
deletion of 1p and 19q often seen in oligodendroglial tumors (Griffin et al., 2006; Jenkins et al., 2006). 
Various studies have shown that tumors displaying a combined loss of 1p/19q, are associated with a 
better prognosis. This might be explained by a less aggressive tumor behavior and a better therapy 
response as compared to tumors without 1p/19q loss (Felsberg et al., 2004). Therefore, 1p/19q loss 
presently plays a role in diagnostics and is seen as a prognostic marker (Lass et al., 2013).  
 
 
1.6 Pituitary adenomas 
Pituitary adenomas are non‐metastasizing benign tumors developing from different cells of the 
pituitary gland (Ezzat et al., 2004; Garcia‐Arnes et al., 2013). Based on the size of the tumor, they are 
divided into microadenomas or macroadenomas. Furthermore, they are classified as functional or 
nonfunctional depending on their overall hormonal activity. Nonfunctional pituitary microadenomas 
often cause no symptoms. Therefore, they are underdiagnosed and may be found in postmortem 
examinations. Tumors with hormonal activity (functional tumors) cause clinical symptoms, such as 
mood disorders, sexual dysfunction, infertility, obesity, hypertension, diabetes mellitus, and 
accelerated heart disease (Asa and Ezzat, 2002). Tumors rapidly growing even without any hormonal 
activity can cause compressive mass effects and symptoms such visual (Asa and Ezzat, 2002; Ezzat et 
al., 2004). Prevalence rates are quite diverse and difficult to assess due to underdiagnoses. One study 
indicated that the prevalence of pituitary adenoma was 16.7% (Ezzat et al., 2004). Mutations in the 
AIP (aryl hydrocarbon receptor‐interacting protein) gene seem to be associated with the 
development of pituitary adenoma, especially in familial cases (Vierimaa et al., 2006; Garcia‐Arnes et 
al., 2013).  
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1.7 Malignant peripheral nerve sheath tumor (MPNST) 
MPNST are rare tumors which usually develop from a peripheral nerve, but may also originate 
from ectopic Schwann cells. About 50% of MPNST are associated with neurofibromatosis type 1 (NF1) 
(Scheithauer et al., 2007). They arise either de novo in normal peripheral nerves or develop from 
neurofibromas (Yamaguchi et al., 2003). MPNST manifest as WHO grade II, III and IV (Scheithauer et 
al., 2007). Usually adults are affected between 30 and 60 years of age, but if the tumor is associated 
with NF1 the age of manifestation is younger than that of sporadic cases. Though both genders are 
affected it was found that sporadic MPNST are more often diagnosed in females, while the NF1‐
associated tumors occur slightly more often in males. The appearance of MPNST varies greatly, but 
histological features include hypercellularity, cytological atypia and increased mitotic activity as well 
as necrosis (Yamaguchi et al., 2003; Scheithauer et al., 2007). Genetic analyses revealed complex 
karyotypes, with numerical and structural chromosomal aberrations. Overall, MPNST tumors show a 
poor prognosis with an overall survival rate of 23% after 10 years (Ducatman et al., 1986). 
 
 
1.8 German Glioma Network (GGN) 
The GGN is a prospective, non‐interventional cohort study that involves several clinical centers at 
different university hospitals in Germany (www.gliomnetzwerk.de) and was supported by the German 
Cancer Aid from 2004 to 2012. The aim of the GGN was to build up a database to connect clinical 
information, i.e. the therapy applied and the clinical course observed, with the molecular basis 
underlying glioblastoma development. The centers of the network represent specialists in 
neurosurgery, neurooncology, neuroradiology, neuropathology, human genetics and biometry. Up to 
now, the network has collected clinical data from over 4000 patients, and tumor samples for the 
molecular analyses of genomic alterations and gene expression are available from over 3000 patients. 
As part of the GGN, this study aimed to generate genomic profiles of the different glioma subtypes, 
by employing array‐based comparative genomic hybridization to allow the identification of 
chromosomal regions harboring potential oncogenes and tumor suppressor genes. Another aim was 
to correlate aberrations in the identified glioma relevant genes with tumor type and clinical course of 
glioma patients to identify new diagnostic and prognostic molecular markers.  
 
 
1.9 Syndromal phenotypes that include cancer predisposition, e.g. Bloom syndrome 
The term syndrome is used when a phenotype is associated with several clinical features. These 
features include intellectual disability, defined as an IQ of below 70, the malformation of inner 
organs, facial and growth anomalies and sometimes cancer predisposition. The underlying genetic 
cause can be microduplications or microdeletions as well as mutations in certain genes. Particularly 
complex phenotypes might not be explained by a single genetic alteration but by the sum of several 
different genetic changes. The genetic basis of syndromal phenotypes can be detected by employing 
INTRODUCTION 
 
- 24 - 
genome‐wide screening methods such as array‐CGH and, more recently, WES (Classen and Riehmer 
et al., 2013). A syndromic phenotype associated with cancer predisposition is the so called Bloom 
syndrome (OMIM BLM# 210900). It was first described by the dermatologist David Bloom in 1954 
(Bloom, 1954) and is a rare disease with approximately 220 diagnosed cases between 1975 and 2003 
(Hickson, 2003). The Bloom syndrome is an autosomal recessive disorder displaying the following 
features: pre‐ and postnatal growth deficiency, sun‐sensitivity causing hypo‐ and hyper‐pigmented 
skin, chromosomal instability and predisposition to malignancy. Other main symptoms have been 
described to be a narrow face, male infertility, a high pitched voice, immune deficiencies, chronic lung 
problems, and learning disabilities. The cancer types most frequently associated with Bloom 
syndrome are non‐Hodgkin’s lymphoma, leukemia and skin tumors (German, 1993; Knoch et al., 
2012). On average, patients with Bloom syndrome develop cancer until an age of about 24 years 
(German, 1997). Moreover, the patients’ death is usually related to cancer and occurs rather early, 
with the oldest described patient with Bloom syndrome being 49 years old when dying of cancer 
(German, 1997). 
Mutations in the BLM gene, mapped to chromosomal band 15q26.1, have been discovered to be 
the cause of Bloom syndrome. The BLM gene is a tumor suppressor and belongs to the family of RecQ 
helicases, which are involved in the removal of mutations during DNA replication and maintain 
chromosome stability (Knoch et al., 2012). 
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1.10 Objectives of the study 
The projects described in this work employ two genome‐wide screening methods implemented to 
assess somatic DNA copy number changes in tumors of the central nervous system and in a patient 
with an unexplained syndromic phenotype including cancer predisposition.  
In 1997, array‐CGH was described for the first time (Solinas‐Toldo et al., 1997) and is nowadays 
commonly used in research projects as well as in diagnostics. Besides array‐CGH analyses, next 
generation sequencing was used to identify DNA sequence variants throughout the human exome in 
the germline of a patient with cancer predisposition.  
 
The first project aimed to identify genomic profiles in low grade gliomas including WHO grade II 
astrocytomas, oligoastrocytomas and oligodendrogliomas as well as in WHO grade III anaplastic 
astrocytomas and anaplastic oligoastrocytomas. Tumor samples from the different glioma entities 
were analyzed using array‐CGH, in order to detect common genetic imbalances in the different WHO 
grade II and III glioma entities.  
 
In the second project, in order to identify molecular aberrations associated with long‐term survival 
of patients with WHO grade IV glioblastoma multiforme, primary tumor samples from 94 GGN 
glioblastoma patients including long‐ and short‐term survivors were analyzed using genome‐wide 
DNA‐microarrays. Molecular profiles were generated as well as bioinformatic analyzes were 
performed to assess the molecular aberrations in the distinct survival groups, taking into account 
established markers such as the IDH1 and IDH2 mutation status as well as MGMT promoter 
methylation.  
 
In the third project, genome‐wide DNA‐microarrays were used to assess and compare DNA copy 
number changes in 27 primary and recurrent glioblastoma tumor pairs from patients of the GGN. The 
27 tumor pairs were all wild‐type IDH1/2 glioblastomas. The aim was to find regions of genomic 
difference between primary and recurrent tumor pairs. Additionally, the goal was to identify 
candidate genes which are associated with therapy response and or tumor recurrence.  
 
The fourth project dealt with the clonal relationship of two intracranial tumors from a 47‐year old 
female patient (patient 1). The two tumors were studied using array‐CGH because histological 
analysis alone could not clarify whether the second tumor was a recurrence of the primary tumor or 
whether they were distinct unrelated lesions. 
 
In the fifth project, two genome‐wide screening methods (array‐CGH and whole exome 
sequencing) were used to identify the genetic basis of the highly complex phenotype of a patient 
(patient 2) presenting with unexplained syndromic intellectual disability and cancer predisposition.  
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2 Materials and methods  
2.1 Materials 
2.1.1 Chemicals and solutions 
Product Manufacturer 
Standard chemicals 
(if not mentioned differently) 
AppliChem, Darmstadt, Germany 
Sigma‐Aldrich, Taufkirchen, Germany 
Merck, Darmstadt, Germany 
ROTH, Karlsruhe, Germany 
2.5x Random Primer Solution Invitrogen, Carlsbad, CA, USA  
20x SSC Invitrogen, Carlsbad, CA, USA  
Amphotericin B MP Biomedicals, Illkirch, France 
Anti‐avidin D LINARIS GmbH, Wertheim‐Bettingen, Germany 
Antifade Vectashield mounting medium Vector Laboratories Inc., Burlingame, CA, USA 
Anti‐mouse IgG TRITC Sigma‐Aldrich, St. Louis, MO, USA 
Betaine Sigma‐Aldrich, St. Louis, MO, USA 
β‐mercaptoethanol ROTH, Karlsruhe, Germany 
Biotin‐16‐dUTP F. Hoffmann‐La Roche Ltd., Basel, Switzerland 
Blue dextran 2000 GE Healthcare Life Sciences, Uppsala, Sweden 
BM condimed Roche, Mannheim, Germany 
Colcemid Roche, Mannheim, Germany 
Cyanine‐3‐dCTP  Perkin Elmer, Waltham, MA, USA 
Cyanine‐5‐dCTP  Perkin Elmer, Waltham, MA, USA 
DAPI Sigma‐Aldrich, Taufkirchen, Germany 
Dextran sulfate  GE Healthcare Life Sciences, Uppsala, Sweden 
Digoxigenin‐11‐dUTP F. Hoffmann‐La Roche Ltd., Basel, Switzerland 
DNAse I F. Hoffmann‐La Roche Ltd., Basel, Switzerland 
DNA polymerase I F. Hoffmann‐La Roche Ltd., Basel, Switzerland 
Dye Saver II solution Genisphere Inc, Hatfield, PA, USA 
ExoSAP‐IT Affymetrix, High Wycombe, UK 
Fetal calf serum PAA Laboratories, Pasching, Austria 
Fixogum rubber cement Marabuwerke GmbH&Co., Tamm, Germany 
Formaldehyde Merck, Darmstadt, Germany 
HEPES‐buffer Gibco, Invitrogen GmbH, Darmstadt, Germany 
Hi‐Di
TM
‐formamide Applied Biosystems, Darmstadt, Germany 
Human Cot‐1 DNA Invitrogen, Carlsbad, CA, USA 
Human genomic DNA: female Promega Corporation, Madison, WI, USA 
Human genomic DNA: male Promega Corporation, Madison, WI, USA 
Klenow fragment 40 U/µl Invitrogen, Carlsbad, CA, USA 
L‐glutamine Sigma‐Aldrich, Taufkirchen, Germany 
Monoclonal mouse anti‐digoxin antibody Sigma‐Aldrich, St‐Louis, MO, USA 
Penicillin/ streptomycin MP Biomedicals, Illkirch, France 
Pepsin Sigma‐Aldrich, St. Louis, MO, USA 
Phenol‐chloroform‐isoamyl alcohol (25:24:1) ROTH, Karlsruhe, Germany 
Proteinase K Sigma‐Aldrich, Taufkirchen, Germany 
REDTaq ReadyMix PCR reaction mix with MgCl2 Sigma‐Aldrich, St. Louis, MO, USA 
Salmon sperm DNA Sigma‐Aldrich, St. Louis, MO, USA 
Sephadex G‐50, superfine Sigma‐Aldrich, Taufkirchen, Germany 
Sodium acetate ROTH, Karlsruhe, Germany 
Tween® 20 Sigma‐Aldrich, Taufkirchen, Germany 
UltraHyb Ultrasensitive Hybridization Solution Invitrogen, Carlsbad, CA, USA 
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2.1.2 Equipment 
Device Manufacturer 
3130XL Genetic Analyzer Applied Biosystems, Darmstadt, Germany 
Centrifuge 5417R (rotor F‐45‐30‐11) Eppendorf AG, Hamburg, Deutschland 
Centrifuge 5810R (rotor A‐4‐81) Eppendorf AG, Hamburg, Deutschland 
HybArray12TM Perkin Elmer, Beaconsfield, UK 
Fluorescence microscope DCX Leica, Wetzlar, Germany 
Leica DM2500 microscope Leica, Wetzlar, Germany 
Leica DM IL LED Leica, Wetzlar, Germany 
Pipettes Eppendorf AG, Hamburg, Deutschland 
NanoDrop 2000 spectrophotometer Thermo Scientific, Schwerte, Germany 
PeqLab, Erlangen, Germany 
NimbleGen Hybridization System 4 Roche, Mannheim, Germany 
NimbleGen Microarray Dryer Roche, Mannheim, Germany 
NimbleGen MS 200 Microarray Scanner Roche, Mannheim, Germany 
Thermocycler, Professional Trio Biometra, Göttingen, Germany 
Thermocycler PTC 200 MJ Research Inc., Bio‐Rad Hercules, CA, USA 
 
 
2.1.3 Consumables 
Product Manufacturer 
10,6k BAC‐array  In division of Bernhard Radlwimmer Group, 
Deutsches Krebsforschungszentrum, Heidelberg, 
Germany (head: Peter Lichter) 
MicroCon YM30 columns Millipore Corporation, Billerica, MA, 
USA 
Multiscreen 96‐well plates, 0.45 µm hydrophilic, low 
protein binding Durapore membrane 
Merck Millipore, Tullagreen, Carrigtwohill, Irland 
NimbleGen X1 mixer, includes mixer port seals Roche, Mannheim, Germany 
NimbleGen oligonucleotide array chromosome 6 
specific (385k) 
Roche, Mannheim, Germany 
NimbleGen oligonucleotide array chromosome 22 
specific (385k) 
Roche, Mannheim, Germany 
QualiPCR plate Kisker Biotech, Steinfurt, Germany 
 
 
2.1.4 Kits 
Product Manufacturer 
BioPrime Array CGH Genomic Labelling System Invitrogen, Carlsbad, CA, USA 
BigDye Terminator v1.1 Cycle Sequencing Kit Applied Biosystem, Warrington, UK 
DyeEx 2.0 Spin Kit Qiagen, Hilden, Germany 
NimbleGen Dual‐Color DNA Labeling Kit Roche, Mannheim, Germany 
NimbleGen Hybridization Kit Roche, Mannheim, Germany 
NimbleGen Wash Buffer Kit Roche, Mannheim, Germany 
NimbleGen Array Processing Accessories Roche, Mannheim, Germany 
Taq DNA polymerase 
including: dNTP’s, 5x Q‐Solution, Taq DNA 
polymerase, 10x PCR buffer 
Qiagen, Hilden, Germany 
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2.1.5 Buffers 
Commonly used buffers 
10x PBS (pH 7.4) 1.4 M 
27 mM 
15 mM 
65 mM 
NaCl 
KCl 
KH2PO4 
Na2HPO4 
20x SSC (pH 7.0) 3 M 
0.3 M 
NaCl 
Na‐Citrat 
Extraction of genomic DNA from EDTA-blood 
Proteinase K [100 mg] dissolved in 10 ml 
buffer 
1% 
2 mM 
SDS 
EDTA (pH 8.0) 
Lysis buffer (pH 7.4) 155 mM 
10 mM 
0.1 mM 
NH4Cl 
KHCO3 
EDTA (pH 7.0) 
Nucleus lysis buffer (pH 8.0) 75 mM 
24 mM 
NaCl 
EDTA (pH 7.0) 
TE‐buffer 10 mM 
1 mM 
Tris (pH 8.0) 
EDTA (pH 8.0) 
DNA extraction from paraffin sections – phenol-chloroform extraction 
DNA isolation buffer 75 mM 
25 mM 
0.5% 
NaCl 
EDTA (pH 8.0) 
Tween20 
Proteinase K See above  
Phenol/ TE‐buffer (pH 7.5) Phenol is equilibrated with TE‐buffer (see above) 
Array-CGH 
dNTP mix 2 mM 
2 mM 
2 mM 
1.1 mM 
dATP 
dGTP 
dTTP 
dCTP 
Wash buffer A (pH 7.0) 50% 
2x 
0.1%  
Formamide 
SSC 
Tween20 
Wash buffer B (pH 7.0) 2x 
0.05% 
SSC 
Tween20 
Wash buffer C (pH 7.0) 1x 
0.05% 
PBS 
Tween20 
FISH 
Cell culture medium 80% 
7% 
10% 
200 mM 
4 mM 
0.4% 
0.2% 
Ham´s F10 medium 
Fetal calf serum 
BM condimed 
L‐glutamine 
HEPES‐buffer 
Penicillin/ streptomycin 
Amphotericin B 
Fixative 3 parts 
1 part 
Methanol 
Acetic acid 
Pepsin ‐ solution 10 mM 
0.07% 
HCl 
Pepsin 
10x PBS (pH 7.4) 1.4 M 
27 mM 
15 mM 
65 mM 
NaCl 
KCl 
KH2PO4 
Na2HPO4 x 2 H2O 
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PBS‐magnesium chloride 5% 
95% 
1 M Magnesium chloride 
1x PBS 
10x NT buffer (storage at ‐20°C) 0.5 M 
50 mM 
0.5 mg/ ml 
Tris‐HCl (pH 7.5) 
Magnesium chloride 
BSA 
Stopmix (storage at 4°C) 20% (w/v) 
1.7 mM 
2 mM 
2 mM 
Blue dextran  
NaCl 
EDTA 
Tris‐HCl (pH 7.5) 
Mastermix 20% (w/v) 
ad 20 ml 
Dextran sulfate 
2x SSC 
Denaturation mixture 10% 
0.7% 
70% 
20x SSC 
HCl 
Formamide 
Blocking solution 0.2% 
0.09 g 
ad 3 ml 
Tween20 
BSA 
4x SSC 
Detection solution 1 part 
3 parts 
Blocking solution 
4x SSC/ Tween20 
Antibody solution I 10 ng/ µl 
ad 1 ml 
Avidin‐FITC 
Detection solution 
Antibody solution II 2.5 ng/ µl 
2 µl 
ad 1 ml 
Anti‐avidin 
Anti‐dig 
Detection solution 
Antibody solution III 10 ng/ µl 
10 µl 
ad 1 ml 
Avidin‐FITC 
Anti‐mouse‐TRITC 
Detection solution 
 
 
2.1.6 Primers 
All primers were ordered from MWG Operon, Ebersberg, Germany, used in a working concentration 
of 10 µM and stored at ‐20°C.  
Gene and exon Forward primer 5’ 3’ Reverse primer 5’ 3’ 
BLM exon 6 gct ttt gtg gcc tac cag ag ggc aat gat gat ttg cta tgg 
BLM exon 13 agc aca cat gaa ttc ctt gc cag ttt gca ttc tac atg tgc 
CHEK2 exon 11 ctg gtc ttc tca cag tac tct g gac aga aca aga acc tgt ctc 
 
 
2.1.7 Software  
Software Manufacturer 
BioEdit Sequence Alignment Editor Ibis Biosciences, Carlsbad, CA, USA 
Gene PixPro 6.1 Molecular Devices Corporation, Sunnyvale, CA, USA 
Leica CW 4000 FISH Leica, Wetzlar, Germany 
NimbleGen MS200 Data Collections Software 
Version 1.2 
Roche, Mannheim, Germany 
NimbleScan Version 2.5 Roche, Mannheim, Germany 
SeqPilot JSI Medical Systems GmbH, Kippenheim, Germany 
SignalMap Version 1.9 Roche, Mannheim, Germany 
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2.1.8 Online resources 
Database URL 
Chipyard framework http://www.dkfz.de/genetics/ChipYard/ 
Ensembl Genome Browser http://www.ensembl.org/index.html 
Genome Trax
TM
 https://portal.biobase‐international.com/cgi‐bin/portal/login.cgi 
GGN www.gliomnetzwerk.de 
MutationTaster http://www.mutationtaster.org 
PolyPhen‐2 http://genetics.bwh.harvard.edu/pph2/ 
PROTEOME
TM
 http://www.biobase‐international.com/product/proteome 
SIFT http://sift.jcvi.org/ 
TCGA http://tcga‐portal.nci.nih.gov/tcga‐portal/AnomalySearch.jsp 
UCSC Genome Browser http://genome.ucsc.edu/ 
 
 
2.1.9 Patients from the GGN 
Being part of the GGN, we received DNA from more than 300 glioma samples. The DNA had been 
extracted from shock‐frozen tumor samples by ultracentrifugation over caesium chloride (van den 
Boom et al., 2003) and was stored at 4°C. Only samples were chosen for molecular analyses with a 
histologically estimated tumor cell content of 80% or more. All tumors were reviewed at the Brain 
Tumor Reference Centre of the German Society of Neuropathology and Neuroanatomy. Classification 
was done according to the World Health Organization (WHO) Classification of Tumors of the Central 
Nervous System (Louis et al., 2007a). For all samples, molecular analysis to detect the IDH1 and IDH2 
mutation status had been performed by Sanger sequencing or pyrosequencing. The MGMT promoter 
methylation status had also been determined. All patients included in this study gave their written 
informed consent for the participation in the GGN and its research projects. 
Characteristics of patients in project 2 are listed in the Results section in Table 11 and Table 12 
(3.2, page 55). Characteristics of patients in project 3 are listed in Table 14 and Table 15 (3.3, page 
69). All patient characteristics data was collected in a database of the GGN and was prepared in 
cooperation with the Institute for Medical Informatics, Statistics and Epidemiology of the University 
of Leipzig. 
 
 
2.1.10 Clinical features of patient 1 
Until female patient 1 presented with headache, reduced performance, deterioration of visual 
acuity and amenorrhoea at an age of 47 years, the medical history had been unremarkable (Hofer et 
al., 2012). By magnetic resonance imaging (MRI) the patient was diagnosed with an intra‐, para‐ and 
suprasellar mass. The tumor was removed surgically and three different Neuropathology reference 
centers made the histological diagnosis: highly fibrotic pituitary adenoma. Three months after the 
initial surgery, patient 1 presented with increased fatigue and electrolyte disturbances including low 
potassium and sodium serum levels. A second tumor was diagnosed in the pituitary region with a size 
of 4.8 x 4.8 cm by computed tomography (CT) and MRI scans with contrast enhancement. After 
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treatment of the electrolyte disturbances, the second tumor was surgically removed using a 
transsphenoidal approach. The tumor could only be partially removed, due to the fact that it was 
tough and vascularized. Therefore, a third resection one week later was necessary, this time via a 
pterional approach. An early postoperative MRI revealed that residual tumor remained bilaterally 
within the cavernous sinus. Therefore, irradiation treatment (49.4 Gy) was initiated. Nevertheless, 
nine months after the third surgery, the patient was in a comatose state and yet another MRI scan 
revealed pronounced tumor progression. In spite of a fourth emergency surgery, the patient died. 
 
 
2.1.11 Clinical features of patient 2 
Patient 2 is the second daughter of non‐consanguineous parents of German descent (Classen and 
Riehmer et al., 2013). Already early in life, certain stigmata became apparent, including slightly 
peculiar facial appearance with a depressed nasal root and widely spaced eyes, numerous café‐au‐lait 
spots (diameter >2 cm) and two small white spots.  
The patient showed an overall psychomotor and mental delay persisting until adult age. At 23 
years of age, her movements show a dystonic atactic component including an asymmetric preference 
of the left side. Speech understanding is present, whereas active speech reached a maximum of two 
words. The patient requires full‐time care and lives in a special institution for fully handicapped 
persons. 
Throughout life, patient 2 showed persistently low body weight and short stature. At birth (38 + 2 
weeks), she was found small for gestational age with a body weight (BW) of 2,160 g (300 g <3rd 
percentile) and a body length (BL) of 46 cm (10th percentile). This tendency was ongoing throughout 
life (see Table 1). 
 
 
Table 1: Growth curve parameters of patient 2 
Age Body weight Body length Head circumference 
At birth 2,160 g (300 g <3
rd 
P) 46 cm (10
th
 P) NA  
11 months 6,410 g (800 g <3
rd
 P) 70 cm (3
rd
 P) 43.3 cm (3
rd
 P) 
8 years 19 kg (3
rd
 P) 125 cm (10
th
 P) 49 cm (10
th
 P) 
19 years 45.5 kg (2 kg <3
rd
 P) 148 cm (8 cm <3
rd
 P) 50 cm (10
th
 P) 
P: percentile 
 
 
In the family of patient 2, the maternal grandfather was diagnosed with colon cancer and died 
from it at the age of 64 years. The maternal grandmother was diagnosed with leukemia and died at 
the age of 59 years. The patient’s first malignancy was diagnosed at the age of eight years and was 
found to be a both‐sided mixed malignant germ cell tumor of the ovaries. According to the staging 
system of the International Federation of Gynecology and Obstetrics (FIGO) it was stage IIIa. On the 
left side, it was classified as a mixed malignant germ cell tumor with components of a mature 
teratoma, immature teratoma, embryonal carcinoma, malignant yolk sac tumor, dysgerminoma and 
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chorion carcinoma with lymphangitic carcinosis. On the right side, it was a mixed malignant germ cell 
tumor with components of a gonadoblastoma and dysgerminoma with syncytial giant cells. As a first 
line treatment, a both‐sided salpingo‐oophorectomy was performed with subsequent treatment with 
a stage‐adapted chemotherapy according to the GPOH MAKEI‐96 protocol for malignant germ cell 
tumors. The chemotherapy was poorly tolerated.  
Later at the age of 19 years, the patient was found to have an acute pre‐B‐lymphoblastic leukemia 
after she had presented with anemia, thrombocytopenia and leukocytosis. The leukemic cells did not 
contain a Philadelphia chromosome or MLL rearrangements, which can often be found in secondary 
leukemias. In the initial treatment, patient 2 responded well to prednisone and received a 
polychemotherapy according to the ALL‐BFM 2000 protocol with the current modifications. As 
before, the chemotherapy was not well tolerated. Nevertheless, the patient went into remission. 
Now at the age of 23 years, the patient is in full remission from both malignancies.  
Written informed consent was obtained from the parents of patient 2. The patient’s history and 
molecular findings have been published in Classen and Riehmer et al., 2013. 
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2.2 Methods 
2.2.1 Extraction of genomic DNA from EDTA‐blood samples 
Genomic DNA was extracted from peripheral blood of patient 2 and her parents. Five to 10 ml of 
EDTA‐blood was transferred into a 50 ml Falcon tube, 35 ml lysis buffer was added. The tube was 
inverted in order to lyse the erythrocytes. The samples were incubated on ice for about 15 minutes 
until the lysis of the erythrocytes was complete, as indicated by the clear red color of the sample. A 
centrifugation step followed for 15 minutes at 1500 rpm and 4°C. The supernatant was discarded; the 
resulting pellet was resuspended in 5 ml nucleus lysis buffer. Then, 320 µl 10% SDS solution and 160 
µl proteinase K (10 mg/ml) were added, the tube was vortexed and incubated overnight at 37°C in a 
water bath. Saturated sodium chloride (NaCl) solution was added, the tube was vortexed and 
centrifuged at 4000 rpm for 10 minutes at room temperature. The supernatant was transferred to a 
new Falcon tube (50 ml) and for precipitation of the DNA, 2.5 ml isopropanol was added. The visible 
DNA was extracted with a yellow pipet tip and washed in 70% ethanol; subsequently, it was dissolved 
in 200 – 500 µl TE‐buffer and stored at 4°C. 
 
 
2.2.2 DNA extraction from paraffin sections – phenol‐chloroform extraction 
The phenol‐chloroform extraction is a biochemical DNA extraction method, which can be used to 
separate proteins, DNA and RNA. It is based on the difference of solubility of the three 
macromolecules. In this case, DNA was extracted from the formalin‐fixed paraffin‐embedded tumors 
of patient 1 as previously described (Weber et al., 1996). 
In order to dissolve the paraffin, 1 ml of Xylol was added to the formalin‐fixed paraffin‐embedded 
tissue and incubated for 15 minutes at 45°C in a water bath, in between the samples were shortly 
vortexed. Thereafter, the samples were centrifuged for 15 minutes at 13000 rpm. The supernatant 
was removed, if necessary the treatment with Xylol was repeated. After removing the supernatant, 1 
ml 100% ethanol was added, the samples were vortexed and centrifuged again for 10 minutes at 
13000 rpm. This washing step was repeated once. The supernatant was removed and the pellets were 
dried for 1 h with an open lid at 37°C. The pellets were dissolved in 1 ml 1 M sodium thiocyanate, 
vortexed and incubated over night at 37°C in a water bath. The next day, the samples were 
centrifuged for 10 minutes at 13000 rpm and the supernatant was removed. After the addition of 1 
ml DNA isolation buffer, the samples were vortexed and centrifuged again at 13000 rpm for 10 
minutes. The supernatant was carefully removed, 400 µl DNA isolation buffer and 20 µl proteinase K 
(10 mg/µl) were added to each sample and incubated over night at 55°C. On day three, 400 µl 
phenol/ TE‐buffer was added and the samples were rotated slowly for 10 – 30 minutes. After that, the 
samples were centrifuged again for 10 minutes at 13000 rpm. The upper aqueous phase, which 
contains the DNA, was removed and transferred into a new reaction tube. 400 µl of phenol‐
chloroform‐isoamyl alcohol (25:24:1) was added, the tubes were vortexed and centrifuged for 10 
minutes at 13000 rpm. This step was repeated once. Then, only 400 µl of chloroform‐isoamyl alcohol 
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(24:1) was added and the tubes were centrifuged as above. The upper aqueous phase was transferred 
into a new tube and twice the volume (800 µl) of cold 100% ethanol (4°C) was added. For DNA 
precipitation, the samples were incubated for several hours at ‐20°C or 30 minutes at ‐80°C and 
centrifuged for 30 minutes at 13000 rpm and 4°C. The supernatant was carefully removed, the pellet 
was washed with 150 µl of 70% ethanol and the tubes were centrifuged for 10 minutes at 13000 rpm. 
The supernatant was removed again, and the pellet was dried completely. Subsequently, each pallet 
it was dissolved in 20 – 40 µl of H2O depending on the pellet size. The DNA samples were then stored 
at 4°C. 
 
 
2.2.3 Determination of DNA concentration 
The concentration of the DNA/RNA can be determined by a spectrophotometric measurement. 
Here, the DNA concentration was determined by using a NanoDrop 2000 spectrophotometer. The 
absorption at 260 nm indicates the concentration of the measured nucleic acid. In order to evaluate 
the DNA quality, the absorption is measured at 260 nm and 280 nm. A 260/280 ratio between 1.8 and 
2.0 indicates a good DNA or RNA quality. Values below 1.8 indicate a contamination with, for 
example, proteins.  
 
 
2.2.4 Fluorescence in situ hybridization (FISH) 
FISH is a molecular cytogenetic method that can be used to detect or verify microdeletions or 
microduplications. FISH was performed on interphase nuclei from peripheral blood of patient 2 and 
her mother. The advantage of interphase FISH is that the chromosomes are much less condensed 
than during metaphase (Strachan and Read, 2011). The first step of FISH is to do a chromosome 
preparation in which interphase nuclei are also present. In order to make a chromosome preparation, 
a cell suspension is required.  
Cell suspensions from peripheral blood of patient 2 and her mother were prepared by the 
cytogenetic diagnostics laboratory of the Institute of Human Genetics, University of Bonn. It was done 
according to the following protocol. Five ml of heparin blood was mixed with 45 ml cell culture 
medium and incubated at 37°C for 1 – 2 h with an open lid of the cell culture flask. Then the lid was 
closed. After 72 h of incubation, 500 µl colcemid (1 µg/100 µl) were added. Colcemid inhibits the 
spindle fiber formation, so cells cannot go into anaphase during mitosis, resulting in an increase of 
cells in metaphase. After incubation with colcemid for 15 – 30 minutes at 37°C, the cell suspension 
was transferred and split into two 50 ml Falcon tubes. Then a centrifugation step followed for 10 
minutes at 1200 rpm. The supernatant was discarded and the cell pellet was resuspended in 40 ml 
0.0375M potassium chloride (KCl). The tubes were then incubated again at 37°C for 20 minutes in a 
water bath and centrifuged for 10 minutes at 1200 rpm. The cell pellet was resuspended with 20 ml 
fixative, consisting of methanol and acetic acid in a ratio of 3:1, and centrifuged for 10 minutes at 
1200 rpm and 4°C. The fixation was repeated several times, the cell suspension was stored at ‐20°C. 
MATERIALS AND METHODS 
 
- 35 - 
2.2.4.1 Generating chromosome preparations 
Before the chromosome spreads were prepared, the glass slides were degreased using a mixture 
of ethanol and acetone (1:1 ratio) and dried. The cell suspension was washed once with the fixative 
(methanol: acetic acid 3:1 ratio), and tubes were centrifuged for 10 minutes at 1200 rpm and 4°C. 
Before the cell suspension was dropped onto the glass slide, the glass slides were dipped shortly into 
the fixative; then approximately 20 µl of the cell suspension was dropped onto the slide. After drying, 
for final fixation the slides were dipped into 70% acetic acid. The chromosome spreads were checked 
under the light microscope and the hybridization area was marked on the glass slide. 
 
 
2.2.4.2 Pretreatment of chromosome preparations 
In order to increase the hybridization efficiency of the labeled DNA probe to the chromosome 
preparations, the chromosome preparations were pretreated with the enzyme pepsin to digest the 
remaining cytoplasm. Subsequently, an additional fixation step was done with formaldehyde to 
preserve the chromosomal morphology. Then the chromosome preparations were dehydrated using 
increasing alcohol concentrations. The following protocol was used. 
The slides were equilibrated shortly in 2x SSC buffer. The pepsin digestion consists of incubation 
with pepsin for 10 minutes at 37°C. Afterwards, the slides were washed twice for 5 minutes in 1x PBS 
and a third time for 5 minutes in 1x PBS supplemented with magnesium chloride (5% of 1 M MgCl2). 
The post‐fixation was done for 10 minutes in a solution containing 2.8% formaldehyde and PBS‐
magnesium chloride. Before dehydration the chromosome preparations were washed once again for 
5 minutes in 1x PBS. Dehydration was done for 3 minutes each in 70%, 90% and 100% ethanol. Then, 
the glass slides were dried.  
 
 
2.2.4.3 Labeling of DNA probes – nick translation 
Nick translation is a method that can be employed to incorporate labeled nucleotides into DNA 
probes. Endonucleases such as DNase I can be used to introduce single strand breaks into double 
stranded DNA templates, so called nicks. These nicks serve as starting points for introduction of 
labeled nucleotides by the DNA polymerase I (Strachan and Read, 2011). The labelled nucleotides 
used were biotin‐16‐dUTP (bio‐dUTP) and digoxigenin‐11‐dUTP (dig‐dUTP), which can be detected by 
avidin or antibodies, respectively. Different DNA probes were labeled; dig‐dUTP was used to label the 
test‐probe, located in a chromosomal area that was suspected of harboring a duplication or deletion. 
Bio‐dUTP was used to label the reference‐probe. 
For labeling of 1 µg DNA the following protocol was used, aqua dest was added to the reaction 
mixture to a final volume of 50 µl. 
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Table 2: Pipetting scheme for nick translation 
Volume Reagent 
5 µl 10x NT‐buffer 
5 µl 0.1 M β‐mercaptoethanol 
5 µl dNTPs 
1 µl Dig‐ or‐ bio‐dUTPs (1 mM) 
1 µl DNase I (1 mg/ml) 
1 µl DNA polymerase I (500 U) 
X µl DNA‐sample (1 µg) 
ad 50 µl H2O 
 
The resulting mixture was incubated for 1 h at 37°C and then cooled on ice to temporarily stop the 
reaction. In order to verify if the DNA probe has the desired length of 100 – 500 bp, agarose gel 
electrophoresis was performed. When necessary, the incubation of the reaction mixture was 
resumed at 37°C, until the desired length was achieved, then the same volume of stopmix (50 µl) was 
added to the mixture. The labeled DNA probe was stored at ‐20°C if not used immediately. 
 
 
2.2.4.4 Preparation of hybridization mixture 
Equal amounts of biotin and digoxigenin‐labeled DNA (15 µl) were mixed with 6 µl human Cot‐1‐
DNA and 1 µl salmon sperm DNA. The unlabeled human Cot‐1‐DNA was added to the hybridization 
mix to suppress repetitive DNA sequences. For precipitation, 1/10 of the volume of 3 M sodium 
acetate (3.7 µl) was added as well as 2.5x the volume of ice cold 100% ethanol (102 µl). The mixture 
was mixed well and incubated for 30 minutes at ‐80°C. Afterwards, the tubes were centrifuged for 30 
minutes at 13000 rpm and 4°C. The supernatant was discarded, and the pellet was washed 3 times 
with 500 µl 70% ethanol and dried.  
 
 
2.2.4.5 Hybridization 
Due to the fact that the DNA probes as well as the template/chromosomes are double stranded, 
they had to be denatured, which was done by heat. The melting temperature, i.e. the temperature at 
which the double stranded DNA separates, depends on the composition of the DNA. The melting 
temperature rises, for example, with an increasing length of the DNA probe and its GC content due to 
the three hydrogen bonds between the complementary nucleotides. Addition of formamide 
destabilizes the hydrogen bonds and therefore reduces the melting temperature.  
The precipitated DNA from the hybridization mix was dissolved in 6 µl formamide for at least 1 h 
at 37°C under constant shaking. 6 µl of a “mastermix”, containing dextran sulfate, which increases the 
hybridization sensitivity, was added and mixed well. The DNA was denatured for 5 minutes at 75°C. 
Preannealing took place for 40 minutes at 37°C. During that time the slides with the chromosome 
preparations were incubated with 100 µl denaturation mixture (formamide, HCl and 20x SSC) for 1.45 
minutes at 72°C in a metal box. Subsequently, the slides were dipped into ice cold 2x SSC and 
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dehydrated for 3 minutes each in ice cold 70%, 90% and 100% ethanol and dried. Then the prepared 
DNA probes were applied to the chromosome preparations, covered with a cover slip and sealed with 
fixogum. Hybridization took place at 37°C overnight in a dry chamber. 
 
 
2.2.4.6 Washing steps and antibody detection 
The slides were washed after hybridization to remove unbound DNA probes and minimize 
background staining. The labeled DNA probes were detected by avidin or antibodies; a counter stain 
with DAPI was used to visualize the chromosomes. 
The slides were taken out of the hybridization chamber and the fixogum seal as well as the cover 
slip were removed. The slides were washed in 2x SSC at 37°C for 10 minutes under constant shaking. 
Then, the slides were washed twice in 0.2x SSC at 53°C for 7 minutes, shortly dipped and equilibrated 
in 4x SSC supplemented with Tween20. Following the washing steps, incubation with 150 µl blocking 
solution (containing BSA, Tween20 and 4x SSC) for 30 minutes at 37°C was performed in a moist 
chamber to block unspecific protein binding. Then, the slides were shortly dipped and equilibrated in 
4x SSC/Tween20, followed by incubation for 30 minutes with 150 µl antibody solution I (containing 
avidin‐FITC) at 37°C in a moist chamber. The slides were washed for 3x 5 minutes in 4x SSC/Tween20 
at 45°C with constant shaking. Then, the slides were incubated with the second antibody solution II 
(containing anti‐avidin and mouse anti‐dig) for 45 minutes at 37°C in a moist chamber. A washing step 
followed as before for 3x 5 minutes in 4x SSC/Tween20 at 45°C with constant shaking. Then, 
incubation with 150 µl antibody solution III (containing avidin‐FITC and anti‐mouse‐TRITC) followed at 
37°C for 30 minutes. The slides were washed again for 3x 5 minutes in 4x SSC/Tween20 at 45°C with 
constant shaking. Then, the counter stain followed by incubation in a DAPI solution (0.03 mg/ ml) for 
5 minutes at room temperature. One drop of antifade was added to the slide, which was then 
covered with a cover slip. Until analyzed by microscopy, the slides can be stored in the dark at 4°C. 
Images were acquired using the Leica epi fluorescence microscope DCX and image analysis was 
performed with the Leica CW 4000 FISH software. Monochromatic fluorescence images using filters 
for FITC, TRITC and DAPI were acquired of at least 20 interphase nuclei per hybridized slide. 
 
 
2.2.5 Array‐based comparative genomic hybridization (array‐CGH) 
Array‐CGH (Solinas‐Toldo et al., 1997; Pinkel et al., 1998) was used for the analysis of DNA samples 
from (i) more than 300 GGN gliomas, (ii) two tumors from patient 1, and (iii) peripheral blood from 
patient 2. This method can be used to identify copy number changes, such as losses, gains and 
amplifications, in a test compared to a control genome. The method is based on the hybridization of 
equal amounts of test and reference DNA together with human Cot‐1‐DNA, to a genomic DNA 
microarray. 
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In this study, a DNA microarray with 10,600 (10,6k array) large insert clones of known 
chromosomal locations was used. The microarrays were generated in Peter Lichter’s group at the 
German Cancer Research Centre (Heidelberg, Germany), who described this method for the first time 
in 1997 (Solinas‐Toldo et al., 1997). The composition of the 10,6k array was as follows: 3428 clones 
were from the 1 Mb clone set of Dr. N. P. Carter, Sanger Institute, Hinxton, Cambridge UK (Fiegler et 
al., 2003); 3000 RCPI (RZPD, Berlin, Germany) and CalTech (Invitrogen, Karlsruhe, Germany) BAC 
clones were added to increase the resolution to 0.5 Mb; 2000 clones covering the gene rich regions 
on chromosomes 1, 19 and 22 were added in order to achieve a tiling‐path coverage of these regions; 
2200 clones were added covering selected disease/ tumor relevant chromosomal regions at high 
resolution. The production of the microarrays was based on the Sanger Institute protocol (Fiegler et 
al., 2003; Fiegler et al., 2007). 
 
 
2.2.5.1 DNA labeling for array‐CGH 
Before hybridization of the DNA to the microarrays, equal amounts of test and reference DNA 
were labeled with Cy3‐dCTP or Cy5‐dCTP using components of a BioPrime Array CGH Genomic 
Labeling System (Invitrogen, Carlsbad, CA, USA). The random primer and the Exo‐Klenow fragment 
were used for the incorporation of the labeled nucleotides and amplification of the starting material. 
The used reference DNA contained pooled genomic DNA isolated from peripheral blood of ten 
healthy men or women. The hybridization was always sex matched. As a starting material, 1 µg of 
genomic DNA was used, which was mixed with 36 µl 2.5x random primer and 32 µl 5 M betaine and 
filled up with ddH2O to a final reaction volume of 77.4 µl. Denaturation of the reaction mixture was 
done at 95°C for 10 minutes in a thermocycler. Subsequently, the samples were cooled down on ice 
and additional components of the labeling mixture were added, such as 9 µl 10x dNTP‐mix; 1.8 µl       
1 mM Cy3‐dCTP’s or Cy5‐dCTP’s and 1.8 µl of Klenow fragment (40 U/µl). Labeling of the DNA took 
place at 37°C overnight for 14 to 16 hours in a thermocycler. 
 
MicroCon YM30 columns were used to purify the samples by removing unincorporated 
nucleotides as well as random primers. The MicroCon columns were used according to the 
manufacturers’ instructions. The labeled DNA was eluted in 100 µl 0.1x SSC. The total amount of DNA 
and the dye incorporation into the labeled DNA were measured with an UV spectrophotometer. The 
absorption at 260 nm (DNA), 550 nm (Cy3) and 650 nm (Cy5) was determined for each sample.  
 
The amount of DNA was calculated using the following formula: 
 
Concentration µg
µl
 = A
260× dilution factor × 50 µg
1000 µg
 
 
 
MATERIALS AND METHODS 
 
- 39 - 
The incorporation rate of Cy3‐dCTP was calculated using the following formula: 
 
Cy3‐dCTP‐incorporation rate dye
bp
 = A
260
A550
×23.15 
 
The ideal value for the Cy3‐dCTP incorporation was approximately one labeled nucleotide every 40 
bp. But the experiment also worked if a labeled nucleotide was incorporated every 60 to 80 bp. 
 
The incorporation rate of Cy5‐dCTP was calculated using the following formula: 
 
Cy5‐dCTP‐incorporation rate dye
bp
 = A
260
A650
×38.58 
 
The ideal value for the Cy5‐dCTP incorporation was approximately one labeled nucleotide every 60 
bp. But the experiment also worked if a labeled nucleotide was incorporated every 80 to 100 bp. 
 
 
2.2.5.2 Array‐CGH sample preparation for hybridization 
Equal amounts of 10 – 15 µg test and reference DNA were co‐precipitated with 120 µg human Cot‐
1‐DNA, 1/10 of the reaction volume of 3 M sodium acetate and 2.5x of the reaction volume of 100% 
ice cold ethanol. The reaction mixture was incubated for at least 30 minutes at ‐80°C and 
subsequently centrifuged for 30 minutes at 13000 rpm and 4°C. The supernatant was discarded and 
the resulting pellet was dissolved in 125 µl UltraHyb hybridization buffer at 37°C overnight while 
constantly shaking. 
 
 
2.2.5.3 Array‐CGH hybridization 
Before a sample was applied to a microarray, the DNA was denatured at 75°C for 10 minutes and a 
preannealing step followed for 30 – 60 minutes at 37°C. During the annealing step, the microarrays 
were positioned in the separate hybridization chambers of the HybArray12 System, which permitted 
the simultaneous hybridization of up to 12 arrays. The hybridization and the subsequent stringency 
washing steps are listed in the table below: 
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Table 3: Protocol of hybridization and stringency washing steps 
Step Temperature Duration 
Denaturation of DNA microarrays 75°C 5 minutes 
Addition/ injection of the probe 42°C  
Distribution of the probe 42°C 30 minutes 
Hybridization 37°C 66 – 72h 
Wash buffer B 37°C 30 sec washing, 5 sec holding 
Wash buffer B 44°C 15 sec washing, 5 sec holding 
Wash buffer A 44°C 20 sec washing, 3 min holding 
Wash buffer B 44°C  20 sec washing, 5 sec holding 
Wash buffer C 25°C  2 min washing, 5 sec holding 
 
 
2.2.5.4 Preparation of the DNA microarrays for scanning 
After the stringency washing steps, the microarrays were dipped into wash buffer C for a few 
seconds. For drying, the microarrays were introduced into a 50 ml Falcon tube and centrifuged for 2 
minutes at 1500 rpm. Then, the microarrays were coated with Dye Saver II solution in order to 
prevent fading of the dyes.  
 
 
2.2.5.5 Scanning of the DNA microarrays 
The microarrays were scanned using the MS200 microarray scanner and the MS200 data collection 
software from NimbleGen, Roche. At first, a scanning area was defined, which was applied to all 
microarrays. Then, the arrays were scanned at a wavelength of 532 nm detecting Cy3 and at a 
wavelength of 635 nm detecting the Cy5. The scanning resolution was set to 5 µm at medium speed 
to increase the sensitivity of the scan. The scan was then saved as a multi‐tiff image file and was 
further analyzed with the Genepix 6.1 software. 
 
 
2.2.5.6 Data processing with the Genepix 6.1 software 
The Genepix 6.1 software was used for the data processing of the multi‐tiff image file. Firstly, a 
gps‐file (genepix settings‐file) or so called grid was uploaded, which included all information 
concerning the array design, such as the number of arrayblocks, the number of spots, the spot 
diameter, the spot distance and the spot name. The grid was placed over the array by a software tool 
which recognized each individual spot, but had to be corrected manually in some cases. Spots which 
could not be recognized by the software were excluded from further analysis. For each array, an 
individual setting was saved. Secondly, a gpr‐file (genepix result‐file) was generated using the 
information from the gps‐file. The gpr‐file summarized all the information about each spot such as 
location of the spot, chromosomal location, spot name, spot diameter and measured intensities. The 
most important features of the gpr‐file are summed up in Table 4.  
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Table 4: Features of the gpr-file 
Specifications 532 nm 635 nm 
Block F532 median F635 median 
Column F532 mean F635 mean 
Row F532 SD F532 SD 
X/Y localization F532 CV F635 CV 
Spot name B532 median B635 median 
Spot diameter B532 mean B635 mean 
 B532 SD B635 SD 
 B532 CV B635 CV 
SD, standard deviation; CV, coefficient of variation; F, feature intensity; B, background 
 
 
2.2.5.7 Data analysis and interpretation  
Data analysis was performed using the Chipyard framework 
(http://www.dkfz.de/genetics/ChipYard/). Information about the hybridized test DNA samples as well 
as patient information were integrated into the database. The microarray data was uploaded to the 
Chipyard program as a gpr‐file. There, the data was further processed, and a quality control of the 
microarrays took place. Spots with low quality were filtered out and the test to control ratio for each 
spot was calculated, and data normalization performed. A txt‐file was generated, including the 
information for each clone (spotted in triplicate) on the microarray, such as the chromosomal 
location with chromosomal starting, mid and end point, a list of genes located in that area, as well as 
the normalized log2 ratios of test versus reference DNA for each clone (i.e. the calculated mean of the 
triplicates). A genomic profile was prepared for each analyzed sample, using the log2 ratios of test 
versus reference DNA of each clone. The data information was taken from the txt‐file generated in 
Chipyard. Using the genomic profile, DNA copy number changes such as gains and losses were 
identified. Some frequency plots as well as the heatmaps from the data using different clustering 
approaches were prepared in cooperation with the Institute for Medical Informatics, Statistics and 
Epidemiology of the University of Leipzig.  
 
 
2.2.6 Oligonucleotide arrays – NimbleGen 
The hybridization of test and reference DNA to oligonucleotide arrays, in order to analyze copy 
number changes, is based on a similar principle as array‐CGH (2.2.5, page 37). The difference is that 
the probes spotted on an oligonucleotide array are much shorter than on a BAC‐array and do not 
contain repetitive sequences. They usually consist of 60 nucleotides, so called 60mers. Advantages of 
oligonucleotide arrays are that they achieve a much higher resolution and that hybridization does not 
require suppression of repetitive sequences. During this study, chromosome specific 385k (385000 
probes) oligonucleotide tiling arrays from NimbleGen, Roche were used to identify the precise 
breakpoints of microduplications detected by BAC array‐CGH in the germline of patient 2 and her 
parents. Equal amounts of test and reference DNA (from Promega) were labeled with the NimbleGen 
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Dual‐Color DNA Labeling Kit according to the manufacturer’s instructions. Only slight modifications 
were made, such as the reduction of the reaction mixture volume. It has been found that it was 
sufficient to label only 500 ng of test as well as reference DNA. The total reaction volume of the DNA 
labeling mixture was also reduced from 80 µl to 40 µl, including 20 µl of Cy3 or Cy5 random nonamers 
mixture and 500 ng DNA filled up to a final reaction volume of 40 µl with nuclease‐free water. 
Denaturation of the samples was done at 98°C for 10 minutes in a thermocycler; subsequent cooling 
was performed in an ice cold water bath. Then, 10 µl of dNTP/ Klenow mastermix was added to each 
sample, including 5 µl 10 mM dNTP‐mix, 4 µl nuclease‐free water and 1 µl of Klenow fragment (3'‐>5' 
exo) 50 U/ μl. The complete reaction mixture of 50 µl was incubated overnight for approximately 14 h 
at 37°C in a thermocycler. The reaction was stopped with 10 µl 0.5 M EDTA solution. For precipitation 
of the labeled DNA samples, 6.5 µl 5 M NaCl were added, the tubes were vortexed and centrifuged. 
The reaction mixture was then transferred into a microcentrifuge tube containing 60 µl isopropanol. 
The mixture was vortexed again and incubated for 10 minutes in the dark at room temperature. 
Subsequently, the tubes were centrifuged for 10 minutes at 12000 rpm and the supernatant was 
carefully removed. A colored pellet, either pink for Cy3 or blue for the Cy5 labeled samples, was then 
visible. The pellet was washed once with 500 µl ice cold 80% ethanol. Again, the tubes were 
centrifuged for 10 minutes and 12000 rpm. After removing the supernatant, the pellet was dried, 
either at room temperature with an open tube lid or for 5 minutes in a SpeedVac. Then, the samples 
were either stored at ‐20°C or rehydrated with 15 µl nuclease free water. For complete dehydration, 
the samples were incubated for 5 minutes at room temperature in the dark. Then the concentration 
of the labeled DNA samples was determined with a Nanodrop spectrometer. According to the 
manufacturer’s instructions for 385k arrays, 6 µg of labeled test DNA and 6 µg of labeled reference 
DNA were needed. 
 
needed µl=
6000 ng
measured concentration ngµl
 
 
Three hours prior to hybridization, the hybridization chambers were heated to 42°C. The 
calculated volumes containing 6 µg of labeled test DNA and 6 µg of labeled reference DNA were 
combined, filled up to a volume of 5 µl with nuclease‐free water, and mixed with 13 µl of the 
hybridization master mix supplied by the hybridization kit. Hybridization master mix was prepared as 
follows according to the manufacturer’s instructions. 
 
Table 5: Pipetting scheme for the hybridization master mix 
Hybridization kit components Amount for 385k array 
2x hybridization buffer 11.8 µl 
Hybridization component A 4.7 µl 
Alignment oligo 0.5 µl 
Final volume 17.0 µl 
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After addition of the hybridization master mix, the samples were vortexed, centrifuged and 
incubated for 5 minutes at 95°C. During this time, the X1 mixers were attached to the arrays 
according to the manufacturer’s instructions. The prepared arrays were incubated for at least 5 
minutes at 42°C. Then, the samples were applied to the arrays, the fill ports were sealed, and 
hybridization took place over night for 16 – 20 hours. 
Post hybridization steps were all performed according to the manufacturer’s instructions. The 
NimbleGen wash buffer kit was used together with the NimbleGen array processing accessories. The 
slides were dried with the NimbleGen microarray dryer. 
The microarrays were scanned using the MS200 microarray scanner and the MS200 data collection 
software from NimbleGen, Roche. Firstly, a scanning area was defined, which was applied to all 
microarrays. Then, the arrays were scanned at a wavelength of 532 nm detecting Cy3 and at a 
wavelength of 635 nm detecting the Cy5. The scanning resolution was set to 2 µm at medium speed 
to increase the sensitivity of the scan. The scan was then saved as a single‐tiff image file and was 
further analyzed with the NimbleScan software version 2.5 for copy number analysis. The NimbleScan 
software was used to align the design file (.ndf) to the array, a procedure called gridding. The design 
file was provided for each array by the manufacturer and describes the position of the probes on the 
array. Then, the segMNT algorithm was used to further process the gridded image files (.tif). 
Averaging windows of 2000 bp, 4000 bp and 10000 bp were used, meaning that the software 
takes the raw signal data of all probes inside the defined window and combines it to one single data 
point. 
In the end, gff‐files were generated, including the log2 ratio data for 532 nm and 635 nm. For 
evaluation and detection of copy number changes, the gff‐files were viewed by the SignalMap 
software. As an additional feature, the software can be used to visualize the positions of genes, 
known segmental duplications of the human genome and ideograms for each chromosome. This 
information was also supplied by the manufacturer (Roche). 
 
 
2.2.7 Sanger sequencing 
Sanger sequencing is a method of DNA sequencing, which is also called the chain termination 
method. This method requires a DNA primer, a DNA polymerase, normal dNTP’s as well as 
dideoxynucleotides (ddNTP’s) labeled with a fluorescent dye, which cause termination of the DNA 
elongation. These ddNTP’s lack a 3’‐OH group, which is needed for a phosphodiester bond formation 
between the nucleotides. As soon as a ddNTP is incorporated, the elongation of the DNA stops 
resulting in synthesized DNA strands of various lengths, that can be separated by size e.g. by capillary 
electrophoresis. During electrophoresis, the DNA fragments pass a laser, the emitted fluorescence is 
measured and the sequence of the DNA is detected. The results are then visualized by an 
electropherogram (Strachan and Read, 2011). 
 
 
MATERIALS AND METHODS 
 
- 44 - 
2.2.7.1 Primer design 
In order to sequence a certain DNA fragment by the Sanger method it needs to be amplified first. 
For amplification, for example, of an exon of a gene, polymerase chain reaction (PCR), a primer pair 
consisting of a forward primer (binding to the sense strand), and a reverse primer (from the anti‐
sense‐strand) in 5’‐3’orientation are needed. The primers are designed on the basis of the gene 
structure, which can be retrieved from databases such as the UCSC Genome Browser or ENSEMBL 
Genome Browser. The goal is to amplify one specific DNA sequence. So when designing primers, it is 
important that they are highly specific and are not able to bind to other DNA sequences, than the 
desired ones. 
 
The following criteria were considered when designing primers: 
• The lengths of the primers were kept between 18 – 24 bp, with an approximately equal 
distribution of all four bases. 
• The primer sequence should not include a repeat of the same nucleotide that is longer than 
three nucleotides. 
• The 3’‐end of the primer should be a G or a C.  
 
In order to amplify an exon from of genomic DNA, the primers should be located at least 60 bp 
before or after the exon/ splice site, otherwise sequencing of the complete exon might be difficult. In 
this study, primers were ordered from Eurofines/ MWG Operon, Ebersberg, Germany. 
 
 
2.2.7.2 Polymerase chain reaction (PCR) 
PCR is an in vitro technique to amplify even minute amounts of DNA and has found numerous 
applications in research and diagnostics. Essential for PCR are primers, which are synthesized 
oligonucleotides with a size of 18 – 25 base pairs. These primers are needed to target defined 
sequences, which have to be known. The DNA is amplified by thermocycling, consisting of three steps. 
The first step is denaturation, i.e. separation of the double stranded DNA template. Secondly, an 
annealing step follows, meaning that the primers are allowed to bind to their complementary 
sequence on the single stranded DNA target. Third and last step is the elongation step, in which the 
DNA polymerase initiates the synthesis of a new DNA fragment (Strachan and Read, 2011). These 
thermocycling steps are repeated up to 40 times until the desired PCR product is present in a 
sufficient amount. 
In order to amplify the DNA fragment from genomic DNA prior to sequencing, PCR was performed 
in a volume of 25 µl including Taq‐DNA polymerase, forward and reverse primer, 100 ng genomic 
DNA and H2O. In this study, the REDTaq ReadyMix PCR reaction mix with MgCl2 from Sigma or the Taq 
DNA polymerase from Qiagen were used. The ReadyMix already includes all components needed for 
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the PCR. When using the Taq DNA polymerase, 10x buffer, dNTP’s and Q‐solution had to be added 
separately. 
 
Table 6: Pipetting scheme for standard PCR using Taq DNA polymerase from Qiagen 
Reagent Volume 
Q‐solution 5 µl 
Buffer (10x) 2.5 µl 
dNTP’s 2.5 µl 
Taq DNA polymerase 0.15 µl 
Fwd‐primer [10 pmol/µl] 1 µl 
Rev‐primer [10 pmol/µl] 1 µl 
DNA [20 ng/µl] 5 µl 
H2O 7.85 µl 
Final volume 25 µl 
 
 
Table 7: Temperature profile of a standard PCR 
Step Temperature Duration Number of cycles 
Pre‐annealing 95°C 5 minutes 1 
Denaturation 
Annealing 
Extension 
95°C 
60°C 
72°C 
30 seconds 
30 seconds 
2 minutes 
 
17 
Denaturation 
Annealing 
Extension 
95°C 
58°C 
72°C 
30 seconds 
30 seconds 
2 minutes 
 
20 
Final extension 72°C 10 minutes 1 
Cooling  4°C Forever  
For all primer pairs, this temperature profile for the PCR was used.  
 
 
2.2.7.3 Enzymatic cleanup of PCR products by ExoSAP‐IT 
After PCR, the products were visualized after separation in a 2% agarose gel, in order to see if the 
PCR yielded a specific PCR product of the desired length. If this was the case, an enzymatic cleanup to 
remove unbound/ unconsumed nucleotides and the primers was performed in the PCR products. For 
this cleanup step two enzymes are used. Exonuclease I removes single‐stranded DNA such as primers 
and other single‐stranded DNA products generated during PCR. The Shrimp Alkaline Phosphatase 
(SAP) removes the unbound dNTP’s. For cleanup of the PCR products, 2 µl of the ExoSAP‐IT solution 
from the kit were mixed with 5 µl of PCR product. The reaction mixture was incubated in a 
thermocycler following the protocol detailed in Table 8.  
 
Table 8: Thermocycling protocol for enzymatic cleanup  
Step Temperature Duration 
Enzymatic reaction 37°C 25 minutes 
Inactivation of enzymes 80°C 30 minutes 
Cooling 12°C Forever 
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2.2.7.4 Sequencing reaction using the BigDye Terminator v1.1 Cycle Sequencing Kit  
In this step, ddNTP’s labeled with a fluorescent dye were incorporated, resulting in DNA fragments 
of various sizes. For the sequencing reactions, the BigDye Terminator v1.1 cycle sequencing kit from 
Applied Biosystems was used according to the manufacturer’s instructions. The same primers were 
used as for the amplification of the specific DNA fragment by PCR (2.2.7.2, page 44), this time diluted 
to a final concentration of 1 pmol/µl. However for sequencing, either the forward or the reverse 
primer was selected. Sometimes sequencing was repeated with the other primer not used in the first 
reaction. The pipetting scheme and thermocycling protocol are shown in Table 9. 
 
 
Table 9: Pipetting scheme for a sequencing reaction 
Reagent Amount 
BigDye Terminator v1.1 1 µl 
5x sequencing buffer 2 µl 
Fwd or rev primer [1 pmol/µl] 1 µl 
PCR product (ExoSAP‐treated) 2 µl 
H2O 4 µl 
Final volume 10 µl 
 
Table 10: Temperature profile of a sequencing reaction 
Step Temperature Duration Number of cycles 
Denaturation 95°C 3 minutes 1 
Denaturation 
Annealing 
Extension 
95°C 
50°C 
60°C 
20 seconds 
30 seconds 
4 minutes 
 
26 
Cooling  12°C Forever  
 
After the sequencing reaction each sample was diluted 1:1 with 10 µl HPLC‐H2O for another cleanup 
step.  
 
 
2.2.7.5 Cleaning up of sequencing reaction and sequencing analysis 
Before the samples were analyzed by the sequencer, the sequencing reaction products were 
cleaned up, in order to remove surplus unbound ddNTP’s from the reaction mixture. During this 
study, two different methods were used, depending on the number of samples analyzed. Sephadex G‐
50 96‐well plates were used when the number of samples was high. After soaking Sephadex G‐50 in 
water, a gel matrix develops, which is used to retain small molecules. For single samples or small 
sample sizes, the DyeEx 2.0 Spin Kit from Qiagen was used according to the manufacturer’s 
instructions.  
In order to prepare the Sephadex plates, the MultiScreen column loader was used, which 
distributes Sephadex G‐50 evenly in each well. A 96‐well MultiScreen plate from Millipore was placed 
on top of it, with the upside facing the MultiScreen column loader plate. Then, both plates were 
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inverted and the Sephadex G‐50 was transferred to the 96‐MultiScreen plate. 300 µl HPLC‐H2O was 
added to each well and incubated for 3 hours at room temperature or overnight at 4°C, to let the 
Sephadex G‐50 swell and form a gel matrix. The MultiScreen plate was centrifuged at 2000 rpm for 5 
minutes, the collecting plate was emptied. The MultiScreen plate was washed once with 150 µl HPLC‐
H2O and centrifuged again as before. During the centrifugation steps, a QualiPCR plate was prepared, 
adding 15 µl Hi‐DiTM‐formamide to each well. The MultiScreen plate was then placed on top of the 
QualiPCR plate, and 20 µl of the diluted sequencing reaction was applied onto the gel matrix. The 
plates were centrifuged once again as described above. During this step, the sequencing reaction 
passes the gel matrix, where the unbound ddNTP’s remained, and the DNA fragments passed through 
and were directly added to the Hi‐DiTM‐formamide. The plates were covered and stored at 4°C until 
they were sequenced on a 3130XL Genetic Analyzer (Applied Biosystems, Darmstadt, Germany). 
Alternatively, the DyeEx 2.0 Spin Kit was used for cleaning up the sequencing reactions, according 
to the manufacturer’s instructions. The spin columns were shortly vortexed to resuspend the resin. 
Then, each the spin column was placed in a 2 ml collecting tube and centrifuged for 3 minutes at 3000 
rpm to remove the buffer and to generate a gel matrix. Each column was transferred to a 
microcentrifuge tube and the diluted sequencing reaction (generated in 2.2.7.4, page 46) was applied 
onto the gel matrix without touching it. After the sample was loaded to the column, the spin column 
was centrifuged again for 3 minutes at 3000 rpm. The flow‐through was then added to 15 µl Hi‐DiTM‐
formamide and stored at 4°C until the probes were sequenced on a 3130XL Genetic Analyzer (Applied 
Biosystems, Darmstadt, Germany). Electropherograms were analyzed using the BioEdit Sequence 
Alignment Editor software or the SeqPilot software.  
 
 
2.2.8 Whole exome sequencing (WES) 
WES on genomic DNA isolated from peripheral blood (2.2.1, page 33) of patient 2 and her parents 
was performed by CeGaT GmbH, Tübingen, Germany. DNA hybridization capture was performed 
using the Agilent SureSelect whole exome enrichment (v4) kit and samples were sequenced one 
exome per lane with 75 bp reads on a SOLiD 5500x1 system according to the manufacturer’s 
protocols. All samples were sequenced to a mean target coverage of >50x. Data were analyzed using 
the CeGaT exome analysis pipeline (Classen and Riehmer et al., 2013).  
Filtering of WES data was based on different steps. Firstly, all variants were removed exhibiting a 
coverage of lower than 20 or a bad quality. Known variants from the CeGaT in‐house exomes were 
also removed. Secondly, only serious variants defined as frameshift mutations, stop gained or lost, 
non‐synonymous coding or essential splice site mutations were retained. Thirdly, predictions of 
variant deleteriousness were performed using online prediction tools such as SIFT, PolyPhen‐2 and 
MutationTaster. Then, in order to find pathogenic or functionally relevant variants, the serious and 
deleterious variants were processed by the mining tool Genome TraxTM (Biobase GmbH, 
Wolfenbuettel, Germany). Genome TraxTM uses peer‐reviewed literature to identify variants and 
provides information about conservation, allele frequency, effect on protein sequence, and 
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deleterious predictions in order to assess the variants. Data filtering using Genome TraxTM was 
particularly based on annotations on inherited disease genes from Human Gene Mutation Database 
(HGMD®), on disease associated mutations from HGMD, and on functional disease‐related SNPs 
(Classen and Riehmer et al., 2013). 
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3 Results 
3.1 Project 1: Array‐CGH analysis of WHO grade II and WHO grade III gliomas 
The first project of this study aimed at characterizing the genomic imbalances in low‐grade gliomas 
including WHO grade II astrocytomas, oligoastrocytomas and oligodendrogliomas as well as WHO 
grade III anaplastic astrocytomas and anaplastic oligoastrocytomas. DNA from tumor samples of the 
different glioma entities was analyzed using array‐CGH, with the purpose to detect DNA copy number 
changes in gliomas of WHO grade II and III. 
 
 
3.1.1 Genomic profiles in WHO grade II gliomas 
In order to characterize DNA of copy number changes on a genome‐wide scale in low‐grade 
gliomas, DNA of tumor samples collected within the GGN were analyzed by array‐CGH (diffuse 
astrocytomas: n=53; oligoastrocytomas: n=17; oligodendrogliomas: n=3). Some selected array‐CGH 
profiles of diffuse astrocytomas of WHO grade II are depicted in Figure 4 sorted according to their IDH 
status. Figure 4A – D shows profiles of astrocytomas, which have been found to be IDH1/2 wild‐type, 
whereas Figure 4E – H depicts genomic profiles of astrocytomas harboring a mutation within the IDH1 
or IDH2 gene. Interestingly, in the IDH1/2 wild‐type astrocytomas copy number changes were 
detected which are typically found in IDH1/2 wild‐type glioblastomas. These genetic alterations 
include copy number gain on chromosome 7 (Figure 4A – D), including a clear amplification of the 
EGFR gene located in 7p11.2 in one case (Figure 4D: 5 clones with a log2 ratio above 1). Further, gains 
of chromosomes 19 and 20 were apparent (Figure 4B and 4D). Another genetic imbalance typical for 
IDH1/2 wild‐type glioblastomas is a loss on chromosome 10, which was also seen in the analyzed 
diffuse astrocytomas (Figure 4B, C and D). Other genetic alterations could be detected both in IDH1/2 
wild‐type and mutant astrocytomas, such as deletions on chromosome 4 (Figure 4A, C, G, H). Further 
copy number gains could be found in single tumors on chromosome 8 (Figure 4F), chromosome 11 
(Figure 4E), and on chromosome 18 (Figure 4E and G). Deletions of chromosomal arm 13q were found 
in three astrocytomas independent of the IDH1/2 status (Figure 4D, F and H). The genomic profiles in 
Figure 4 suggest that DNA copy number changes are more heterogeneous in IDH1/2 mutant 
astrocytomas than in IDH1/2 wild‐type astrocytomas.  
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Figure 4: Array-CGH profiles of WHO grade II diffuse astrocytomas. 
A-D: Selected array‐CGH profiles from astrocytomas with an IDH1/2 wild‐type status show a varying degree of 
chromosomal alterations. E-H: selected array‐CGH profiles from astrocytomas with an IDH1/2 mutant status. 
The midpoints of all BAC clones are plotted in genomic order from 1p to Yq on the x‐axis against their 
normalized log2 test to reference ratio on the y‐axis.  
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Figure 5 shows array‐CGH profiles of oligoastrocytomas (WHO grade II) (Figure 5A, B) and 
oligodendrogliomas (WHO grade II) (Figure 5C, D). In all four profiles, a combined loss of 
chromosomal arms 1p and 19q could be detected, which are known copy number changes in tumors 
with an oligodendroglial component. Additional changes in the copy number on chromosomes 4, 8, 
13, and 15 could only be detected in the mixed tumors containing an astroglial component in addition 
to oligodendroglial cells (Figure 5A, B). 
 
 
 
Figure 5: Array-CGH profiles of WHO grade II oligoastrocytomas and oligodendrogliomas. 
A and B: selected array‐CGH profiles of WHO grade II oligoastrocytomas. C and D: selected array‐CGH profiles of 
WHO grade II oligodendrogliomas. In all four tumors, a signature typical for oligodendroglial tumors with a 
combined loss of 1p and 19q can be seen. The midpoints of all BAC clones are plotted in genomic order from 1p 
to Yq on the x‐axis against their normalized log2 test to reference ratio on the y‐axis.  
 
 
3.1.2 Frequency of genomic alterations in WHO grade II gliomas 
In order to identify and compare common genomic alterations in different WHO grade II glioma 
entities, frequency plots were prepared that were stratified according to the IDH1/2 status. 
Frequency plots aid in analyzing larger numbers of samples due to the fact that they indicate how 
often a certain chromosomal region is affected by gains or losses in a certain tumor entity. 
Unfortunately, not all samples analyzed by array‐CGH could be included when preparing these 
frequency plots. Therefore, the number of samples, which were entered in this analysis, is lower than 
the total number of analyzed samples. 
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No clear difference in the frequency of genomic imbalances between IDH1/2 wild‐type (n=13) and 
mutant (n=19) astrocytomas was detected (Figure 6). This may be due to the fact that the numbers of 
tumor samples, the frequency plots are based on are quite low. The most frequent gain in IDH1/2 
wild‐type and mutant astrocytomas, was of chromosomal arm 7q found in 40% – 50% of cases. Loss 
of chromosome 10 was detected in 20% of IDH1/2 wild‐type and mutant tumors. However, in IHD1/2 
mutant tumors it only affected the long arm of chromosome 10. The most frequent loss in IDH1/2 
wild‐type and mutant astrocytomas was in the long arm of chromosome 19.  
 
 
 
Figure 6: Frequency plots of genomic alterations in WHO grade II diffuse astrocytomas stratified according to 
IDH1/2 status. 
A: Frequency of genomic imbalances in of 13 IDH1/2 wild‐type astrocytomas of WHO grade II. B: Frequency of 
genomic imbalances in 19 astrocytomas of WHO grade II harboring an IDH1/2 mutation. Gains are indicated by 
green bars, losses are indicated by red bars. Gains and losses are plotted in genomic order from 1p to Yq on the 
x‐axis. The y‐axis indicates the fraction of cases with copy number changes. 
 
 
3.1.3 Genomic profiles in WHO grade III gliomas 
WHO grade III gliomas are characterized by a more aggressive behavior than diffuse astrocytomas 
of WHO grade II, and are associated with nuclear atypia, an increased cellularity and significant 
proliferative activity, suggesting that an increased number of copy number alterations may underlie 
these histological changes. Therefore, also WHO grade III gliomas such as anaplastic astrocytomas 
(n=49) and anaplastic oligoastrocytomas (n=36) were analyzed using array‐CGH in order to 
characterize their genomic profile. When, comparing the array‐CGH profiles of the anaplastic 
astrocytomas WHO grade III (Figure 7, page 53) with those of WHO grade II astrocytomas (Figure 4, 
page 50), it can be seen that the WHO grade III tumors displayed more genetic imbalances and that 
the number of affected chromosomes (e.g. chromosomes 3, 4, 6, and 14) is more numerous as 
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compared to the WHO grade II tumors. The genomic profiles depicted in Figure 7A and B are from 
anaplastic astrocytomas with an IDH1/2 wild‐type status, as opposed to tumors harboring an IDH1/2 
mutation shown in Figure 7C and D. In the IDH1/2 wild‐type tumors, a gain of chromosome 7 and/ or 
a loss of the entire chromosome 10 could be detected, while the chromosome 10 loss only affects 
part of the long arm in one IDH1/2 mutant case (Figure 7C) and chromosome 7 gains are not found.  
 
 
 
Figure 7: Array-CGH profiles of WHO grade III anaplastic astrocytomas. 
A and B: Array‐CGH profiles from anaplastic astrocytomas with an IDH1/2 wild‐type status. C and D: Array‐CGH 
profiles from anaplastic astrocytomas with an IDH1/2 mutant status. The midpoints of all BAC clones are plotted 
in genomic order from 1p to Yq on the x‐axis against their normalized log2 test to reference ratio on the y‐axis. 
 
 
3.1.4 Frequency of genomic alterations in WHO grade III gliomas 
In order to identifiy and compare common genomic imbalances in anaplastic astrocytomas of 
WHO grade III, with wild‐type or mutant IDH1/2, frequency plots were prepared stratified according 
to the IDH1/2 status. Here, differences in the two frequency profiles comparing IDHwt and IDHmut 
could be seen (Figure 8, page 54). Figure 8A displays the sum of genetic imbalances in eight anaplastic 
astrocytomas with wild‐type IDH1/2, demonstrating a clear gain of chromosome 7 in about 80% of 
the cases as well as a loss of chromosomal arm 9p and losses of chromosomes 10 and on 
chromosomal arm 14q in about 75% of the cases. Other less frequent genomic alterations were gains 
on chromosomes 9, 18 and 19 in about 25% – 50% of the cases as well as the loss on chromosomal 
arm 22q in about 50%. Figure 8B shows the genetic imbalances in 19 anaplastic astrocytomas 
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harboring IDH1/2 mutations. In these tumors, the gain on chromosome 7 was less frequent (50%) and 
affected the long arm only in most cases. The loss of chromosome 10 could ony be detected in 25% of 
the cases and also affected only the long arm. In contrast to the IDH1/2 wild‐type tumors, the loss of 
chromosomal arm 19q was more frequent (50%) in the IDH1/2 mutated tumors. Further differences 
between the two frequency plots in Figure 8 are the gains on chromosomes 18 and 19, which were 
not or only rarely present in IDH1/2 mutant tumors. 
 
 
 
Figure 8: Frequency plots of genomic alterations in anaplastic astrocytomas of WHO grade III stratified 
according to IDH1/2 status.  
A: Frequency of genomic imbalances in eight IDH1/2 wild‐type anaplastic astrocytomas of WHO grade III.          
B: Frequency of genomic imbalances in 19 anaplastic astrocytomas of WHO grade III harboring an IDH1/2 
mutation. Gains are indicated by green bars, losses are indicated by red bars. All alterations are plotted in 
genomic order from 1p to Yq on the x‐axis. The y‐axis indicates the fraction of cases with copy number changes. 
 
 
Anaplastic oligoastrocytomas are WHO grade III tumors containing an oligodendroglial in addition 
to the astrocytic component. In this study, 28 IDH1/2 mutant anaplastic oligoastrocytomas were 
analyzed. A frequency plot for IDH1/2 wild‐type tumors was not prepared, due to the fact that only 
one tumor in this cohort was found to be IDH1/2 wild‐type. Analyzing the IDH1/2 mutant tumors 
using array‐CGH revealed various chromosomal imbalances, the sums of which are displayed in the 
frequency plot in Figure 9. A combined loss of chromosomal arms 1p and 19q was found in about 75% 
of the cases. Other chromosomal aberrations were much less common and involved losses on 
chromosome 4, 13q, 14q and 15q in about 25% – 30% of the cases, as well as a gain on chromosome 
7 in about 25%. 
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Figure 9: Frequency plot of genomic alterations in IDH1/2 mutant WHO grade III anaplastic oligoastrocytomas 
Gains are indicated by green bars, losses are indicated by red bars. Alterations are plotted in genomic order 
from 1p to Yq on the x‐axis. The y‐axis indicates the fraction of cases with copy number changes. 
 
 
In summary, it could be shown that WHO grade II gliomas including diffuse astrocytomas, 
oligoastrocytomas and oligodendrogliomas display less frequently copy number changes than gliomas 
of WHO grade III. Furthermore, a small group of IDH1/2 wild‐type astrocytomas of WHO grade II were 
detected to display glioblastoma‐like imbalances, i.e. gains on chromosome 7, 19 and 20 as well as 
losses of chromosomes 9 and 10. In contrast, deletions of chromosomal arms 1p and 19q were 
frequently found in oligodendroglial tumors or in mixed astrocytic tumors displaying an 
oligodendroglial component. Combined loss of 1p and 19q was significantly less frequent in astrocytic 
tumors.  
 
 
3.2 Project 2: Characterization of long‐term survivors of glioblastoma using genome‐wide 
profiling 
The prognosis of glioblastoma, WHO grade IV, the most malignant glioma type, is poor with only a 
minority of patients showing long‐term survival of more than three years after diagnosis. Survival in 
primary glioblastoma patients is usually shorter than in patients with secondary glioblastomas 
(Ohgaki and Kleihues, 2005b). This may be due to the fact that IDH1/2 mutations are commonly 
found in secondary glioblastomas which are associated with longer survival. There are a few cases of 
primary glioblastoma patients that have IDH1/2 mutant tumors, while 80% – 90% of primary 
glioblastomas are IDH1/2 wild‐type. It was the aim of project 2 to elucidate the genomic imbalances 
in primary glioblastomas of long‐term survivors and to compare them with those of intermediate‐
term and short‐term survivors. Project 2 has been published in Reifenberger and Weber et al., 2014. 
 
 
3.2.1 Patient characteristics of 94 glioblastoma patients 
In total, 94 patients were included in project 2, all presenting with a histopathological reference 
diagnosis of glioblastoma. Clinical, histological, and molecular data were collected for each case and 
are summed up in Table 11. This table includes the more basic data, like age at diagnosis, gender, KPS 
(Karnofsky performance scale), extent of surgery as well as the reference diagnosis. Additionally, 
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molecular markers such as the MGMT promoter methylation status and the IDH1 and IDH2 mutation 
status were also included. The patients were divided into three groups according to their survival 
times (group A, B and C). Group A (n=28) comprises long‐term survivors that show an overall survival 
(OS) of more than 36 months. Group B (n=20) represents short‐term survivors, showing a 
progression‐free survival (PFS) of less than 6 months and an OS of less than 12 months. Group C 
(n=46) was defined as patients with an intermediate survival. Death in all patients was tumor‐related.  
Comparing the three survival groups, the long‐term survivors (group A) with a median age of 52 
years at diagnosis were younger than the short‐term survivor group B (median age 63 years) and the 
intermediate survival group C (median age 59 years) (p=0.02). No differences between the survival 
groups were found when gender, KPS and the extent of resection at initial surgery were compared. 
MGMT promoter methylated tumors (p<0.001) and IDH1/2 mutant tumors (p<0.001) were more 
frequently found within group A. Being the most frequent first‐line therapy, radiotherapy (RT) plus 
TMZ (temozolomide), was received by all patients in group B and most of group A (24/28) and group 
C (40/46). The remaining 10 out of the 94 patients received either, no additional therapy except for 
surgical resection, only radiotherapy or only TMZ. PFS was, as expected, significantly longer in group 
A patients, with a mean of 26.2 months, than in the other groups (3.5 months for group B and 6.1 
months for group C (p<0.001)). Patients from group A and group C more often received a salvage 
therapy than patients from group B.  
 
 
 
Table 11: Clinical, histological, and molecular patient characteristics according to survival groups  
(Reifenberger and Weber et al., 2014).  
 Total 
n=94 
Group A 
n=28 
Group B 
n=20 
Group C 
n=46 
Age at diagnosis (years)  
Median (range) 58 (25‐80) 52 (25‐74) 63 (37‐80) 59 (28‐74) 
Age classes 
<51 29 (30.9%) 14 (50.0%) 3 (15.0%) 12 (26.1%) 
51‐60 23 (24.5%) 6 (21.4%) 5 (25.0%) 12 (26.1%) 
61‐70 36 (38.3%) 6 (21.4%) 9 (45.0%) 21 (45.7%) 
>70 6 (6.4%) 2 (7.1%) 3 (15.0%) 1 (2.2%) 
Gender 
Female 34 (36.2%) 14 (50.0%) 8 (40.0%) 12 (26.1%) 
Male 60 (63.8%) 14 (50.0%) 12 (60.0%) 34 (73.9%) 
KPS 
<70 5 (5.3%) 1 (3.6%) 2 (10.0%) 2 (4.3%) 
70‐80 45 (47.9%) 17 (60.7%) 9 (45.0%) 19 (41.3%) 
90‐100 44 (46.8%) 10 (35.7%) 9 (45.0%) 25 (54.3%) 
Surgery 
Total 47 (50.0%) 12 (42.9%) 8 (40.0%) 27 (58.7%) 
Subtotal 27 (28.7%) 8 (28.6%) 8 (40.0%) 11 (23.9%) 
Partial 12 (12.8%) 3 (10.7%) 4 (20.0%) 5 (10.9%) 
Biopsy 2 (2.1%) 1 (3.6%) ‐ 1 (2.2%) 
Unknown 6 (6.4%) 4 (14.3%) ‐ 2 (4.3%) 
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Review diagnosis 
Glioblastoma 84 (89.4%) 22 (78.6%) 19 (95.0%) 43 (93.5%) 
Giant cell glioblastoma 1 (1.1%) ‐ ‐ 1 (2.2%) 
Gliosarcoma 3 (3.2%) 1 (3.6%) 1 (5.0%) 1 (2.2%) 
Glioblastoma with 
oligodendroglial component 
6 (6.4%) 5 (17.9%) ‐ 1 (2.2%) 
MGMT promoter methylation status 
Methylated 41 (43.6%) 21 (75.0%) 5 (25.0%) 15 (32.6%) 
Weakly methylated 9 (9.6%) 4 (14.3%) 2 (10.0%) 3 (6.5%) 
Unmethylated 44 (46.8%) 3 (10.7%) 13 (65.0%) 28 (60.9%) 
IDH1/2 mutation status 
IDH1 mutant 14 (14.9%) 10 (35.7%) 1 (5.0%) 3 (6.5%) 
IDH2 mutant 1 (1.1%) 1 (3.6%) ‐ ‐ 
IDH1/2 wildtype 79 (84.9%) 17 (60.7%) 19 (95.0%) 43 (93.5%) 
First-line therapy 
No therapy 1 (1.1%) 1 (3.6%) ‐ ‐ 
RT 8 (8.5%) 3 (10.7%) ‐ 5 (10.9%) 
RT plus TMZ 84 (89.4%) 24 (85.7%) 20 (100%) 40 (87.0%) 
TMZ 1 (1.1%) ‐ ‐ 1 (2.2%) 
Median PFS (95%-CI) in months 
(events) 
6.4 
(2.7‐10.1) 
(89/94) 
26.2 
(24.4‐28.0) 
(23/28) 
3.5 
(2.8‐4.3) 
(20/20) 
6.1 
(5.4‐6.8) 
(46/46) 
First salvage therapy 
Surgery alone 15 (16.0%) 3 (10.7%) 1 (5.0%) 11 (23.9%) 
Surgery plus CT 32 (34.0%)  8 (28.6%) 3 (15.0%) 21 (45.7%) 
RT plus CT 5 (5.3%) 3 (10.7%) ‐ 2 (4.3%) 
CT alone 13 (13.8%) 5 (17.9%) 1 (5.0%) 7 (15.2%) 
OP plus other 1 (1.1%) ‐ ‐ 1 (2.2%) 
No therapy 28 (29.8%) 9 (32.1%) 15 (75.0%) 4 (8.7%) 
Lines of salvage therapy 
1 12 (12.8%) 5 (17.9%) 1 (5.0%) 6 (13.0%) 
2 4 (4.3%) 2 (7.1%) ‐ 2 (4.3%) 
>2 3 (3.2%) 2 (7.1%) ‐ 1 (2.2%) 
Median OS (95%-CI) in months 
(events) 
18.7 
(16.6‐22.7) 
(85/97) 
50.4 
(42.0‐58.8) 
(19/28) 
4.6 
(4.1‐5.1) 
(20/20) 
16.7 
(14.6‐18.8) 
(46/46) 
 
 
All the above mentioned criteria were also analyzed for IDH1/2 wild‐type glioblastoma patients 
only (Table 12), because IDH1/2 wild‐type glioblastomas show a distinct chromosomal profile and 
behavior. The IDH1/2 wild‐type cohort included 79 patients and was also subdivided into the three 
survival groups (group Awt, group Bwt, group Cwt). After the stratification for IDH1/2 wild‐type tumors, 
a difference in median age at diagnosis could no longer be seen. Still, the MGMT promoter 
methylated tumors were more frequent in group Awt (p=0.002). 
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Table 12: Clinical, histological, and molecular characteristics of patients with IDH1/2
wt
 tumors according to 
survival groups (Reifenberger and Weber et al., 2014).  
 Total
wt
 
n=79 
Group A
wt
 
n=17 
Group B
wt
 
n=19 
Group C
wt
 
n=43 
Age at diagnosis (years) 
Median (range) 61 (25‐80) 59 (25‐74) 64 (37‐80) 61 (38‐74) 
Age classes 
<51 16 (20.3%) 4 (23.5%) 2 (10.5%) 10 (23.3%) 
51‐60 22 (27.8%) 6 (35.3%) 5 (26.3%) 11 (25.6%) 
61‐70 35 (44.3%) 5 (29.4%) 9 (47.4%) 21 (48.8%) 
>70 6 (7.6%) 2 (11.8%) 3 (15.8%) 1 (2.3%) 
Gender 
Female 30 (38.0%) 10 (58.8%) 8 (42.1%) 12 (27.9%) 
Male 49 (62.0%) 7 (41.2%) 11 (57.9%) 31 (72.1%) 
KPS 
<70 4 (5.1%) ‐ 2 (10.5%) 2 (4.7%) 
70‐80 38 (48.1%) 12 (70.6%) 8 (42.1%) 18 (41.9%) 
90‐100 37 (46.8%) 5 (29.4%) 9 (47.4%) 23 (53.5%) 
Surgery 
Total 41 (51.9%) 8 (47.1%) 7 (36.8%) 26 (60.5%) 
Subtotal 25 (31.6%) 6 (35.3%) 8 (42.1%) 11 (25.6%) 
Partial 8 (10.1%) 1 (5.9%) 4 (21.1%) 3 (7.0%) 
Biopsy 2 (2.5%) 1 (5.9%) ‐ 1 (2.3%) 
Unknown 3 (3.8%) 1 (5.9%) ‐ 2 (4.7%) 
Review diagnosis 
Glioblastoma 74 (93.7%) 15 (88.2%) 18 (94.7%) 41 (95.3%) 
Giant cell glioblastoma 1 (1.3%) ‐ ‐  1 (2.3%) 
Gliosarcoma 
Glioblastoma with 
oligodendroglial component 
3 (3.8%) 
1 (1.3%) 
1 (5.9%) 
1 (5.9%) 
1 (5.3%) 
‐ 
1 (2.3%) 
‐ 
MGMT promoter methylation status 
Methylated 31 (39.2%) 12 (70.6%) 5 (26.3%) 14 (32.6%) 
Weakly methylated 5 (6.3%) 2 (11.8%) 1 (5.3%) 2 (4.7%) 
Unmethylated 43 (54.4%) 3 (17.6%) 13 (68.4%) 27 (62.8%) 
First-line therapy 
No therapy ‐ ‐ ‐ ‐ 
RT 4 (5.1%) ‐ ‐ 4 (9.3%) 
RT plus CT 75 (94.9%) 17 (100%) 19 (100%) 39 (90.7%) 
CT ‐ ‐ ‐ ‐ 
Median PFS (95%-CI) in months 
(events) 
5.8 
(4.7‐6.9) 
(78/79) 
24.0 
(20.4‐27.7) 
(16/17) 
3.8 
(3.1‐4.4) 
(19/19) 
6.1 
(5.3‐6.9) 
(43/43) 
First salvage therapy 
Surgery alone 12 (15.2%) ‐ 1 (5.3%) 11 (25.6%) 
Surgery plus CT 29 (36.7%) 6 (35.3%) 3 (15.8%) 20 (46.5%) 
RT plus CT 4 (5.1%) 3 (17.6%) ‐ 1 (2.3%) 
CT alone 
OP plus other 
11 (13.9%) 
1 (1.3%) 
4 (23.5%) 
‐ 
1 (5.3%) 
‐ 
6 (14.0%) 
1 (2.3%) 
No therapy 22 (27.8%) 4 (23.5%) 14 (73.7%) 4 (9.3%) 
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Lines of salvage therapy 
1 10 (12.7%) 4 (23.5%) 1 (5.3%) 5 (11.6%) 
2 3 (3.8%) 1 (5.9%) ‐ 2 (4.7%) 
>2 2 (2.5%) 1 (5.9%) ‐ 1 (2.3%) 
Median OS (95%-CI) in months 
(events) 
17.0 
(13.6‐20.3) 
(74/79) 
45.0 
(37.3‐52.6) 
(19/19) 
4.7 
(4.3‐5.1) 
(12/17) 
17.9 
(14.5‐21.3) 
(43/43) 
 
 
3.2.2 Analysis of genomic imbalances in primary glioblastomas by array‐CGH 
From 89 of the 94 patients described in Table 11 and Table 12 (3.2.1, page 55), glioblastoma 
samples were analyzed by array‐CGH. For 70 of the 94 gene expression was determined by 
hybridization to Affymetrix Gene Chip® Human Genome U133 Plus 2.0 arrays in cooperation with the 
GGN and the Institute of Neuropathology, University of Düsseldorf (data not shown; Reifenberger and 
Weber et al., 2014). Unsupervised analysis of the array‐CGH data showed several distinct tumor 
clusters (Figure 10A). In Figure 10, four tumor characteristics are given in addition to the genomic 
imbalance data. First of all, the molecular subtype was determined for each tumor sample according 
to Verhaak et al., 2010 and is depicted in row 1. Most tumors are found to display either, a 
mesenchymal, a classical or a proneural molecular signature. As the second and third category, the 
MGMT promoter methylation and IDH1/2 status were determined and are given in row 2 and 3, 
respectively. In row 4, the survival group is given as long‐term (group A), short‐term (group B) and 
intermediate (group C). No clustering according to the molecular subtype, the MGMT promoter 
methylation status, and the survival groups was apparent (Figure 10). But as apparent in row 3, most 
IDH1/2 mutant tumors form subclusters in the right side of the heatmap. Most of the IDH1/2 wild‐
type glioblastomas demonstrated gains on chromosome 7, losses of chromosomal arm 9p and of 
chromosome 10. Additionally, in about half of the cases gains of chromosomes 19 and 20 and/ or 
losses on chromosomal arms 13q and 22q were detected (Figure 10A). In contrast, IDH1/2 mutant 
tumors demonstrated more heterogeneous imbalance patterns with frequent losses of chromosomal 
arm 1p and 19q. Even though there is no clear clustering based on survival groups or MGMT 
promoter methylation status, two subclusters at the right of the heatmap uniformly show MGMT 
promoter methylated tumors from group A (long‐term survivors) (Figure 10A). However, almost all of 
these tumors also carry an IDH1/2 mutation, so that the three parameters are not independent from 
each other.  
Supervised clustering of genomic imbalances was performed based on the three survival groups. 
This approach revealed the frequent glioblastoma associated imbalances, gains on chromosomes 7, 
19 and 20 as well as losses on chromosomes 10, 13q and 22q, in most of group B and group C tumors 
but only a subset of group A tumors (Figure 10B). However, group A tumors without the frequent 
glioblastoma associated imbalances, most of which carried losses of chromosomal arms 1p and/ or 
19q, had an IDH1/2 mutation. So the different genomic imbalances in these tumors from long‐term 
survivors most likely related to the IDH1/2 status and are no independent prognostic parameters.  
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Figure 10: Heatmap of genomic imbalances in 89 glioblastomas analyzed by array-CGH. 
A: The result of an unsupervised clustering of the array‐CGH data is shown. Depicted on top of the heatmap are 
the molecular subtype (1: classical (CL), mesenchymal (MES), and proneural (PN)), the MGMT promoter 
methylation status (2), the IDH1/2 mutation status (3) and survival groups (4: group A, B and C). Certain 
subclusters were apparent; most IDH1/2
mut
 tumors were clustering together apart from the IDH1/2
wt
 tumors. 
Characteristic for the group of IDH1/2
wt
 tumors were gains on chromosome 7 and losses of chromosome 10 and 
chromosomal arm 9p. In larger subgroups of tumors, gains on chromosomes 19 and 20 and losses on 
chromosomal arm 13q and 22q were detected. IDH1/2
mut
 tumors demonstrated more heterogeneous 
aberration patterns. Group A was distributed more or less evenly over all clusters, showing a shift towards 
IDH1/2
mut
 and MGMT promoter methylated tumors to the right of the heatmap. B: Heatmap of supervised 
clustering of array‐CGH data based on survival groups, revealing the typical glioblastoma imbalances in a subset 
of group A, in the majority of group B and group C tumors (Reifenberger and Weber et al., 2014).  
 
 
Frequency plots of the genomic imbalances in the 89 glioblastoma samples were prepared based 
on survival groups for tumors with an IDH1/2wt status. A separate frequency plot for the IDH1/2mut 
tumors was also prepared (Figure 11). Frequency plots indicate how often a certain chromosomal 
region is gained or lost in a given set of samples. The frequency plots for group Awt, Bwt and Cwt were 
very similar and showed frequent gains on chromosome 7 (approximately 90%), as well as on 
chromosomes 19 and 20 (40% – 50% of cases). Chromosome 10 was lost in most cases (90%). In 
contrast, the frequency plot of IDH1/2mut showed a different pattern, exhibiting chromosomal 
imbalances more widely distributed over various chromosomes. Here, the gain and loss on 
chromosomes 7 (50%) and 10 (40%) were less frequent and more commonly affected the long arm: 
gain on 7q and loss on 10q were both found in around 50% of tumors. Moreover, losses of 
chromosomal arms 1p and 19q were more frequent in IDH1/2mut tumors when compared to the wild‐
type tumor groups (1p: 40% – 50%; 19: 80%). It can also be noted, that in the wild‐type tumors 
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chromosome 19 was frequently gained (40% – 50% of cases), whereas the long arm of chromosome 
19 was lost in the IDH1/2mut tumors.  
 
 
 
Figure 11: Frequency plots of genomic imbalances according to survival groups and IDH1/2 status. 
Shown are the patterns of genomic imbalances in glioblastomas in the three distinct survival groups (group A
wt
 
(n=17), group B
wt
 (n=19) and group C
wt
 (n=43)) and in IDH1/2
mut
 (n=15) tumors. The three IDH1/2
wt
 groups have 
a similar pattern of genomic imbalances with frequent gains on chromosome 7, 19, and 20 as well as a frequent 
loss of chromosome 10. In the IDH1/2
mut
 tumors, a different pattern of genomic imbalances was apparent, the 
gain and loss on chromosomes 7 and 10, respectively, were less frequent. Losses on chromosomal arms 1p and 
19q were more frequent in IDH1/2
mut
 tumor samples. Gains are indicated by green bars, while losses are 
indicated by red bars. Gains and losses are plotted in genomic order from 1p to Yq on the x‐axis. The y‐axis 
indicates the fraction of cases with copy number changes (Reifenberger and Weber et al., 2014). 
 
 
Interestingly, four tumors showed combined losses on 1p and 19q (Figure 10), which is a typical 
change for low‐grade tumors or secondary glioblastomas, especially those with an oligodendroglial 
component. But clinical and histological review confirmed that these tumors were primary 
glioblastomas without a history of preexisting low‐grade lesions. However, three of them also 
displayed an oligodendroglial tumor component. 
The results displayed in Figure 10 and Figure 11 indicate that the genomic imbalances identified 
are linked to the IDH1/2 mutation status, rather than long‐term versus short‐term survival. IDH1/2 
wild‐type tumors show a different pattern of DNA copy number changes then IDH1/2 mutant tumors.  
It is of interest to compare frequencies of copy number changes of selected genes in different 
tumor groups. Table 13 summarizes the frequency of gene copy number changes in selected 
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chromosomal regions, harboring glioma‐related tumor suppressor genes or oncogenes. The table 
gives frequencies of copy number changes in IDH1/2 wild‐type glioblastomas from the distinct 
survival groups as well as in IDH1/2 mutant tumors. After adjusting for multiple testing, there was no 
significant difference in the frequency of any copy number change in the long‐term survival group 
(group A) as compared to the groups with shorter survival times (see column “p‐value IDH1/2wt”). 
Taking the IDH1/2 status into account, several significant differences were detected in the IDH1/2wt 
versus IDH1/2mut tumors (see column “p‐value IDH1/2mut”). Frequencies of low and high level 
amplifications were different for PMS2, EGFR, HGF, CDK6, XRCC1, whereas frequencies of low or high 
level losses were different for CDKN2C, CDKN2A/B, PTEN, XRCC1 and XRCC3. The association between 
gene copy number changes in candidate genes and survival groups with respect to IDH1/2 mutation 
were analyzed by Fisher’s Exact Test using IBM SPSS Statistics Version 20. 
 
 
Table 13: Frequency of copy number changes in different chromosomal regions containing glioma-associated 
tumor suppressor genes or oncogenes (modified from Reifenberger and Weber et al., 2014). 
Chromosomal 
region (hg19) 
Candidate 
genes 
Group A
wt
 
n=17 
Group B
wt
 
n=19 
Group C
wt
 
n=43 
p-value 
IDH1/2
wt
 
Group 
IDH1/2
mut
 
n=15 
p-value 
IDH1/2
mut
 
Low- and high-level amplifications 
1q32.1 MDM4 
(RP11‐563I16) 
PIK3C2B  
(RP11‐739N20) 
6/15 (40%) 3/17 
(18%) 
16/38 
(42%) 
0.199 1/12 
(8%) 
0.092 
1q44  
 
AKT3 
(RP11‐269F20,  
RP11‐370K11) 
3/15 
(20%) 
3/16 
(19%) 
6/41 
(15%) 
0.756 1/12 
(8%) 
0.681 
4q12 PDGFRA 
(RP11‐231C18) 
5/15 
(33%) 
1/16 
(6%) 
10/40 
(25%) 
0.146 2/12 
(17%) 
1.0 
6p21.1 CCND3 
(RP5‐973N23, 
RP11‐533O20) 
2/15 
(13%) 
2/17 
(12%) 
2/41 
(5%) 
0.453 1/12  
(8%) 
1.0 
7p22.1 PMS2 
(RP11‐90J23) 
11/13 
(85%) 
13/15 
(87%) 
28/35 
(80%) 
0.906 4/11 
(36%) 
0.003 
7p11.2 EGFR 
(RP5‐1091E12, 
RP11‐339F13) 
14/15 
(93%) 
14/15 
(93%) 
31/33 
(94%) 
1.0 4/11 
(36%) 
<0.001 
7q21.11 HGF 
(RP5‐1098B1) 
9/12 
(75%) 
12/13 
(92%) 
34/37 
(92%) 
0.239 5/9 
(56%) 
0.027 
7q21.2 CDK6 
(RP5‐850G1) 
13/14 
(93%) 
10/11 
(91%) 
34/39 
(87%) 
1.0 7/11 
(64%) 
0.050 
7q31.2 MET 
(CTB‐13N12) 
11/11 
(100) 
13/14 
(93%) 
28/35 
(80%) 
0.252 6/10 
(60%) 
0.061 
13q34 SOX1 
(RP11‐310D8) 
0/15 0/16 5/41 
(12%) 
0.217 3/12 
(25%) 
0.083 
14q32.33 AKT1 
(RP11‐982M15) 
3/12 
(25%) 
2/14 
(14%) 
11/29 
(38%) 
0.257 0/9 0.097 
19p13.3 STK11 
(RP11‐50C6) 
4/12 
(33%) 
8/15 
(53%) 
17/28 
(61%) 
0.290 4/11 
(36%) 
0.511 
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19q13.31 XRCC1 
(CTB‐61I7, 
RP11‐46C6, 
RP11‐122E7)  
6/15 
(40%) 
5/17 
(29%) 
16/39 
(41%) 
0.758 1/12 
(8%) 
0.052 
19q13.32 ERCC2 
(RP11‐43E18) 
3/10 
(30%) 
3/13 
(23%) 
19/37 
(51%) 
0.178 2/12 
(17%) 
0.190 
20q12 TOP1 
(RP3‐511B24) 
2/10 
(20%) 
6/15 
(40%) 
22/36 
(61%) 
0.050 3/10 
(30%) 
0.320 
High level amplifications 
1q32.1 MDM4 
(RP11‐563I16), 
PIK3C2B 
(RP11‐739N20) 
1/15 
(7%) 
0/17 
 
5/38 
(13%) 
0.333 0/12 0.585 
1q44 AKT3 
(RP11‐269F20, 
RP11‐370K11) 
0/15 0/16 1/41 
(2%) 
1.0 0/12 1.0 
4q12 PDGFRA 
(RP11‐231C18) 
2/15 
(13%) 
0/16 2/40 
(5%) 
0.302 0/12 1.0 
6p21.1 CCND3 
(RP5‐973N23, 
RP11‐533O20) 
0/15 0/17 0/41 ‐ 0/12 ‐ 
7p22.1 PMS2 
(RP11‐90J23) 
0/13 0/15 0/35 ‐ 0/11 ‐ 
7p11.2 EGFR 
(RP5‐1091E12, 
RP11‐339F13) 
10/15 
(67%) 
4/15 
(27%) 
21/33 
(64%) 
0.043 0/11 0.001 
7q21.11 HGF 
(RP5‐1098B1) 
0/12 0/13 0/37 ‐ 0/9 ‐ 
7q21.2 CDK6 
(RP5‐850G1) 
0/14 0/11 0/39 ‐ 0/11 ‐ 
7q31.2 MET 
(CTB‐13N12) 
0/11 0/14 0/35 
(0%) 
‐ 0/10 ‐ 
13q34 SOX1 
(RP11‐310D8) 
0/15 0/16 1/41 
(2%) 
1.0 0/12 1.0 
14q32.33 AKT1 
(RP11‐982M15) 
0/12  0/14 0/29 ‐ 0/9 ‐ 
19p13.3 STK11 
(RP11‐50C6) 
0/12 1/15 
(7%) 
1/28 
(4%) 
1.0 0/11 1.0 
19q13.31 XRCC1 
(CTB‐61I7, 
RP11‐46C6, 
RP11‐122E7) 
0/15 0/17 0/39 ‐ 0/12 ‐ 
19q13.32 ERCC2 
(RP11‐43E18) 
0/10 0/13 0/37 ‐ 0/12 ‐ 
20q12 TOP1 
(RP3‐511B24) 
0/10 0/15 0/36 ‐ 0/10 ‐ 
Low- and high-level losses 
1p36.32 AJAP1 
(RP11‐319A11) 
1/7 
(14%) 
6/12 
(50%) 
7/28 
(25%) 
0.258 3/8 
(38%) 
0.692 
1p36.23 CAMTA1 
(RP11‐92O17, 
RP11‐338N10) 
4/15 
(27%) 
8/17 
(47%) 
11/38 
(29%) 
0.364 4/11 
(36%) 
1.0 
RESULTS 
 
- 64 - 
1p32.3 CDKN2C 
(RP11‐116M11) 
1/12 
(8.3%) 
4/16 
(25%) 
9/36 
(25%) 
0.553 6/11 
(55%) 
0.058 
1q42.12 PARP1 
(RP11‐15H13) 
0/12 0/12 4/33 
(12%) 
0.476 0/10 1.0 
6q26 PARK2 
(RP11‐30F7, 
RP11‐1069J22) 
3/13 
(23%) 
3/17 
(18%) 
8/36 
(22%) 
1.0 3/12 
(25%) 
0.718 
9p23‐p24.1 PTPRD 
(RP11‐175E13, 
RP11‐12I16) 
7/14 
(50%) 
11/16 
(69%) 
14/41 
(34%) 
0.056 6/12 
(50%) 
0.765 
9p21.3 CDKN2A/B 
(RP11‐149I2) 
13/15 
(87%) 
13/16 
(81%) 
35/41 
(85%) 
0.906 6/12 
(50%) 
0.013 
10q23.31 PTEN 
(RP11‐380G5) 
15/15 
(100%) 
16/16 
(100%) 
39/40 
(98%) 
1.0 5/12 
(42%) 
<0.001 
13q14.2 RB1 
(RP11‐305D15, 
RP11‐174I10) 
5/14 
(36%) 
6/16 
(38%) 
17/41 
(42%) 
0.946 3/12 
(25%) 
0.521 
14q32.33 XRCC3 
(RP11‐73M18) 
1/11 
(9%) 
2/14 
(14%) 
11/38 
(29%) 
0.362 6/10 
(60%) 
0.021 
17p13.1 TP53 
(P5‐1030O14, 
RP11‐199F11) 
3/14 
(18%) 
6/16 
(27%) 
8/40 
(17%) 
0.379 5/12 
(29%) 
0.289 
17q11.2 NF1 
(RP11‐1107G21, 
CTD‐2370N5) 
0/15 
(0%) 
5/17 
(29%) 
8/41 
(20%) 
0.078 1/12 
(8%) 
0.681 
19q13.31 XRCC1 
(CTB‐61I7, 
RP11‐46C6, 
RP11‐122E7) 
1/15 
(7%) 
2/17 
(12%) 
7/39 
(18%) 
0.661 9/12 
(75%) 
<0.001 
19q13.32 TIMP3 
(RP11‐419C14, 
XXbac‐677f7, 
RP11‐616G18) 
5/15 
(33%) 
9/17 
(53%) 
15/41 
(37%) 
0.472 4/12 
(33%) 
0.759 
 
High-level losses 
1p36.32 AJAP1 
(RP11‐319A11) 
0/7 0/12 0/28 ‐ 0/8 ‐ 
1p36.23 CAMTA1 
(RP11‐92O17, 
RP11‐338N10) 
1/15 
(7%) 
0/17 1/38 
(3%) 
0.441 2/11 
(18%) 
0.087 
1p32.3 CDKN2C 
(RP11‐116M11) 
0/12 0/16 0/36 ‐ 0/11 ‐ 
1q42.12 PARP1 
(RP11‐15H13) 
0/12 0/12 0/33 ‐ 0/10 ‐ 
6q26 PARK2 
(RP11‐30F7, 
RP11‐1069J22) 
0/13 0/17 0/36 ‐ 0/12 ‐ 
9p23‐p24.1 PTPRD 
(RP11‐175E13, 
RP11‐12I16) 
0/14 0/16 0/41 ‐ 0/12 ‐ 
9p21.3 CDKN2A/B 
(RP11‐149I2) 
5/15 
(33%) 
9/16 
(56%) 
22/41 
(54%) 
0.382 3/12 
(25%) 
0.129 
10q23.31 PTEN 
(RP11‐380G5) 
1/15 
(7%) 
1/16 
(6%) 
0/40 0.187 0/12 ‐ 
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13q14.2 RB1 
(RP11‐305D15, 
RP11‐174I10) 
0/14 0/16 0/41 ‐ 0/12 ‐ 
14q32.33 XRCC3 
(RP11‐73M18) 
0/11 0/14 0/38 ‐ 0/10 ‐ 
17p13.1 TP53 
(P5‐1030O14, 
RP11‐199F11) 
0/14 
 
0/16 0/40 ‐ 0/12 ‐ 
17q11.2 NF1 
(RP11‐1107G21, 
CTD‐2370N5) 
0/15 
 
0/17 0/41 ‐ 0/10 ‐ 
19q13.31 XRCC1 
(CTB‐61I7, 
RP11‐46C6, 
RP11‐122E7) 
0/15 0/17 0/39 ‐ 0/12 ‐ 
19q13.32 ERCC2 
(RP11‐43E18) 
0/10 0/13 0/37 ‐ 1/12 
(8%) 
0.167 
22q12.3 TIMP3 
(RP11‐419C14, 
XXbac‐677f7, 
RP11‐616G18) 
0/15 0/17 0/12 ‐ 0/12 ‐ 
 
 
 
3.2.3 Combined analyses of genomic and expression data – gene dosage effects 
For 70 of the glioblastoma samples, mRNA expression data was also available, prepared in 
cooperation with the GGN and the Institute of Neuropathology, University of Düsseldorf. In order to 
see if there was a gene dosage effect on mRNA expression a combined analysis of these two data sets 
was performed. Figure 12 and Figure 13 show the results of a combined analysis of array‐CGH and 
expression data in 70 glioblastomas. 
The gene expression data obtained was related to the previously delineated neural, proneural, 
classical and mesenchymal glioblastoma subtypes (Verhaak et al., 2010). While none of the tumors 
displayed a neural expression profile, proneural, classical and mesenchymal signatures were 
identified. A supervised clustering of the chromosomal imbalances according to the molecular 
subtypes defined by the expression data is depicted in Figure 12. The heatmap indicates that all 
classical and mesenchymal tumors are IDH1/2 wild‐type and frequently harbor gains on 
chromosomes 7, 19, and 20 as well as losses on chromosomes 10 and 22q. The proneural cases 
showed a more heterogeneous array‐CGH pattern, composed of more losses than gains. In a subset 
of proneural tumors with mutant IDH1/2, deletions of chromosomal arms 1p and/ or 19q were 
detected.  
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Figure 12: Heatmap of supervised clustering of array-CGH data based on molecular subtypes of glioblastomas 
(classical, mesenchymal, proneural) inferred from gene expression data. 
Depicted on top of the heatmap are the survival groups (A: long‐term survivor, B: short‐term survivor, C: 
intermediate survivor), the MGMT promoter methylation status, the IDH1/2 mutation status, and the molecular 
subtypes (blue: classical (CL), green: mesenchymal (MES), and purple: proneural (PN)). All mesenchymal and 
classical tumors are IDH1/2
wt 
and show typical genomic imbalances including gain on chromosome 7 and loss of 
chromosome 10. IDH1/2
mut
 tumors are all in the proneural group and frequently show 1p and 19q losses. The 
graph below the heatmap indicates the total fraction of chromosomal segments demonstrating copy number 
gains or losses in each tumor sample (Reifenberger and Weber et al., 2014).  
 
 
 
Genomic alterations such as copy number variants might influence the expression of genes located 
in the affected chromosomal regions. Therefore, each chromosome was analyzed separately and the 
influence of the detected gain or loss on the gene expression was assessed by box plots. The box blots 
in Figure 13 demonstrate that there are a number of cis‐regulatory gene dosage effects on gene 
expression, which are similar in the IDH1/2 wild‐type survival groups but different in the IDH1/2 
mutant group. Percentages of cases with gains or losses involving each chromosome and the relative 
expression values for all genes located on a particular chromosome are shown for the distinct survival 
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groups. Although, losses on chromosome 14 were significantly less frequent in the long‐term survival 
group Awt, than in the short or intermediate survival group (Bwt or Cwt), this difference had only slight 
effects on the differential gene expression. For the IDH1/2 mutant tumors, a frequent chromosome 1 
loss was detected which also resulted in a significant reduction of gene expression. A similar effect is 
also seen for the IDH1/2 wild‐type groups and chromosome 10. Here, a frequent monosomy in 
IDH1/2 wild‐type tumors results in a reduced expression of the genes on this chromosome. In 
contrast, IDH1/2 mutant tumors display a higher expression of these genes and a less frequent loss of 
chromosome 10. Further, the frequent gain of chromosome 7 was also associated with a higher gene 
expression in IDH1/2 wild‐type tumors. In addition, significant changes between the IDH1/2 wild‐type 
groups and the IDH1/2 mutant tumors could be detected for chromosomes 19 and 20. Here, the gain 
of the chromosome yielded an increased gene expression in the IHD1/2 wild‐type groups.  
Analyzing the short and the long arms of each chromosome separately for gene dosage effects, 
revealed similar results in most cases as when the entire chromosomes were analyzed. This also 
included the chromosomes 7 and 10 (data not shown). In the case of chromosome 1 and 19, the gene 
dosage effects were restricted to genes located on the chromosomal arms 1p and 19q (data not 
shown). 
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Figure 13: Demonstration of the gene dosage effect by combination of array-CGH and mRNA expression data. 
In the box plots, the percentage of gains or losses for each chromosome and the relative expression values of all 
genes located on the respective chromosomes in the different patient groups are shown. Stars demonstrate 
significant differences. Gene dosage effects were detectable for several copy number changes, for example 
gains of chromosome 7 and losses of chromosomes 10 and 19. Differences were mostly seen between the 
IDH1/2
wt
 and IDH1/2
mut
 tumors. Among the IDH1/2
wt
 tumors, significant changes were seen for the loss of 
chromosome 14, which was less frequent in group A
wt
, or the loss of chromosome 19 which was more frequent 
in group C
wt
 tumors. But both changes did not have a significant gene dosage effect. Please note the scales: For 
chromosome 7 the box plots indicate gains close to 100% and likewise for chromosome 10 almost losses in 
100% groups A
wt
, B
wt
, C
wt
 (ceiling effect) (Reifenberger and Weber et al., 2014). 
 
 
In summary, the characterization of long‐term survivors in 98 primary glioblastoma patients using 
genome‐wide profiling revealed that the survival is more closely related to the IDH1/2 mutation 
status than to any other genetic alteration. IDH1/2 wild‐type glioblastomas displayed a genomic 
profile distinct from that of IDH1/2 mutant tumors. Patients with glioblastomas harboring IDH1/2 
mutations had a better prognosis and a higher probability for long‐term survival. In addition, MGMT 
promoter methylation was more often found in the group of long‐term survivors.  
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3.3 Project 3: Genomic patterns of recurrence in IDH1/2 wild‐type glioblastomas, WHO 
grade IV  
Glioblastoma show a tendency to recur in spite of combined surgical resection, radiotherapy and 
TMZ chemotherapy. After recurrence tumor grade is unchanged, i.e. it is still WHO grade IV, and the 
histopathology is similar. The question arises whether there are differences in the primary and the 
recurrent tumor on a molecular level. Genome‐wide DNA microarrays were used to assess and 
compare the chromosomal imbalances of 27 primary and recurrent glioblastoma tumor pairs. All 27 
tumors pairs were classified as IDH1/2 wild‐type tumors. This is important, because IDH1/2 wild‐type 
tumors genetically differ from the ones containing an IDH1/2 mutation and, therefore display a 
distinct genomic profile (3.2.2, Figure 11, page 61). The aim of this project was to identify possible 
DNA copy number differences between primary and recurrent tumor from the same patient, and if 
so, to determine candidate genes that are located within the chromosomal regions with a copy 
number difference that are associated with therapy response and or tumor recurrence. Project 3 has 
been published in Riehmer et al., 2014 (in press). 
The clinical, histological, and molecular patient characteristics in the study group are listed in  
Table 14. The study group included 27 patients, 17 male and 10 female, with a median age of 63 
years. All patients underwent a tumor resection as first line therapy, additionally the majority were 
treated with radiotherapy (RT) and TMZ chemotherapy (22/27, 81.5%). The remaining 5 patients 
(18.5%) were treated with RT alone. Considering the MGMT promoter methylation status, 59% of 
tumors were unmethylated, as compared to 41% of tumors being methylated. The median time 
between primary and secondary surgery was 9.1 months. While the overall survival was on average 
16 months (Table 15, page 77), all patients have died eventually. 
In order to determine whether the selected 27 patients in this study were representative of 
glioblastoma patients with similar initial disease characteristics, a reference group was selected, 
consisting of 52 patients from the initial GGN cohort (Weller et al., 2009). Patients in this reference 
group were also treated with surgery and RT plus TMZ, or surgery and RT alone, had at least one 
surgical reintervention due to disease progression. All tumors were IDH1/2 wild‐type. In comparison, 
the 27 patients in the study group did not differ significantly from the patients of the reference group. 
One exception was the patients’ age at diagnosis, which was slightly but not significantly younger for 
the reference group with a median age of 57 years (p=0.083) (Table 14). 
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Table 14: Clinical, histological, and molecular patient characteristics of study and reference group (Riehmer et 
al., 2014, in press).  
 All patients (n=27) Reference group (n=52) 
Age at diagnosis (years) 
  Median 63 
38‐70 
57 
29‐74   Range 
Age classes 
  <50 years   5  (18.5%) 16  (30.8%) 
  51‐60 years   8  (29.6%) 21  (40.4%) 
  61‐70 years 14  (51.9%) 12  (23.1%) 
  > 70 years   ‐    3  (5.8%) 
Gender 
  Male 17  (63.0%) 39 (75.0%) 
  Female 10  (37.0%) 13 (25.0%) 
KPS 
  90‐100 15  (55.6%) 30  (60.0%) 
  70‐80 10  (37.0%) 18  (36.0%) 
  <70   2  (7.4%)   2  (4.0%) 
  No data   ‐    2  
Primary surgery 
  Gross total resection 14  (53.8%) 32  (62.7%) 
  Subtotal resection (50‐99%)   9  (34.6%) 16  (31.4%) 
  Partial resection (<50%)   3  (11.5%)   3  (5.9%) 
  No data   1    1  
Location (primary tumor) 
  Frontal 6  (23.1%) 13  (25.0%) 
  Temporal 5  (19.2%) 16  (30.8%) 
  Parietal 6  (23.1%) 7  (13.5%) 
  Occipital ‐    5  (9.6%) 
  Other ‐  1  (1.9%) 
  Not localized to one site 9  (34.6%) 9  (17.3%) 
  Multifocal ‐  1  (1.9%) 
  No data 1  ‐  
Review diagnosis 
  Glioblastoma 25  (92.6%) 49  (94.2%) 
  Gliosarcoma   1  (3.7%)   1  (1.9%) 
  Giant cell glioblastoma   1  (3.7%)   2  (3.8%) 
First-line therapy 
RT only 5  (18.5%) 6  (11.5%) 
RT plus TMZ   22  (81.5%) 46  (88.5%) 
Second-line therapy 
  Surgery alone  10  (37.0%) 13  (25.0%) 
  Surgery plus RT    ‐    1  (1.9%) 
  Surgery plus RT plus TMZ/other CT    3  (11.1%)   5  (9.6%) 
  Surgery plus RT plus other CT    ‐    5  (9.6%) 
  Surgery plus TMZ/other CT    3  (11.1%)   9  (17.3%) 
  Surgery plus other CT  11  (40.7%) 19  (36.5%) 
MGMT promoter methylation (primary tumor) 
  Strong methylation   9  (33.3%) 20  (38.5%) 
  Weak methylation   2  (7.4%)   6  (11.5%) 
  No methylation 16  (59.3%) 26  (50.0%) 
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Second surgery 
  Gross total resection 8  (30.8%) 25  (51.0%) 
  Subtotal resection (50‐99%) 14  (53.8%) 19  (38.8%) 
  Partial resection (<50%) 4  (15.4%)   5  (10.2%) 
  No data   1  3  
Location (recurrent tumor) 
  Frontal 6  (22.2%) 12  (24.0%) 
  Temporal 6  (22.2%) 11  (22.0%) 
  Parietal 1  (3.7%)   6  (12.0%) 
  Occipital 3  (11.1%)   4  (8.0%) 
  Other 1  (3.7%)   2  (4.0%) 
  Not localized to one site 9  (33.3%) 14  (28.0%) 
  Multifocal 1  (3.7%) 1  (2.0%) 
  No data ‐    2  
 
 
3.3.1 Frequency and pattern of DNA copy number changes in the primary glioblastomas 
Array‐CGH of 27 primary and recurrent tumor pairs was performed. In Figure 14 the frequency of 
DNA detected copy number changes (A) and the pattern of copy number changes (B) in the primary 
tumors are shown. The frequency plot of the 27 primary glioblastomas shows a typical profile for 
IDH1/2 wild‐type glioblastomas. These typical changes include a gain on chromosome 7 (90%) as well 
as losses on chromosomal arm 9p (80%) and chromosome 10 (95%). In about half of the tumors, gains 
on chromosomes 19 and 20 were also detected. In one third of the tumors, a loss on the 
chromosomal arm 13q was also detected (Figure 14A). Unsupervised clustering of the array‐CGH data 
revealed two major clusters, separated mainly on the basis of the presence or absence of gains on 
chromosomes 19 and 20 (Figure 14B). 
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Figure 14: Frequency and pattern of DNA copy number changes in primary glioblastomas (n=27). 
A: The frequency plot of 27 primary glioblastomas shows a gain on chromosome 7 and losses on chromosomal 
arm 9p and chromosome 10 for almost all cases. For about half of the cases, gains of chromosomes 19 and 20 
were also detected. The frequency pattern shown here is typical for glioblastomas with IDH1 and IDH2 wild‐
type status. Gains are highlighted in green and losses in red. The copy number changes are plotted in genomic 
order from 1p to Yq on the x‐axis. The y‐axis indicates the fraction of cases with copy number change. B: The 
heatmap shows the results of unsupervised clustering of array‐CGH data from the primary glioblastomas (n=27). 
Two subclusters are apparent, reflecting the presence or absence of gains on chromosomes 19 and 20. Green 
indicates a gain of chromosomal material and red a loss (Riehmer et al., 2014, in press). 
 
 
3.3.2 Comparison of genomic profiles in primary and recurrent glioblastoma pairs yields 
three subgroups 
An overall aim was to identify possible chromosomal copy number differences between primary 
and recurrent tumors. Therefore, the genomic profiles of primary and recurrent glioblastomas were 
compared. In order to correct for the different tumor cell content in the analyzed tumor samples, 
robust linear regression was used for pairwise value adjustment. Difference profiles of primary and 
recurrent tumor pairs were generated for all tumors, enabling to detect qualitative differences in the 
array‐CGH profiles of primary and recurrent tumor pairs. 
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These difference profiles showed three distinctive patterns (relapse signatures) named Equal, 
Sequential, and Discrepant. Based on the difference profiles, the glioblastoma pairs were classified 
into one of these relapse groups. Equal pairs had a balanced difference profile, meaning that no 
qualitative difference between the genomic profile of the primary and respective recurrent tumor 
could be detected. Seven of the 27 tumor pairs (26%) were classified as Equal, an example is shown in 
Figure 15 (page 74). Sequential pairs had difference profiles showing additional copy number changes 
in the recurrent tumors. An example of a tumor pair belonging to the Sequential group, which 
encompassed nine of 27 samples (33%), is depicted in Figure 16 (page 75). The third group was 
termed Discrepant, demonstrating the most pronounced differences between primary and recurrent 
tumor. The term Discrepant was chosen, because the difference profile did not only show additional 
copy number changes, but, in addition, some chromosomal imbalances were no longer present in the 
recurrent tumor. Eleven of the 27 tumor pairs (41%) were classified as Discrepant, an example is 
shown in Figure 17 (page 76). 
Clinical characteristics of patients in each molecular relapse group are listed in Table 15 (page 77). 
For most parameters studied, no noticeable differences were detected, in the three patient groups. 
The age distribution for the Equal and Sequential groups was similar. In the Discrepant group, the age 
was higher, with a higher fraction of patients between 60 and 70 years of age. Nevertheless, the 
median age at diagnosis was similar in all groups. Considering the gender distribution, the Equal 
group consisted almost only of males, while in the Sequential and Discrepant groups, the gender 
distribution was almost identical. The median KPS was 90 in all three groups. The extent of resection 
was also similar in all groups, although the fraction of patients with gross total resection was lower in 
the Equal group. In the Sequential group, no patient had a frontal localization of the tumor, instead 
more patients were found to have multiple locations compared to the Equal and Discrepant groups. 
In addition, there was a higher fraction of cases treated with radiotherapy only in the Sequential 
group. No differences regarding the overall survival (p=0.375) or time between primary and 
secondary surgery (p=0.334) were found when comparing the three relapse groups. 
 
RESULTS 
 
- 74 - 
 
Figure 15: Comparison of genomic profiles in paired primary and recurrent glioblastomas: example for an 
Equal tumor pair.  
Genomic profiles of glioblastoma pair 27/28 are shown, together with the completely balanced difference 
profile (bottom), demonstrating that the primary (case 27: top profile) and recurrent (case 28: middle profile) 
tumor share all copy number changes. In all genomic profiles, the midpoints of all BAC clones are plotted in 
genomic order from 1p to Yq on the x‐axis against their normalized log2 test to reference ratio on the y‐axis 
(Riehmer et al., 2014, in press). 
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Figure 16: Comparison of genomic profiles in paired primary and recurrent glioblastomas: example for a 
Sequential tumor pair. 
Genomic profiles of tumor pair (25/26) are shown, including the difference profile (bottom). Though primary 
(case 25: top profile) and recurrent tumor (case 26: middle profile) share copy number changes, additional copy 
number changes can be detected in the recurrent tumor (horizontal blue line, additional gain: here on 8q (copy 
number up regulation in recurrent tumor); horizontal pink line, additional loss: here on 17p (copy number down 
regulation in recurrent tumor)). Horizontal gray lines in the array‐CGH profiles of the primary and the recurrent 
tumor indicate a copy number change present in both primary and recurrent tumor. In all genomic profiles, the 
midpoints of all BAC clones are plotted in genomic order from 1p to Yq on the x‐axis against their normalized 
log2 test to reference ratio on the y‐axis (Riehmer et al., 2014, in press). 
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Figure 17: Comparison of genomic profiles in paired primary and recurrent glioblastomas: example for a 
Discrepant tumor pair. 
Genomic profiles of tumor pair (19/20), including the difference profile (bottom), demonstrating that the 
primary (case 19: top profile) and the recurrent (case 20: middle profile) share copy number changes. Additional 
copy number changes are apparent (horizontal blue line, additional amplification: here on 3q (copy number up 
regulation in recurrent tumor); horizontal pink line, additional loss: here of chromosome 3 (copy number down 
regulation in recurrent tumor)). Changes no longer present are also depicted (horizontal yellow line, gain in the 
primary tumor no longer present in the recurrent tumor: here on 7q and 9q (copy number down regulation in 
the recurrent tumor); horizontal purple line, a loss in the primary tumor no longer present in the recurrent 
tumor: here of chromosome 21 (copy number up regulation in recurrent tumor)). Horizontal gray lines in the 
array‐CGH profiles of the primary and the recurrent tumor indicate a copy number change present in both 
primary and recurrent tumor. In all genomic profiles, the midpoints of all BAC clones are plotted in genomic 
order from 1p to Yq on the x‐axis against their normalized log2 test to reference ratio on the y‐axis (Riehmer et 
al., 2014, in press). 
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Table 15: Clinical characteristics of study group by molecular relapse pattern  
(Riehmer et al., 2014, in press). 
  
Equal 
(n=7) 
Sequential 
(n=9) 
Discrepant 
(n=11) 
Total 
(n=27) 
Age at diagnosis (years) 
Median 58 58 64 63 
Range 44‐70 38‐66 49‐68 38‐70 
Age classes (years) 
<50 2 2 1 5 
51‐60 2 3 3 8 
61‐70 3 4 7 14 
Gender 
Male 6 5 6 17 
Female 1 4 5 10 
KPS 
90‐100 4 5 6 15 
70‐80 3 2 5 10 
<70 ‐ 2 ‐ 2 
MGMT promoter methylation (primary tumor) 
No methylation 5 4 7 16 
Weak methylation ‐ 2 ‐ 2 
Strong methylation 2 3 4 9 
MGMT promoter methylation (recurrent tumor) 
No methylation 5 5 8 18 
Weak methylation ‐ 2 ‐ 2 
Strong methylation 
No data 
2 
0 
1 
1 
3 
‐ 
6 
1 
Primary surgery 
Gross total resection 2 5 7 14 
Subtotal resection (50‐99%) 4 2 3 9 
Partial resection (<50%) 1 2 0 3 
No data 0 0 1 1 
Location region (primary tumor) 
Frontal  1 ‐ 5 6 
Temporal 2 2 1 5 
Parietal 1 1 4 6 
Not localized to one side 3 5 1 9 
No data 0 1 ‐ 1 
Location side (primary tumor) 
Left 5 2 6 13 
Right 2 7 5 14 
First-line therapy 
RT only 1 3 1 5 
RT plus TMZ 6 6 10 22 
TMZ cycles 
0‐2 1 3 3 7 
3‐5 2 0 4 6 
6‐7 3 1 3 7 
11 0 2 0 2 
No data  1 3 1 5 
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Time between primary and secondary surgery 
Months 
Median (95% CI) 
7.4 
(6.7‐8.2) 
10.9 
(6.9‐14.8) 
9.1 
(5.5‐12.8) 
9.1 
(5.9‐12.4) 
Overall survival 
Months 15.9 17.9 14.9 16.0 
Median (95% CI) (15.4‐16.4) (12.3‐23.6) (8.2‐21.6) (14.2‐17.7) 
 
 
3.3.3 Aberration frequency in the three molecular relapse groups 
In order to compare the copy number changes in the molecular relapse groups (Equal, Sequential 
and Discrepant), frequency plots were prepared for primary and recurrent tumors. Figure 18 
demonstrates the frequency and extent of genomic imbalances in primary and recurrent tumors with 
Equal, Sequential and Discrepant signatures. The frequencies of the most common copy number 
changes were similar in the primary tumors of the three groups. Frequent chromosomal imbalances 
were gains on chromosomes 7, 19, and 20 as well as losses on chromosomes 10, chromosomal arms 
13q and 22q. 
 
 
 
Figure 18: Frequency plots of primary and recurrent glioblastomas according to the molecular relapse 
subtype: Equal (A), Sequential (B), and Discrepant (C).  
Primary glioblastomas from the three relapse groups depicted on the left side show chromosomal imbalances at 
similar frequencies. Gains on chromosomes 7, 19 and 20 as well as losses on chromosome 10 and chromosomal 
arm 13q, are found at similar frequencies in all groups. Losses on chromosome 9 are less frequent in the Equal 
group when compared to the Sequential and Discrepant tumors. Frequency plots for the recurrent tumors are 
shown on the right side. A: The frequency plots for the Equal tumor pairs (n=7) are identical. B: For the 
Sequential group (n=9) few additional changes are seen in the recurrent tumors. C: In the Discrepant group 
(n=11), some differences in primary and recurrent tumors can be seen. Gains are indicated in green, losses are 
indicated in red. Gains and losses are plotted in genomic order from 1p to Yq on the x‐axis. The y‐axis indicates 
the fraction of cases with copy number changes (Riehmer et al., 2014, in press). 
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Even though a circumscribed loss on chromosome arm 9p was found in tumors of all groups, the 
region of loss was larger in the Sequential and Discrepant group, i.e. in these cases the loss more 
frequently encompassed the entire short arm and sometimes even the long arm of chromosome 9 
(Figure 18 and Figure 19). Additionally, losses in chromosomal sub‐band 9p21.3 were more 
pronounced in primary tumors with Sequential and Discrepant signatures. While the primary tumors 
of the Equal group only showed losses of chromosomal sub‐band 9p21.3, Sequential and Discrepant 
tumors also exhibited pronounced losses, of this chromosomal region (Figure 19 and Table 16). Losses 
with a log2 test to reference ratio in the range of 0.3 to ‐1 may correspond to heterozygous deletions, 
whereas pronounced losses with a ratio lower than ‐1 more likely correspond to homozygous 
deletions. The log2 ratio of the lowest blue or orange clones in Figure 19 containing the genes 
CDKN2A/B or ELAVL2 in Sequential or Discrepant tumors even reached a value of ‐2. 
 
 
 
Figure 19: Comparison of array-CGH profiles on chromosomal arm 9p in Equal versus Sequential (A) and Equal 
versus Discrepant (B) primary tumors.  
Midpoints of BAC clones from all tumors (Equal (n=7): grey clones; Sequential (n=9): blue clones; Discrepant 
(n=11): orange clones) were plotted in genomic order from 9p24.3 to 9p11.2 on the x‐axis against their 
normalized log2 test to reference ratio on the y‐axis. While equal tumors (grey clones) show a circumscribed loss 
in 9p21.3 harboring genes like FOCAD, CDKN2A/CDKN2B and ELAVL2, they are balanced in other parts of 9p. 
Sequential (blue) and Discrepant (orange) tumors show losses throughout 9p. Additionally, losses in 9p21.3 are 
more pronounced in Sequential and Discrepant than in Equal tumors (see arrows pointing to clones containing 
FOCAD, CDKN2A/CDKN2B, and ELAVL2: upper arrow for each gene, pointing to the grey clone with the most 
pronounced loss; lower arrow for each gene, pointing to the blue (A) or orange (B) clone with the most 
pronounced loss) (Riehmer et al., 2014, in press). 
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Since the short arm of chromosome 9 displayed the biggest difference in the frequency plots 
(Figure 18, page 78), a literature search was done in order to identify genes located on chromosomal 
arm 9p that are reported to be associated with glioma tumorigenesis. The identified genes were 
LRRN6C/LINGO2 (9p21.1‐p21.2); ELAVL2, CDKN2A/CDKN2B, FOCAD (9p21.3); NFIB (9p22.3‐p23); and 
PTPRD (9p23‐p24.1).  
Table 16 summarizes the number of cases with a loss (log2 ratio ‐0.3 to ‐1) and a pronounced loss 
(log2 ratio <‐1) on 9p in primary glioblastomas from the three molecular relapse groups. There was no 
pronounced loss of the 9p clones selected here in Equal tumors. The most frequently lost gene loci 
were ELAVL2, CDKN2A/CDKN2B, and FOCAD. Losses of these three genes were more often detected 
in the Sequential and Discrepant group when compared to Equal tumors. In order to compare copy 
number changes in Equal and non‐Equal tumors, the Sequential and Discrepant groups were 
combined. This comparison showed that significantly more non‐Equal tumors had losses or 
pronounced losses of ELAVL2 than Equal tumors (p=0.025), while the differences were not quite 
significant for CDKN2A/CDKN2B and FOCAD (p=0.055 and p=0.067). 
 
 
Table 16: Distribution of losses in glioma-associated genes on 9p in different molecular relapse groups  
(p‐values relate to all cases with loss comparing Equal and non‐Equal tumors) (Riehmer et al., 2014, in press). 
Clone 
(chromosomal 
localization) 
Gene Number of primary tumors  
with loss (log2 test/reference ratio: -0.3 to -1)/ 
pronounced loss (log2 test/reference ratio: <-1) 
Equal 
(n=7) 
Sequential 
(n=9) 
Discrepant 
(n=11) 
Non-Equal  
(Sequential plus Discrepant, 
n=20) 
RP11‐32I2 
(9p21.1‐p21.2) 
LRRN6C/ 
LINGO2 
0/ 
0 
0/ 
0 
3/ 
0 
3/ 
0 
RP11‐31K16 
(9p21.3) 
ELAVL2 1 /  
0 
1 /  
3  
8 /  
1  
 
9 /  
4  
(p=0.025) 
RP11‐149I2 
(9p21.3) 
CDKN2A/ 
CDKN2B 
4 / 
0 
3 / 
3 
 
5 / 
5 
 
8 / 
8 
(p=0.055) 
RP11‐512L9 
(9p21.3) 
FOCAD 1 / 
0 
4 / 
1 
 
6 / 
0 
 
10 / 
1 
(p=0.067) 
RP11‐280O24 
(9p22.3‐p23) 
NFIB 0 / 
0  
1 / 
0 
2 / 
0 
3 / 
0 
RP11‐175E13 
(9p23‐p24.1) 
PTPRD 0 / 
0 
2 / 
0 
2 / 
0 
4 / 
0 
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3.3.4 Regions of genomic difference between primary and recurrent tumor pairs  
The next aim was to identify regions with a different copy number in primary as compared to 
recurrent tumors and to identify candidate genes residing in these regions associated with therapy 
response and tumor recurrence. For that reason and in order to visualize the different types of 
genomic differences in the tumor pairs, a heatmap was generated in cooperation with the Institute 
for Medical Informatics, Statistics and Epidemiology of the University of Leipzig. This heatmap, 
depicted in Figure 20, was sorted by the three molecular relapse groups (Equal, Sequential and 
Discrepant). Each possible chromosomal difference in the primary versus the recurrent tumor was 
assigned a certain color. Dark blue indicated a novel gain in the recurrent tumor; a novel loss in the 
recurrent tumor was indicated by a pink color code; a gain no longer present in the recurrent tumor 
was indicated as orange, a loss no longer present in the recurrent tumor was indicated by a purple 
color code. The color yellow was assigned to a gain in the primary tumor recurring as a loss in the 
recurrent tumor. All chromosomal regions, which exhibit a copy number that differs in primary versus 
recurrent tumor pairs, are given with the color code in Figure 20. 
By definition, there is no genomic difference between Equal tumor pairs, as shown in Figure 15 
(page 74). So the heatmap for the Equal group is entirely gray. Sequential tumors had only novel gains 
or losses (dark blue or pink). In contrast, all types of differences were found in the Discrepant tumors 
(Figure 20A). In order to identify recurrent chromosomal differences, a second heatmap was 
prepared showing only the regions that were involved in the same type of change in at least two 
tumor cases (Figure 20B). Strikingly, in 14 of 20 non‐Equal tumor pairs, at least one recurrent copy 
number change difference was found. No consistent difference in therapy, survival or MGMT 
promoter methylation status was detected in the distinct molecular relapse groups. 
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Figure 20: Regions of genomic differences in primary and recurrent glioblastoma pairs.  
The heatmaps sorted by molecular relapse groups demonstrate all differing genomic regions (A) and regions of 
genomic difference observed at least twice (B). In the Equal tumor group, no differences in copy number 
changes were observed. In the Sequential group, only additional aberrations in the recurrent tumors were 
detected (pink: additional loss; dark blue: additional gain). In the Discrepant group, all kinds of copy number 
differences were detected (orange: gain no longer present in the recurrent tumor; yellow: gain in the primary 
tumor that is a loss in the recurrent tumor; purple: loss that is no longer detected in the recurrent tumor; pink: 
additional loss; dark blue: additional gain). No consistent difference in therapy, survival or MGMT status was 
detected in the distinct molecular relapse groups. Molecular relapse group: grey, Equal; blue, Sequential; 
orange, Discrepant. Therapy: red, temozolomide + radiation; blue, radiation only. OS: purple, <1.5 years; light 
blue, >1.5 years. Prim‐rec, time between surgery for primary and recurrent tumor: purple, <1 year; light blue, >1 
year. MGMT rec, MGMT promoter methylation in recurrent tumor: light blue: no methylation; light pink: weak 
methylation; dark pink: strong methylation. MGMT prim, MGMT promoter methylation in primary tumor: light 
blue, no methylation; light pink, weak methylation; dark pink: strong methylation (Riehmer et al., 2014, in 
press). 
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In order to identify candidate genes playing a role in tumor recurrence, the gene content of 
chromosomal regions affected at least twice by a copy number change in primary versus recurrent 
tumors was assessed using the ENSEMBL or UCSC Genome Browser. For all genes the literature was 
interrogated for an association with tumor recurrence or cancer therapy response. Using this 
strategy, 46 genes were identified to have a potential association with tumor recurrence or therapy 
response. Twenty‐four of these genes were glioma‐related. The results of this survey are listed in 
Table 17, which also indicates whether the copy number of a candidate gene increased or decreased 
in the recurrent tumors.  
 
Table 17: Chromosomal regions affected at least twice by copy number difference and candidate genes 
involved.  
Listed are chromosomal regions with copy number increase or decrease in in recurrent versus primary 
glioblastomas, candidate genes associated with tumor recurrence or therapy response according to the 
literature, and type of copy number change in the recurrent tumors (Riehmer et al., 2014, in press).  
Chr. band Candidate genes (references) Copy number change 
in recurrent versus 
primary tumor 
1p36.23‐
p22 
CAMTA1* (Schraivogel et al., 2011), PARK7* (Vasseur et al., 2009; 
Hinkle et al., 2011), UBE4B (Zage et al., 2013), PLOD1 (Cleator et 
al., 2006; Gilkes et al., 2013) 
Increase 
1p36.21 PDPN* (Ernst et al., 2009; Peterziel et al., 2012), PRDM2* (Roversi 
et al., 2006) 
Decrease 
1q41‐
q42.12 
CAPN2* (Ma et al., 2012), PARP1* (Csete et al., 2009; van Vuurden 
et al., 2011; Huang et al., 2014) 
Decrease 
3q27.3‐
q28 
HRG* (Kärrlander et al., 2009), RFC4 (Arai et al., 2009), BCL6 (Horn 
et al., 2013), SST* (Massa et al., 2004), TP63* (Su et al., 2013; 
Yamaki et al., 2013) 
Decrease 
6q25.1 ARID1B* (Sausen et al., 2013) Decrease  
7q11.2 
 
LIMK1* (Prudent et al., 2012), LAT2* (Kühne et al., 2009; Svojgr et 
al., 2012) 
Decrease 
7q21.11‐
q22.1 
HGF* (Guo et al., 2012), AZGP1 (Yip et al., 2011; Huang et al., 
2012), SERPINE1* (Colin et al., 2009), CUX1 (Li et al., 2013), RELN 
(Okamura et al., 2011) 
Decrease 
17p13‐ 
p11.2 
TNFSF13* (Roth et al., 2001; Petty et al., 2009),
 
ZBTB4 
(Chadalapaka et al., 2012), DVL2* (Pulvirenti et al., 2011), CLDN7 
(Lourenço et al., 2010), TP53* (Zheng et al., 2012), EFNB3* (Li et 
al., 2012), AURKB* (Hodgson et al., 2009; Raverot et al., 2010), 
NTN1 (Link et al., 2007), RCVRN (Maeda et al., 2002), MAP2K4 
(Ohtsuka and Zhou, 2002; Tesser‐Gamba et al., 2012), ELAC2 
(Tavtigian et al., 2001), PMP22 (Simpson et al., 2010), TRIM16 
(Raif et al., 2009), MPRIP* (Coupienne et al., 2011), FLCN (Cash et 
al., 2011), SREBF1* (Guo et al., 2009; Guan et al., 2011), LLGL1 
(Lassmann et al., 2007), ALDH3A2 (Ohhira et al., 1996), ALDH3A1 
(Hu et al., 2009) 
Decrease 
19q13.32‐ 
q13.33 
CLPTM1 (Folgueira et al., 2005), RELB* (Josson et al., 2006; Lee et 
al., 2013), FGF21 (Osawa et al., 2009) 
Increase 
22q13.2 EP300* (Zhao et al., 2011; Sen et al., 2011), XRCC6* (Bau et al., 
2011), TSPO* (Bertomeu et al., 2010; Chelli et al., 2008) 
Decrease 
Bolded entries indicate genes associated with tumor recurrence or therapy response according to the literature. 
*Genes associated with glioma according to the literature 
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The 46 identified candidate genes associated with therapy response and tumor recurrence, were 
further analyzed regarding their function. To this end, an ontology search and network analysis using 
the PROTEOMETM software (Biobase, GmbH, Wolfenbuettel, Germany) was performed. Hereby, the 
candidate genes were found to encode proteins involved in several cellular processes such as cell 
proliferation, cell cycle, apoptosis, cell adhesion, cellular response to stress or hypoxia, intracellular 
signal transduction, surface receptor signaling, transcription factor activation and chromatin 
remodeling. The results of this analysis are listed in Table 18. 
 
 
Table 18: Functions of the 46 identified candidate genes associated with therapy response or tumor 
recurrence. Candidate genes are located in the chromosomal regions affected by recurrent copy number 
difference in recurrent versus primary glioblastomas (Riehmer et al., 2014, in press).  
Function* Candidate genes 
Cell proliferation ALDH3A1, ALDH3A2, AURKB, AZGP1, BCL6, ELAC2, EP300, HGF, LLGL1, 
MAP2K4, PMP22, RCVRN, SST, TNFSF13, TP53, TRIM16, TSPO 
Cell cycle/DNA replication ALDH3A1, CAMTA1, EP300, HGF, PRDM2, RFC4, TP53, TP63, ZBTB4 
Cell death AURKB, HGF, MAP2K4, PARK7, PARP1, PRDM2, RELB, SST, TNFSF13, TP53, 
TP63, UBE4B, XRCC6 
Extracellular matrix 
component/organization 
PLOD1, RELN 
Cell adhesion/migration CLDN7, EP300, FLCN, HGF, LLGL1, NTN1, PDPN, RELB, RELN, SERPINE1, 
TP63 
Surface receptor signaling AZGP1, BCL6, DVL2, ELAC2, EP300, EFNB3, FGF21, FLCN, HRG, LIMK1, 
MAP2K4, NTN1, PARP1, RCVRN, RELN, SREBF1, SST, TNFSF13, TP53, 
XRCC6 
Intracellular signal transduction AZGP1, CAPN2, DVL2, EP300, FGF21, HGF, LAT2, MAP2K4, MPRIP, PARK7, 
RELB, SERPINE1, SREBF1, SST, TNFSF13, TP53 
Cellular response to stress DVL2, EP300, MAP2K4, MPRIP, PARK7, PARP1, TP53, XRCC6 
Cellular response to hypoxia PARP1, TP63, XRCC6 
Transcription factor activity ARID1B, BCL6, CUX1, EP300, PARP1, PRDM2, RELB, SREBF1, TP53, TP63, 
ZBTB4 
Chromatin remodeling/ 
modification 
ARID1B , AURKB, PARP1, FGF21, EP300, XRCC6  
*according to PROTEOME
TM
 ontology and own literature search 
 
 
Regulators of apoptosis, in particular members of the p53 family and pathway, showed a changed 
copy number in 13 of 14 non‐Equal (Sequential and Discrepant) tumor pairs displaying a recurrent 
copy number difference. The copy numbers of TP53, TP63 and EP300 were downregulated directly or 
indirectly in nine recurrent tumors. Direct down regulation was detected in seven cases. Indirect 
down regulation via UBE4B copy number increase was found in two cases. In two additional recurrent 
tumors, copy numbers of positive regulators of apoptosis (PRDM2 and PARP1), were decreased. In 
another recurrent tumor, an increased copy number of a negative regulator of apoptosis (RELB) was 
detected. In one of the 14 recurrent non‐Equal tumors, the copy number of the apoptosis regulators 
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mentioned before was not changed. But in this case, the copy number of the chromatin remodeler 
ARID1B was decreased (Table 19). 
 
 
Table 19: Genes encoding regulators of apoptosis or chromatin remodelers.  
The copy number of which is changed in at least two recurrent tumors from non‐Equal pairs. A copy number 
increase or decrease of these genes is found in all 14 recurrent non‐Equal tumors that carry a copy number 
difference observed more than once (Riehmer et al., 2014, in press).  
Functional group 
 
Gene (copy number change 
in recurrent versus primary 
tumor) 
Tumor pairs 
TP53 family or pathway TP53 
(decrease) 
Direct  25 vs. 26; 29 vs. 30; 51 vs. 52* 
Indirect via 
UBE4B copy 
number 
increase 
39 vs. 40*; 59 vs. 60* 
TP63 (decrease) 19 vs. 20; 43 vs. 44; 51 vs. 52* 
EP300 (decrease) 17 vs. 18; 57 vs. 58 
Positive regulators of apoptosis PARP1 (decrease) 51 vs. 52*; 63 vs. 64* 
PRDM2 (decrease) 37 vs. 38; 39 vs. 40* 
Negative regulators of apoptosis RELB (increase) 13 vs. 14; 59 vs. 60* 
Chromatin remodelers ARID1B (decrease) 39 vs. 40*; 55 vs. 56 
PARP1 (decrease) 51 vs. 52*; 63 vs. 64* 
*affected by copy number change of more than one gene listed here encoding an apoptosis regulator or 
chromatin remodeler  
Non‐bold, Sequential pairs; bold, Discrepant pairs. 
 
 
In summary, primary and recurrent glioblastomas from the same patient were analyzed in 27 
cases in order to determine genetic patterns of glioblastoma progression. Array‐CGH profiles were 
compared and yielded three molecular relapse groups named Equal, Sequential and Discrepant. 
Regions of genomic difference between primary and recurrent tumors were identified and found to 
harbor 46 candidate genes associated with tumor recurrence or therapy response. In particular, copy 
numbers of genes encoding apoptosis regulators were frequently changed at progression explaining 
why the tumor cells evaded apoptosis. Losses of chromosomal band 9p21.3 harboring genes such as, 
ELAVL2, CDKN2A/CDKN2B, and FOCAD were significantly more common in primary tumors from non‐
Equal pairs possibly causing an alteration of the clonal composition in the recurrent tumors.  
 
 
3.4 Project 4: Genomic profiling to assess the clonal relationship between histologically 
distinct intracranial tumors 
Array‐CGH was used to retrospectively analyze the clonal relationship of two tumor samples from 
a 47‐year old female patient (patient 1: more detailed patient description can be found in 2.1.10 and 
in Hofer et al., 2012). The primary tumor was initially classified as an unusual pituitary adenoma by 
three independent reference pathologists. Pituitary adenoma are considered benign, nevertheless, in 
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this case the tumor recurred shortly (3 months) after the initial surgery. Histologically, the second 
tumor differed from the primary tumor (2.1.10, page 30). Nine months later the patient died, 
suggesting that the patient had been affected by a malignant tumor.  
Though the two tumor samples were different in their histopathology, the question arose if the 
first and the second tumor contained the same copy number changes and thus most likely had the 
same cellular origin. In order to address this question, array‐CGH was performed on DNA isolated 
from the fibrotic appearing areas of the first tumor. This array‐CGH analysis revealed a complex 
pattern of chromosomal imbalances, affecting all chromosomes but one (chromosome 16). If not the 
entire chromosome, then at least a chromosomal arm was affected by losses (x1 in karyotype) or 
gains (x3 in karyotype). From the profile shown in Figure 21A the following karyotype could be 
deducted: 
[arr(3,6,9,10,11,13q,14q,18p,X)x1,(1q,2,4,5,7,8,12,15q,17p,17q21.33q25.3,18q,19,20,21q,22q)x3].  
The second profile shown in Figure 21B was obtained from DNA extracted from the second tumor 
(third surgery). This profile showed a similarly complex karyotype containing the following additional 
copy number changes: (partial) loss of 1p, 4, 16, 17, 19, 21q [karyotype: 
arr(1p,3,4p16.1q35.2,6,9,10,11,13q,14q,16,17q11.2q21.2,18p,19q13.2q13.43,21q,X)x1,(1q,2,4p16.1p
16.3,5,7,8,12,15,17p,17q21.33q25.3,18q,19p13.3q13.13,20,22q)x3]. About 80% of the 29 detected 
copy number changes in the second tumor were already present in the first tumor sample, providing 
strong evidence for a clonal relationship and suggesting that the second lesion indeed represented a 
recurrent tumor of the first lesion.  
Additionally, histological and immunohistochemical analysis revealed that the second tumor 
showed characteristics of a malignant peripheral nerve sheath tumor (MPNST), WHO grade IV (data 
not shown). For this reason, the array‐CGH data shown here were compared with the profiles of 122 
cases of listed in the Progenetix database 
(http://www.progenetix.org/progenetix/I95403/ideogram.svg). The most frequent copy number 
changes found in the database for MPNST (losses on 1p, 9, 10, 11, 13q, 17p; gains on 1q, 2, 5, 6, 7, 8, 
12, 15q, 17q, 18, 20, and 21q) were almost all detected in the second analyzed tumor, with only few 
exceptions such as 17p loss and gains on 6 and 21q. Thus, there is a concordance of 83% between the 
imbalances in the second tumor analyzed here and the MPNST cases reported in the literature. 
Moreover, these results suggest that array‐CGH can be successfully used to identify the clonal 
relationship between two histologically distinct tumors. This analysis has been published in Hofer et 
al., 2012. 
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Figure 21: Genome-wide array-CGH profiles of the first (A) and the second (B) intracranial tumor of patient 1. 
Both profiles show a highly similar pattern of DNA copy number changes. The midpoints of all BAC clones are 
plotted in genomic order from 1p to Yq on the x‐axis against their normalized log2 test to reference ratio on the 
y‐axis (modified from Hofer et al., 2012). 
 
 
3.5 Project 5: Dissecting the genotype in a patient with cancer predisposition using whole 
exome sequencing in addition to genome‐wide copy number analysis 
In the previous projects of this study DNA from tumor samples was analyzed by array‐CGH in order 
to detect somatic chromosomal imbalances on a genome‐wide scale in large cohorts of tumors of the 
central nervous system. Genome‐wide screening methods such as array‐CGH or whole exome 
sequencing (WES) can also be used to analyze the germline of a patient with the aim to identify the 
genetic basis of a phenotype such as cancer predisposition.  
Here, patient 2 presenting with cancer predisposition combined with syndromic intellectual 
disability was analyzed with two genome‐wide genetic screening methods in order to explain this 
highly complex phenotype. This complex phenotype consisted of facial anomalies (depressed nasal 
root and widely spaced eyes), skin lesions (numerous café‐au‐lait and hypopigmented spots), and two 
neoplastic diseases (a both‐sided mixed malignant germ cell tumor of the ovaries and an acute pre‐B‐
lymphoblastic leukemia) in the first two decades of life. The patient also presented with psychomotor 
and mental delay persisting until adult age as well as low body weight and short stature (more 
detailed patient description can be found in section 2.1.11, page 31). 
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Figure 22 shows the facial features of patient 2 at the ages of 11 months (A and B) and 23 years (C 
and D), whereas Figure 22E depicts areas of skin displaying hypo‐ and hyperpigmentation on the 
patient’s back at 23 years of age. 
 
 
 
Figure 22: Facial features and skin lesions of patient 2. 
A and B: Patient 2 at 11 months of age. C and D: Patient 2 at 23 years of age. The facial features are in line with 
the diagnosis of Bloom syndrome. E: Areas of skin displaying hypo‐ and hyperpigmentation on patient’s back at 
the age of 23 years (Classen and Riehmer et al., 2013).  
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Figure 23: Genome-wide BAC array-CGH profile of DNA from peripheral blood of patient 2 (A). 
B: Enlargement of chromosome 6 displaying the duplicated BAC clone RP3‐470B24. C: Enlargement of 
chromosome 22 displaying the duplicated BAC clone XX‐91c. The midpoints of all BAC clones are plotted in 
genomic order from 1p to Yq on the x‐axis against their normalized log2 test to reference ratio on the y‐axis. 
 
 
Since the patient presented with a complex phenotype including intellectual disability, which is 
often caused by chromosomal imbalances such as microduplications or microdeletions, the initial 
approach was to analyze DNA from peripheral blood of patient 2 using a 10.6k BAC array (Figure 23). 
Threshold were set and every clone displaying a log2 test to reference ratio of greater than 0.3 or 
smaller than ‐0.3 indicating a microduplication or microdeletion was looked at in more detail. Using 
the database of genomic variants of the ENSEMBLE Genome Browser or the UCSC Genome Browser, 
it was checked whether aberrant clones overlapped with known non‐pathogenic copy number 
changes. Clones located on chromosomes 2 and 5 fulfilled the set criteria for the normalized log2 ratio 
and did not overlap with known genomic variants. Therefore, a chromosome 2 and a chromosome 5 
specific oligonucleotide array were performed. However, the microduplications and microdeletion 
were not verified and thus considered false‐positive (data not shown). With the BAC array also a gain 
in the chromosomal band 22q11.21 of one clone (XX‐91c) was detected (Figure 23C). Additionally, 
another gain was found involving one clone (RP3‐470B24) in chromosomal band 6q27 (Figure 23B). In 
order to verify the two copy number changes on chromosomes 22q and 6q, the patient’s DNA as well 
as DNA from both parents were hybridized to chromosome 22 and chromosome 6 specific 
oligonucleotide arrays. This approach aimed at fine mapping the microduplications and determining 
their exact breakpoints. The parents were analyzed in order to identify whether the microduplications 
occurred de novo or were inherited. Figure 24 displays an enlargement of the duplicated region on 
chromosome 22 verified by oligonucleotide array‐CGH. The microduplication was shown to have a 
size of 2.518 Mb in the chromosomal band 22q11.21 (hg18:chr22: 17,276,999‐19,794,999) 
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encompassing around 50 genes (top of Figure 24). Furthermore, the mother of patient 2 carried the 
same microduplication on chromosome 22, whereas the father did not. 
 
 
 
Figure 24: Enlargement of chromosomal band 22q11.21 from array-CGH profiles of patient 2 and her parents. 
Array‐CGH was performed on a chromosome 22 specific tiling oligonucleotide array, demonstrating a 
microduplication of 2.518 Mb in the chromosomal band 22q11.21 (hg18:chr22: 17,276,999‐19,794,999), 
indicated by the shaded area. The duplication was found in patient 2 and her mother, but not in her father. The 
microduplication encompassed around 50 genes including DGCR2, CLTCL1, CDC45L, SEPT5 and GP1BB, displayed 
at the top of the array‐CGH profiles (Classen and Riehmer et al., 2013). 
 
 
In order to verify the gain in chromosomal band 6q27 involving the BAC clone RP3‐470B24 and to 
investigate its inheritance, DNA from patient 2 as well as both parents was hybridized on a 
chromosome 6 specific oligonucleotide array. The fine mapping revealed a microduplication of    
0.261 Mb in size in 6q27 (hg18: chr6:168,076,999‐168,337,999) in patient 2 and her mother. This 
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duplication involved three genes, depicted at the top of Figure 25, and partially disrupting the MLLT4 
gene. 
 
 
 
Figure 25: Enlargement of chromosomal band 6q27 from array-CGH profiles of patient 2 and her parents.  
Array‐CGH was performed on a chromosome 6 specific tiling oligonucleotide array, showing a microduplication 
of 0.261 Mb in chromosomal band 6q27 (hg18: chr6:168,076,999‐168,337,999) in patient 2 and her mother but 
not the father. The microduplication partially encompassed and possibly disrupted the MLLT4 gene (Classen and 
Riehmer et al., 2013).  
 
 
The microduplication on chromosome 22 was further verified by interphase FISH on lymphocytes 
of patient 2 as well as her mother. The results are demonstrated in Figure 26. A BAC clone that was 
located in the duplicated area (RP11‐1151A3; hg18: chr22:17,445,949‐17,587,300) was used for FISH 
(red signals). As a control, a BAC clone located more distally on chromosome 22 outside of the 
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duplicated region was used and (green signals: RP11‐307O16; hg18: chr22:20,764,128‐20,965,434). 
FISH analysis confirmed the 22q11.21 microduplication in patient 2 and her mother.  
 
 
 
Figure 26: Interphase FISH analysis confirmed 22q11.21 microduplication in patient 2 and her mother. 
Interphase FISH analysis using BAC clone RP11‐1151A3 (three red signals, indicated by white arrow) from 
chromosomal band 22q11.21 in patient 2 and her mother confirmed the microduplication. Hybridization of BAC 
clone RP11‐307O16 from chromosomal band 22q11.22 was used as a control (two green signals, open arrows) 
(Classen and Riehmer et al., 2013). 
 
 
In summary, the genome‐wide screen for genomic imbalances using array‐CGH identified two 
microduplications on chromosomes 6q and 22q. Both microduplications were confirmed by at least 
one independent method, also indicating that both chromosomal alterations were inherited from the 
healthy mother. Both microduplications encompass a number of genes, which might be associated 
with the leukemia patient 2 had developed (DGCR2, CLTCL1, CDC45L, SEPT5 and GP1BB (chromosome 
22) and MLLT4 (chromosome 6)). The microduplication on 22q11.21 might also partly explain the 
intellectual disability in patient 2. 
 
 
3.5.1 Whole exome sequencing on DNA from peripheral blood of patient 2 and her mother 
The highly complex phenotype of patient 2, including the intellectual disability and leukemia, 
could be in part explained by the detected microduplications in 22q and 6q (Figure 24 and Figure 25). 
The fact that the healthy mother displayed the same genetic alterations suggested that there was an 
additional genetic cause for the patient’s phenotype. Furthermore, the cause underlying the bilateral 
ovarian germ cell tumor as well as the skin lesions remained unsolved. Therefore, as a second 
genome‐wide screening method WES was performed on DNA from peripheral blood of the three 
family members (patient 2, mother and father) by CeGaT GmbH, Tübingen, Germany to detect DNA 
sequence variants. The initial approach was a trio‐based de novo analysis (as described in 1.3.3, page 
14) aiming to find de novo variants possibly responsible for the unexplained phenotypic features. The 
maternally as well as the paternally inherited variants are subtracted and only the de novo variants in 
the patient are retained. This approach detected a variant in the CHEK2 gene 
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(CHEK2,c.1427C>T;p.Thr476Met) (Figure 27). Due to the fact that the results obtained still did not 
completely explain the complex phenotype of patient 2, a different filtering strategy of the WES data 
was applied in which the parents variants were not taken into account. Therefore, the total number 
of variants (26,974) identified by WES in patient 2 were filtered as follows. In order to reduce the 
number of detected variants to a manageable number, the filter strategies listed in Table 20 were 
applied. First of all, the number of variants could be remarkably reduced to 1,795 variants by 
removing bad quality and known variants from in‐house exomes. In a second step, the data mining 
tool Genome TraxTM was used to extract HGMD mutations and COSMIC somatic disease mutations 
and 30 variants remained. Genome TraxTM primarily utilizes curation of peer‐reviewed literature and 
provides information about conservation, allele frequency, effect on protein sequence, and 
deleterious predictions, as context to support assessment of the variants (2.2.8). Afterwards, non‐
coding or synonymous variants were removed, as well as variants predicted to be benign by three 
prediction programs (Mutation Taster, PolyPhen‐2 and SIFT). The four filter steps resulted in 12 
variants which were further analyzed for their association with cancer. The remaining 3 variants in 2 
genes were finally verified by Sanger sequencing (Figure 27).  
 
 
Table 20: WES data filtering strategy in patient 2 (modified from Classen and Riehmer et al., 2013). 
Filtering steps Number of variants 
in patient 2 
Total number of variants in exome from peripheral blood 26,974 
After removing bad quality and known variants from in house exomes (CeGaT) 1,795 
 
After extracting ‘‘HGMD mutations’’ and ‘‘COSMIC somatic disease mutations’’ using 
Genome Trax
TM
 
30 
After removing non‐coding or synonymous variants 20 
After removing variants predicted to be benign by MutationTaster, PolyPhen‐2 and 
SIFT 
12 
Variants related to “cancer“ 3 
 
 
Two of the cancer related variants were located in the BLM gene. Both were identified to be stop 
mutations. The first BLM variant in exon 6 (BLM,c.1642C>T;p.Gln548X) was inherited from the healthy 
mother, since it was detected both in patient 2 and her mother. In contrast, the other variant found 
in the BLM gene in exon 13 (BLM,c.2695C>T;p.Arg899X) was found to be inherited from the healthy 
father. Patient 2 was, therefore, compound heterozygous for two stop mutations in the BLM gene. 
Importantly, mutations in the BLM gene are known to cause Bloom Syndrome associated with cancer 
predisposition (German et al., 2007). The diagnosis Bloom syndrome not only explains the cancer 
predisposition in patient 2, but also the other unclear phenotypic features, such as the skin lesions. 
This filtering strategy had also identified a heterozygous de novo rare missense variant in the CHEK2 
gene (rs142763740, genotype frequency C/T: 0.001). This identified variant was classified as disease 
causing by MutationTaster and SIFT and known validated as a HGMD disease mutation. 
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Figure 27: Electropherograms showing mutations identified by WES and verified by Sanger sequencing. 
Using WES and a filtering tool identified compound heterozygous BLM stop mutations and a de novo CHEK2 
mutation, which were verified by Sanger sequencing. The de novo CHEK2 mutation 
(CHEK2,c.1427C>T;p.Thr476Met) is a validated “HGMD disease mutation”. The first BLM stop 
(BLM,c.1642C>T;p.Gln548X; exon 6) mutation was found in patient 2 and her mother, the second BLM stop 
mutation (BLM,c.2695C>T;p.Arg899X; exon 13) was identified in patient 2 and her father. The affected 
nucleotide positions are marked by arrows (Classen and Riehmer et al., 2013). 
 
 
Figure 28 summarizes the genetic findings in patient 2 found by employing two genome‐wide 
screening methods. The described genetic findings together explain the highly complex phenotype of 
patient 2. Firstly, using array‐CGH microduplications in 6q27 and 22q11.21 were identified, both 
inherited from the healthy mother (microduplication 6q: gray; microduplication 22q: black). The 
microduplication in 22q11.21 partially explains the intellectual disability. The severe intelectual 
disability might be caused by an additive effect of the microduplication 22q11.21 and the Bloom 
syndrome, both are associated with mild developmental delay. Additionally, both duplicated 
chromosomal regions harbor genes, which are related to leukemia. In order to explain the malignant 
germ cell tumor of the ovaries, the skin lesions, and the short stature, which could not be explained 
by the detected microduplications. WES was performed, revealing 3 mutations in 2 genes, which are 
associated with cancer. Both parents carry heterozygous stop mutations in the BLM gene (light gray), 
which are located in different exons (horizontal and vertical stripes), leading to compound 
heterozygous BLM mutations in patient 2 causing Bloom syndrome. The genetic findings described 
here, explain most features adding up to the complex phenotype in patient 2, e.g. short stature, mild 
craniofacial dysmorphia, hypo‐ and hyperpigmented skin lesions and cancer predisposition (Classen 
and Riehmer et al., 2013). 
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Figure 28: Pedigree of patient 2 and her family showing the detected genetic alterations. 
The square represents the father; the circles represent the female members of the family (mother and 
daughter). Both parents carry heterozygous stop mutations in the BLM gene (light gray) but in different exons 
(horizontal and vertical stripes). In the mother, microduplications in 22q11.21 (black) and 6q27 (gray) were also 
identified. Patient 2 inherited both BLM mutations and microduplications from the parents, and additionally 
carried a heterozygous de novo CHEK2 (dark gray) mutation. Patient 2 is affected by combinations of Bloom 
syndrome, 22q11.21 microduplication syndrome and multi cancer susceptibility syndrome (modified from 
Classen and Riehmer et al., 2013).  
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4 Discussion 
Since the development of genome‐wide screening methods, it has become easier to analyze copy 
number or single nucleotide variants throughout the exome or genome in large cohorts. This made it 
possible to compare e.g. the genomic profiles of tumors on a genome‐wide scale in order to detect 
frequency and patterns of genetic alterations in distinct tumor entities. Nowadays, methods such as 
array‐CGH and NGS are also applied in a diagnostic setting. For example, in patients with 
developmental disabilities or congenital anomalies, array‐based analysis is a first‐tier diagnostic test 
(Miller et al., 2010), in order to detect possible causative copy number changes.  
In this study two genome‐wide screening methods have been applied in order to analyze somatic 
genomic imbalances in diverse tumors of the central nervous system as well as germline copy number 
and single nucleotide variants in a patient displaying a complex phenotype including cancer 
predisposition. Approximately 300 glioma samples were analyzed by array‐CGH which had been 
collected by the German Glioma Network and characterized with respect to their IDH1/2 mutation 
status and MGMT promoter methylation status. Additionally, information on clinical course of 
patients was thoroughly collected.  
 
 
4.1 Project 1: Array‐CGH analysis of WHO grade II and WHO grade III gliomas 
Approximately 140 diffuse gliomas of WHO grade II and anaplastic gliomas of WHO grade III were 
analyzed by array‐CGH in order to identify molecular subtyped distinguishing WHO grade II and III 
glioma entities (astrocytomas, oligoastrocytomas and oligodendrogliomas) possibly irrespective of the 
tumor grade. An exemplary array‐CGH profile for each different histological entity and each tumor 
grade was shown (3.1, page 49), as well as frequency plots in order to visualize frequent genetic 
imbalances found in the different tumor entities (3.1.2, page 51; 3.1.4, page 53). Due to the results in 
project 2 (3.2, page 55) which corroborated previous studies (e.g. Toedt et al., 2011), indicating that 
IDH1/2 wild‐type glioblastomas display a distinct genomic profile from IDH1/2 mutant glioblastomas, 
IDH1/2 status was also taken into consideration when analyzing WHO grade II and grade III gliomas. 
Some IDH1/2 wild‐type gliomas of WHO grade II and III indeed demonstrated a genomic profile, 
which showed genetic imbalances often found in primary glioblastomas such as gain on chromosome 
7 and loss on chromosome 10. Here, this was found for both diffuse astrocytomas of WHO grade II 
and anaplastic astrocytomas of WHO grade III. This finding is in agreement with previous studies that 
described gains of chromosome 7 in about 50% of diffuse astrocytomas and at a similar frequency in 
anaplastic astrocytomas (Schröck et al., 1996; Wessels et al., 2002; Reifenberger and Collins, 2004). 
The loss of chromosomal arm 10q was found in anaplastic astrocytomas (Balesaria et al., 1999; 
Ichimura et al., 1998). In anaplastic astrocytomas this study additionally found a frequent deletion of 
chromosomal arm 22q, which was also described previously (Hartmann et al., 2004). This genetic 
aberration was frequently detected in the anaplastic astrocytomas with an IDH1/2 wild‐type status. In 
contrast, the combined loss of 1p and 19q was reported to be rare in astrocytomas but frequent in 
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oligoastrocytomas (Mueller et al., 2002; Riemenschneider and Reifenberger, 2009). These findings are 
in concordance with the results presented here. 
Since some WHO grade II and III gliomas display genomic imbalance patterns typical for 
glioblastomas, these tumors should again be checked histopathological diagnosis, to rule out that 
they are not underdiagnosed glioblastomas. Additional analyses taking the patient information into 
account might be helpful. In addition, the array‐CGH data should be evaluated together with the gene 
expression data for these tumors to identify gene dosage effects. 
 
 
4.2 Project 2: Characterization of long‐term survivors of glioblastoma using genome‐wide 
profiling 
Glioblastoma multiforme is an aggressive disease associated with short survival times (Smith and 
Jenkins, 2000), with survival in primary glioblastoma patients being significantly shorter than in 
patients with secondary glioblastoma (Ohgaki and Kleihues, 2005a). Long‐term survival, defined as an 
overall survival of more than 36 months, is rare and this phenomenon is still poorly understood. It 
appears as though socioeconomic, environmental and occupational factors do not play major roles 
(Krex et al., 2007). Molecular markers such as MGMT promoter methylation and IDH1/2 mutation 
seem to be important and are more frequently found in tumors from long‐term survivors than in 
tumors from unselected glioblastoma patients (Krex et al., 2007; Hartmann et al., 2013). Apart from 
the MGMT promoter methylation and IDH1/2 status, primary glioblastomas of long‐term survivors 
are poorly characterized on the molecular level.  
However, a few studies demonstrated that glioblastomas from long‐term survivors showed a 
distinct gene expression profile or characteristic changes in DNA methylation (Barbus et al., 2011; 
Donson et al., 2012; Shinawi et al., 2013). Collectively, these data suggest marked differences in 
tumor biology as a major factor underlying glioblastoma long‐term survival. This study aimed to 
further investigate this hypothesis. Therefore, a clinically well‐characterized cohort of 94 primary 
glioblastoma patients was surveyed. Patients displayed long‐term, short‐term or intermediate overall 
survival and all patients had been treated according to the current standards (Stupp et al., 2005). The 
aim was to assess the molecular aberrations in the distinct survival groups taking into account 
established molecular markers such as IDH1 and IDH2 mutation as well as MGMT promoter 
methylation. Of most of the 94 primary glioblastoma samples, transcriptome‐wide profiling data was 
also available (data not shown; Reifenberger and Weber et al., 2014). Stratification for IDH1/2 
mutation status has been shown to be important, because IDH1/2 wild‐type tumors display a distinct 
molecular profile (Toedt et al., 2011). Furthermore, IDH1/2 mutations are more frequent in secondary 
glioblastomas and can, therefore, be used as a diagnostic tool for the differentiation between primary 
and secondary glioblastoma (Balss et al., 2008; Hartmann et al., 2009). For the MGMT promoter 
methylation status in this cohort, it was shown that MGMT promoter methylation was more frequent 
in patients with long‐term OS (Table 12, page 58). This can be seen in concordance with the fact that 
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patients with a methylated MGMT promoter showed a better response to treatment strategies 
involving TMZ (Hegi et al., 2005).  
Taking the genome and transcriptome data into account, this study confirmed that there is an 
overrepresentation of tumors with MGMT promoter methylation and IDH1/2 mutations among 
glioblastomas from long‐term survivors (Reifenberger and Weber et al., 2014). The frequency plots 
generated from the array‐CGH data confirmed that there is a distinct genomic profile for IDH1/2 wild‐
type tumors in comparison to IDH1/2 mutant tumors (Figure 11, page 61) supporting previous studies 
(Toedt et al., 2011; Sturm et al., 2012). Gain on chromosome 7 as well as loss on chromosome 10 
were more frequent in IDH1/2 wild‐type tumors and usually involved the entire chromosome. In 
addition, in about half of the cases gains of chromosomes 19 and 20 were found as well as a loss of 
chromosomal arm 9p. In contrast, tumors harboring IDH1/2 mutations displayed a less distinctive 
genomic profile with imbalances in many different chromosomes. Despite this heterogeneous pattern 
of copy number changes in most IDH1/2 mutant glioblastomas, four of 15 cases (26%) showed a more 
specific change, i.e. a combined loss of chromosomes 1p and 19q. The combined loss of 1p and 19q is 
typical for low‐grade tumors and secondary glioblastomas possessing an oligodendroglial component 
(Reifenberger et al., 1994). Histological reevaluation confirmed that the 1p/19q deleted tumors 
indeed were glioblastomas that, however, contained an oligodendroglial tumor component 
(Reifenberger and Weber et al., 2014).  
Considering the frequency of gene copy number changes of glioma‐associated tumor suppressor 
genes or oncogenes, no significant differences were observed between the three IDH1/2 wild‐type 
survival groups after adjusting for multiple testing. When comparing IDH1/2 wild‐type and mutant 
tumors, significant differences were detected in the following genes: PTEN, XRCC3 and XRCC1 located 
in chromosomal regions showing a loss, as well as EGFR, PMS2 and HGF located in regions displaying 
a chromosomal gain. All six genes have already been described to be glioma‐associated or have been 
investigated in more detail in glioma subgroups (Birchmeier et al., 2003; Kiuru et al., 2008; Verhaak et 
al., 2010; Felsberg et al., 2011). For example, mutations in the PTEN (phosphatase and tensin 
homolog) gene have been described to be a marker of the mesenchymal glioma subgroup defined by 
Philipps et al. and Verhaak et al. (Philipps et al., 2006; Verhaak et al., 2010). XRCC1 (X‐ray repair cross‐
complementing protein 1) and XRCC3 (X‐ray repair cross‐complementing protein 3) are both DNA 
repair genes, and SNPs in these genes were investigated in respect to an increased risk of developing 
a brain neoplasm in a large cohort including 320 glioblastoma patients compared to a control cohort 
(Kiuru et al., 2008). The study did not demonstrate a significant association of the analyzed 
polymorphisms of either gene with brain tumorigenesis, but suggested that a combination of SNPs in 
both genes might play a role. EGFR (epidermal growth factor receptor) amplification, which is 
frequently found in glioblastoma, is also a marker for the different subgroups defined by Verhaak et 
al. and Philipps et al. (Philipps et al., 2006; Verhaak et al., 2010). Chromosomal alterations of the 
EGFR locus were frequently found in primary but not in secondary glioblastomas (Gan et al., 2009; 
Riemenschneider and Reifenberger, 2009). PMS2 (postmeiotic segregation increased 2) is a DNA 
mismatch repair gene that has also been analyzed in the context of with glioblastoma, especially in 
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correlation with MGMT promoter methylation (Felsberg et al., 2011). HGF (hepatocyte growth factor) 
is known to play a role in tumor progression in various malignancies e.g. of the lung and liver 
(Birchmeier et al., 2003). Recently, HGF was shown to be associated with poor prognosis of patients 
with glioma and to influence the chemosensitivity of glioma cell lines to cisplatin in vitro (Guo et al., 
2012). 
It is likely that the distinct gene expression profiles in IDH1/2 wild‐type versus mutant tumors 
found in this study are caused by the IDH1/2 mutation‐associated global changes in DNA methylation, 
also known as glioma CpG island methylator phenotype (G‐CIMP) (Noushmehr et al., 2010; Sturm et 
al., 2012). Clustering analysis of the molecular evaluation in this study revealed that long‐term 
survival of IDH1/2 wild‐type glioblastoma patients is not linked to distinct DNA copy number changes 
or expression profiles (Reifenberger and Weber et al., 2014), suggesting that host‐related factors 
seem to be more important in the group of long‐term survivors. 
By bioinformatics analysis of this study data, it could be shown that various previously reported 
gene signatures associated with long‐term glioblastoma survival are preferentially related to IDH1/2 
status but do not predict survival independent from IDH1/2 mutations. For example, Donson et al. 
reported an increased expression of immune function‐related genes in gliomas of long‐term 
survivors, including a notable T‐cell signature that was present within this prognostic immune gene 
set (Donson et al., 2012). Application of this signature to the data set of this cohort, however, 
demonstrated an association with IDH1/2 mutation but not with IDH1/2 independent long‐term 
survival (Reifenberger and Weber et al., 2014). Likewise, the prognostic gene signature reported by 
Nutt et al. using expression profiling of anaplastic oligodendrogliomas versus primary glioblastomas 
(Nutt et al., 2003) was also linked to IDH1/2 mutation but not to survival in IDH1/2 wild‐type patients. 
Analysis of prognostic methylation signatures reported as being linked to IDH1/2 mutation 
(Noushmehr et al., 2010) or to long‐term survival of glioblastoma patients (Shinawi et al., 2013), 
revealed no association with long‐term survival in patients with IDH1/2 wild‐type glioblastomas. 
Additionally, no distinctive gene expression profile in IDH1/2 wild‐type glioblastomas from long‐term 
survivors was identified in an independent cohort of TCGA (The Cancer Genome Atlas) patients. 
Taken together, analyzing the DNA copy number changes, IDH1/2 mutation, and MGMT promoter 
methylation status of 89 primary glioblastoma samples revealed that IDH1/2 mutations are 
associated with distinct genomic changes defining a characteristic molecular subtype. This subtype is 
characterized by better prognosis and a higher probability for long‐term survival. Additionally, MGMT 
promoter methylation is also more frequently found in long‐term survivors treated according to the 
current standards including IDH1/2 mutant and wild‐type tumors. Considering the pattern of genomic 
aberrations and mRNA expression profiles, no distinct changes were found for long‐term survivors 
with IDH1/2 wild‐type glioblastomas.  
Since only IDH1/2 mutations and MGMT promoter methylation were found to play an important 
role for the prognosis of primary glioblastomas so far, future studies should focus on the analysis of 
more subtle genetic and epigenetic alterations implementing techniques such as whole genome or 
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epigenome sequencing. Furthermore, proteomic or post‐transcriptional alterations should be 
considered as they might be associated with long‐term survival independently of the IDH1/2 status.  
In addition, also host‐related factors need to be considered as well, these have been poorly 
understood up to now. Here, the anti‐tumor immune response seems to be an attractive future 
research area.  
 
 
4.3 Project 3: Genomic patterns of recurrence in IDH1/2 wild‐type glioblastomas, WHO 
grade IV 
Glioblastoma have a tendency to recur despite the combined treatment of surgical resection, 
radiotherapy and temozolomide treatment. The recurrent glioblastoma displays the same tumor 
grade as the primary glioblastoma, i.e. WHO grade IV. To date, the treatment strategy for the 
recurrent tumor is, therefore, similar to that for the primary tumor and consists of the combination of 
surgery, temozolomide treatment and other chemotherapy. It is unclear if the recurrent tumor 
exhibits the same genomic changes as the primary tumor. Therefore, 27 primary and recurrent tumor 
pairs were analyzed on the molecular level, raising the question if the recurrent tumor displays 
different copy number changes than the primary tumor. If so, the patient might benefit from a 
different salvage therapy. 
So far, the molecular characterization of primary and recurrent tumors from the same patient has 
been limited to small numbers of cases or has not been very extensive (Ito et al., 2007; Spiegl‐
Kreinecker et al., 2007; Martinez et al., 2010; Felsberg et al., 2011; Nickel et al., 2012). For example, 
Ito et al. described a case, in which primary and recurrent glioblastoma were compared (Ito et al., 
2007). They reported that the recurrent tumor exhibited less chromosomal imbalances than the 
primary tumor. The primary tumor displayed a loss of heterozygosity of 1p, 10q and 19q, whereas the 
recurrent tumor only exhibited allelic loss of 10q. It was stated that this might be due to the fact that 
the primary tumor encompassed different tumor subclones, and that only the subclone exhibiting a 
1p/19q loss was eliminated by the treatment. The recurrent tumor might have developed from the 
therapy resistant tumor subclone harboring the chromosomal changes that might be responsible for 
therapy resistance (Ito et al., 2007). 
Genomic patterns of progression from primary to recurrent glioblastoma have not been 
established. This requires genome‐wide analysis of tumor pairs from an extensive number of cases, 
which was done in this study of 27 primary and recurrent glioblastoma pairs. Stratification according 
to the IDH1/2 mutation status was done, because IDH1/2 wild‐type tumors display a distinct genomic 
profile, as it was shown in this study (3.2, page 55) and previously described (Toedt et al., 2011). 
Furthermore, it is important for the analysis of DNA copy number differences that an adjustment of 
differences of the tumor cell content of primary and recurrent tumors is performed, in order to 
achieve a correct comparison between the tumor pairs. 
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Array‐CGH was used to determine DNA copy number changes in 27 primary and recurrent 
glioblastoma pairs, all tumors displaying a wild‐type IDH1/2 status. The aim was to identify candidate 
genes that are associated with therapy response and tumor recurrence. 
The selected 27 glioblastoma patients had representative clinical characteristics and had had 
surgical resection of the primary and recurrent tumor. The clinical course of these patients was 
followed up by the German Glioma Network. Single genomic profiles were processed and qualitative 
differences determined by pairwise comparison of profiles from primary and corresponding recurrent 
tumor (Riehmer et al., 2014, in press). A pattern of DNA copy number changes typical for IDH1/2 wild‐
type glioblastomas was detected, including gain on chromosome 7 and losses on chromosomal arm 
9p and chromosome 10 in almost all cases, as well as gains on chromosomes 19 and 20 and losses on 
chromosomal arm 13q in about half of the tumors, as described earlier (Beroukhim et al., 2007). 
Comparing the genomic profiles of primary and recurrent tumor pairs, difference profiles were 
generated, and three distinct molecular relapse groups were identified and defined for the first time 
(Riehmer et al., 2014, in press). Seven Equal, nine Sequential and eleven Discrepant tumor pairs were 
identified (3.3.2, page 72). Equal tumor pairs had balanced difference profiles, Sequential tumor pairs 
showed additional DNA copy number changes in the recurrent tumor, and Discrepant tumor pairs 
demonstrated not only additional changes but also chromosomal imbalances that were no longer 
present in the recurrent tumor. With the achieved resolution, this analysis indicated that about a 
quarter of the recurrent tumors were genetically identical with the primary tumor (defined as Equal 
group). In contrast, the Sequential and the Discrepant group displayed genetic differences in the 
recurrent tumor when compared to its corresponding primary tumor.  
Considering the theory that tumors might consist of different subclones, each harboring different 
chromosomal changes, the tumors defined as Equal might be monoclonal. This single clone appears 
to be stable and genetically unaffected by time and radio‐ and chemotherapy (Riehmer et al., 2014, in 
press) (Figure 29, page 102). In contrast, Sequential tumors might have started monoclonally. Over 
time the tumor acquired additional changes, perhaps as a consequence of therapy, and therefore, 
became polyclonal (Figure 29A). Alternatively, Sequential tumors could have started polyclonally 
consisting of a major clone having the initially detected genetic imbalances and additional minor 
clones harboring different genetic alterations. In this case, the alterations of the minor clones would 
not be detectable by array‐CGH in the primary tumor due to small cell numbers, but could 
subsequently be detected in the recurrent tumor due to clonal expansion during or after therapy 
(Figure 29B). In the case of Discrepant tumors it can be speculated that they start polyclonally, some 
clones expand in the recurrent tumor in comparison to the primary tumor and therefore become 
detectable. On the other side, some clones disappear or the cell number of this clone is reduced, so 
that the genetic alterations harbored by these clones are no longer detectable. This would explain the 
phenomenon that primary tumors of Discrepant pairs display genetic alterations that are lost in the 
respective recurrent tumors (Figure 29C and D). Discrepant tumors might additionally acquire 
genomic alterations over time. The data presented in this study provides evidence that primary 
glioblastomas can consist of either one or several clones (Riehmer et al., 2014, in press). These 
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findings are in concordance with a recent report analyzing the genetic composition of cells within 
primary glioblastomas. Here, flow sorting and array‐CGH were used and detected monogenomic 
tumors containing only one clone or polygenomic tumors containing multiple clones (Stieber et al., 
2014). 
 
 
Figure 29: Scheme of possible genetic and clonal evolution in the defined molecular relapse groups.  
Equal tumors are monoclonal (dark blue) in the primary and the recurrent tumor. Sequential tumors can start 
monoclonally (A) and have acquired additional changes in the recurrent tumor (black star, plus and diamond). 
Alternatively, the Sequential tumor starts polyclonally (B), but the minor subclones are not yet detectable due 
to small numbers of cells (light blue, pink and green circles). After recurrence, these clones either expand and 
become detectable (pink and green) or get eliminated (light blue) due to therapy. Discrepant tumors start 
polyclonally (C and D). C: In the recurrent tumor, some subclones have expanded (pink and green) or their size 
is reduced (orange) or they disappeared (blue). The chromosomal imbalances in the orange and light blue 
clones are no longer detectable in the recurrent tumor. D: Tumor starts polyclonally, some clones expand 
(green and pink) and even acquire additional changes (black star, plus and diamond), which are then detectable 
in the recurrent tumor. Other clones disappear (light blue) or are reduced in size (orange).  
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A comparison of the primary tumors from the three molecular relapse groups (Equal, Sequential 
and Discrepant) with respect to common DNA copy number changes showed that most genetic 
imbalances had the same frequencies in the three groups (Figure 18, page 78). However, losses on 
chromosomal arm 9p were larger and more pronounced in the primary tumors from Sequential and 
Discrepant tumor pairs. Especially, loss of chromosomal band 9p21.3 harboring genes like ELAVL2, 
CDKN2A/CDKN2B, FOCAD and the glioma susceptibility SNP rs4977756 (Shete et al., 2009) was 
significantly or remarkably more frequent in primary tumors from Sequential and Discrepant (non‐
Equal) pairs (Riehmer et al., 2014, in press). Since non‐Equal tumors are genomically less stable than 
Equal tumors, the loss of chromosomal material from 9p21.3 may facilitate (or at least be a marker 
for) genetic instability, yielding recurrent tumors, that display a different composition on the cellular 
and genetic level from their corresponding primary tumors. Through its products p14, p15 and p16, 
the CDKN2A/CDKN2B gene cluster is involved in the apoptosis regulation via p53 signalling and G1/S 
progression via the RB pathway. Therefore, the CDKN2A/CDKN2B gene cluster plays an important role 
in glioma pathogenesis (Cancer Genome Atlas Research Network, 2008). Additive effects may come 
from the loss of the glioma susceptibility SNP rs4977756 which is located within the CDKN2B-AS1 
gene encoding the non‐coding RNA ANRIL. This RNA is required for silencing CDKN2B (Kotake et al., 
2011). Furthermore, the FOCAD gene also located in chromosomal band 9p21.3 was shown to have 
tumor suppressor function in gliomas (Brockschmidt et al., 2012). 
In the chromosomal regions of genomic differences between primary and recurrent non‐Equal 
tumor pairs 46 candidate genes were identified that were associated with therapy response or tumor 
recurrence according to the literature (Table 18, page 84). The identified candidate genes are 
involved in various processes playing a role in tumor progression, such as cell proliferation, migration, 
as well as cellular response to stress and hypoxia. In all non‐Equal recurrent tumors carrying a 
genomic difference identified more than once, the copy number of genes encoding regulators of 
apoptosis, in particular the p53 family and pathway, and chromatin remodelers were changed 
(Riehmer et al., 2014, in press). This implies that during the expansion and reduction of tumor clones 
in non‐Equal tumors, clones are selected for that escape apoptosis because the copy number of a 
positive regulator of apoptosis was decreased, or the copy number of a negative regulator of 
apoptosis was increased (Riehmer et al., 2014, in press).  
Apart from TP53 the identified genes encoding apoptosis regulators included TP63, EP300, UBE4B, 
PARP1, PRDM2, and RELB (Table 18 and Table 19, pages 84 and 85). While the p53 protein encoded 
by TP53 is a well known positive regulator of apoptosis in glioblastoma, p63 encoded by TP63 is a p53 
homolog that modulates the p53 pathway (reviewed in England et al., 2013), p300 encoded by EP300 
facilitates p53 function (Tang et al., 2013), and UBE4B (ubiquitination factor E4B) promotes p53 
polyubiquitination and degradation (Wu et al., 2011). In ten recurrent tumors from non‐Equal pairs, a 
decrease in copy number of either TP53, TP63 or EP300 as well as an increase in copy number of 
UBE4B was detected, influencing the p53 pathway in a similar way. Notably, UBE4B has not been 
implicated in glioma pathogenesis previously. PARP1 (poly(ADP‐ribose) polymerase‐1) and PRDM2 
(PR domain containing 2) have also been described to have the potential to induce cell death (He et 
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al., 1998; Koh et al., 2005). RELB (v‐rel avian reticuloendotheliosis viral oncogene homolog B) appears 
to mediate survival signals that protect cells from apoptosis in most cells (reviewed in Sonenshein, 
1997). The results presented here, namely a decrease in copy number of PARP1 or PRDM2, or an 
increase in copy number of RELB, which has been found in six recurrent non‐Equal tumors, may 
represent an alternative mechanism that reduces apoptosis. 
Chromatin regulators have been increasingly found to play a role in the pathogenesis of cancer 
including neuroblastoma (Sausen et al., 2013; reviewed in Shain and Pollack, 2013). The copy number 
of ARID1B (AT‐rich interaction domain‐containing protein 1B) encoding a subunit of the SWI/SNF 
chromatin remodeling complex or of PARP1, the gene product of which is known to also act in the 
regulation of chromatin structure (reviewed in Wacker et al., 2007) was found to be decreased in four 
recurrent tumors. Previous studies reported on a role of PARP1 in glioblastoma susceptibility 
(McKean‐Cowdin et al., 2009). ARID1B was described as a candidate tumor suppressor gene in 
glioblastomas, due to the fact that it was identified to be the only gene located in a small overlapping 
region of deletion at 6q26 in six glioblastoma cases (Ichimura et al., 2006). 
The comparison of primary and recurrent tumors implies that on the genetic level most recurrent 
tumors differ quite considerably from their primary tumors, even though the histopathologic 
appearance and the tumor grade were the same. As a consequence from these results, the recurrent 
glioblastomas are not necessarily the same tumors as their corresponding primary glioblastoma and 
may therefore benefit from different treatment approaches. Three copy number differences 
(involving regions harboring TP63, EP300 and RELB) identified in a total of seven tumor pairs in this 
data set might provide a basis for novel targeted therapy options in recurrent glioblastoma (Riehmer 
et al., 2014, in press). This is supported by several recent findings. Firstly, it was shown that 
temozolomide induces TP63 expression resulting in an inhibition of glioblastoma progression (Yamaki 
et al., 2013). In the data set presented here, a decreased TP63 copy number was found in the 
recurrent tumors of three patients, whose primary tumors had been treated by surgical resection, 
radiotherapy and temozolomide (RT/TMZ). From this data it can be inferred that the basis of their 
recurrence following temozolomide treatment was identified, implying that these recurrent tumors 
might have benefited from a therapy with a different chemotherapeutic agent. The detected copy 
number change in these recurrent tumors additionally involved the SST gene encoding for 
somatostatin, which is located in close proximity to the TP63 gene in the chromosomal band 3q27.3. 
Somatostatin and its analog are known to have an inhibitory effect on experimental and human 
gliomas (Merlo et al., 1999; Barbieri et al., 2009), so these recurrent tumors might have benefited 
from a therapy with somatostatin analog. Secondly, it has been found that the protein p300 acts as 
an activator of the GFAP (glial fibrillary acidic protein) gene and as a repressor of the NES (nestin) 
gene, thus inducing differentiation of glioblastoma cells (Panicker et al., 2010). Furthermore it has 
been shown that the inhibition of p300 expression by RNA interference enhanced the invasion 
potential of glioblastoma cells in vitro (Panicker et al., 2010). In this data set, two recurrent tumors 
displayed a decreased copy number of EP300 suggesting that an alternative effective treatment in 
these cases may be an anti‐invasive drug inducing differentiation such as valproic acid (Berendsen et 
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al., 2012). Thirdly, it was recently shown that the loss of RELB attenuated glioma cell survival, motility 
and invasion (Lee et al., 2013). In orthotopic mouse xenografts, RelB diminished tumor growth (Lee et 
al., 2013). These findings highlight the therapeutic potential of inhibiting the alternative NF‐κB (RelB‐
mediated) pathway in order to treat glioblastoma (Lee et al., 2013). Recurrent tumors of this data set 
demonstrated an increased RELB copy number, suggesting that for these glioblastomas inhibiting 
kinases which are activated in alternative NF‐κB signaling, i.e. NF‐κB inducing kinase (NIK) and IKKα, 
by small molecules or chemical compounds might be an effective treatment (Gardam and Beyaert, 
2011; Nogueira et al., 2011). 
Taken together, this analysis of primary and recurrent glioblastoma pairs provides evidence that 
about 75% of IDH1/2 wild‐type recurrent glioblastoma have evolved genetically in comparison with 
their primary tumors. Moreover, the genetically evolution might be facilitated by the loss of genetic 
material from chromosomal band 9p21.3 in the primary glioblastomas. Characterization of genetic 
differences between primary and recurrent glioblastomas might allow identifying effective salvage 
therapies which target the new genetic properties of the recurrent tumor and will be beneficial for 
the patients.  
In order to assess TMZ‐resistance in more detail and to unravel the underlying mechanisms, a 
future approach could be to generate TMZ‐resistant glioma cell lines followed by an analysis of the 
chromosomal differences between the wild‐type versus the resistant cell line. Such an approach may 
be helpful to identify genes or genomic regions playing a role in TMZ‐resistance.  
 
 
4.4 Project 4: Genomic profiling to assess the clonal relationship between histologically 
distinct intracranial tumors 
Array‐CGH was used to assess the clonal relationship between two distinct intracranial tumors 
from the same patient (patient 1), the first tumor of which was initially classified as an unusual 
pituitary adenoma by three independent reference pathologists. Pituitary adenomas are non‐
metastasizing benign tumors (Ezzat et al., 2004, Garcia‐Arnes et al., 2013), which can cause symptoms 
if hormonally active or fast growing (Ezzat et al., 2004; Asa and Ezzat, 2002). The first tumor was 
detected with a MRI scan as an intra‐, para‐ and suprasellar mass suggestive of pituitary adenoma. 
After operative removal of the tumor, the patient recovered without any additional focal neurological 
deficits (Hofer et al., 2012). Diagnosis of intraoperative smear and frozen section revealed 
predominantly connective tissue with few clusters of epithelial cells. Similar findings were found by 
the histological analysis of the formalin‐fixed paraffin‐embedded material demonstrating loosely 
packed fibrous connective tissue of low to intermediate cellularity and interspersed islands of cells 
with epithelial aspect (Hofer et al., 2012). These islands were diagnosed as pituitary cells. But only 
three months after the first surgery, a secondary lesion was diagnosed with a CT and MRI scan in the 
pituitary region. This tumor was removed in two operations over a period of one week. Nevertheless, 
there was some residual tumor bilaterally within the cavernous sinus according to an early 
postoperative MRI scan (Hofer et al., 2012). Nine months later, the patient showed pronounced 
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tumor progression and despite a fourth operation in order to decompress the tumor, the patient 
died. The samples of the second, third and fourth surgeries were microscopically similar and 
contained tissue of high cellularity, with features which were not present in the tissue samples of the 
first operation. Due to the fact that the tumors of the first and the second operation showed different 
histologic features, array‐CGH was used to determine if the first and the second tumor shared the 
same genomic imbalances and were, therefore, of the same origin (Hofer et al., 2012). Array‐CGH 
analysis (3.4, page 85) revealed that approximately 80% of the genetic alterations detected in the 
second tumor were already present in the first tumor, indicating a clonal relationship of the first and 
second tumor. Therefore, it is likely that the second tumor is actually a recurrent tumor. 
Histological and immunohistochemical analysis of the second tumor showed typical characteristics 
of MPNST WHO grade IV (Hofer et al., 2012). Therefore, array‐CGH profiles of the primary and 
secondary tumor of patient 1 were compared with previously described array‐CGH profiles of 122 
malignant peripheral nerve sheath tumor (MPNST) cases listed in the Progenetix database. MPNST 
are associated with complex karyotypes containing numerical and structural chromosomal 
aberrations involving almost all chromosomes (Jhanwar et al., 1994; Mertens et al., 1995; Scheithauer 
et al., 2007). The most frequent copy number changes summarized for MPNST in the database are 
gains on 1q, 2, 5, 6, 7, 8, 12, 15q, 17q, 18, 20, and 21q and losses on 1p, 9, 10, 11 13q, and 17p. 
Interestingly, almost all of these chromosomal aberrations were also detected in the secondary tumor 
described here, with the exception of gains on chromosome 6 and chromosomal arm 21q and the loss 
of chromosomal arm 17p. These findings show a concordance of 83% between the imbalances of the 
second tumor of patient 1 and the previously reported MPNST cases listed in the database.  
Considering the location of the tumor in patient 1 in the sellar region, it was unlikely that this 
tumor was an MPNST, because MPNSTs are rarely found in the sellar region due to the absence of 
larger peripheral nerves (Krayenbühl et al., 2007; Kim et al., 2007; Mohammed et al., 2010). Several 
reports have described a growth into the sella turcica from a suprasellar or perisellar location (Perone 
et al., 1984; Maartens et al., 2003). Alternatively, these tumors may originate from ectopic Schwann 
cells (Whee et al., 2002; Bhagat et al., 2002). The fact that in the analyzed specimen no peripheral 
nerve was detected supports the idea that the analyzed tumor originated from ectopic Schwann cells 
(Hofer et al., 2012). MPNST arise commonly from neurofibromas (Scheithauer et al., 2007), which was 
not the case in patient 1 because she did not present with neurofibromatosis.  
Considering that patient 1 presented with an aggressive and rapid clinical course, it is likely that 
the first tumor diagnosed as an unusual pituitary adenoma was indeed an MPNST that infiltrated the 
pituitary gland. Due to its low cellular density it was apparently misinterpreted as a fibrotic pituitary 
adenoma. The array‐CGH profiles support the idea that the first and the second tumor have the same 
cellular origin since they share 80% of genetic imbalances. Therefore array‐CGH is a potent tool to 
identify the clonal relationship of tumors even in cases when they appear as two histologically distinct 
tumors.  
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This study demonstrates that genome‐wide screening methods, such as array‐CGH are important 
tools to unravel the molecular basis of certain pathologies, especially if they present with an 
unexpected clinical course.  
 
 
4.5 Project 5: Dissecting the genotype in a patient with cancer predisposition using whole 
exome sequencing in addition to genome‐wide copy number analysis 
When patient 2 presented with a highly complex phenotype including cancer predisposition (a 
both‐sided mixed malignant germ cell tumor of the ovaries and an acute pre‐B‐lymphoblastic 
leukemia), intellectual disability and anomalies of skin pigmentation, it was at first hypothesized that 
a single monogenic disease caused all of the symptoms. Syndromes including cognitive impairment, 
cancer predisposition and anomalies of skin pigmentation, e.g. neurofibromatosis type 1, tuberous 
sclerosis‐1 or tuberous sclerosis‐2 were suspected, but not confirmed. 
Due to the complexity of the displayed symptoms, the original hypothesis was challenged. It was 
suspected that all symptoms might be explained by a microduplication or microdeletion syndrome. In 
the past few years, the number of microduplication or microdeletion syndromes that were described 
has been steadily increasing, due to advancement in technologies such as array‐CGH. Using array‐
CGH, submicroscopic copy number changes, so called copy number variations (CNV), can be detected. 
The challenge is to differentiate between a benign and a pathogenic copy number variation. A CNV is 
usually considered pathogenic if it is not inherited but occurs de novo (e.g. Alesi et al., 2011), or if it is 
not detected in a high number of unrelated healthy control individuals (e.g. Willatt et al., 2005). 
Intellectual disability is characterized by an impaired cognitive function, which might be caused by 
maternal drug abuse during pregnancy, perinatal oxygen distress or postnatal infections. More 
recently, genetic alterations such as microduplications or microdeletions have been identified to be 
causative (reviewed in Weise et al., 2012). These microduplication or microdeletion syndromes 
usually involve many genes in close proximity to each other. Also the gene dosage might play an 
essential role for causing specific clinical signs.  
As primary approach, DNA from the peripheral blood of patient 2 was analyzed by array‐CGH and, 
indeed, a 2.5 Mb microduplication in chromosomal band 22q11.21 was detected, reported to cause 
the 22q11.21 microduplication syndrome (Ensenauer et al., 2003, reviewed in Portnoi, 2009). In 
addition, a 0.26 Mb microduplication in 6q27 was detected, in part encompassing the MLLT4 gene. 
However, both microduplications were inherited from the healthy mother.  
The chromosomal region 22q11.2 harbors approximately 50 genes and has been shown to be 
susceptible to chromosomal rearrangements. Microdeletions in this region are associated with 
genomic diseases such as the DiGeorge/ velocardiofacial syndromes (Ensenauer et al., 2003). The 
genomic rearrangements in this region are facilitated by segmental duplications (regions of low copy 
repeats) allowing for mispairing and unequal crossing over between two homologous chromosomes 
(Portnoi, 2009). The 22q11.2 microduplication syndrome is associated with intellectual disability, and 
therefore gave a possible explanation for the intellectual disability in patient 2, but it is usually not as 
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severe (Portnoi, 2009). However, it has been described that the phenotype has a high variability, i.e. 
patients may have cognitive deficits that range from learning disabilities to mental retardation 
(Ensenauer et al., 2003; Yobb et al., 2005). This could explain why the mother, carrying the same 
microduplication, did not show any signs of intellectual disability and displayed a normal phenotype. 
The 22q11.21 microduplication explained the intellectual disability in patient 2, but is typically neither 
associated with skin hyper‐ and hypopigmentation nor related to malignant diseases early in life. 
However, one patient carrying a 22q11.21 microduplication had been described with a pre‐B acute 
lymphoblastic leukemia (Chang et al., 2011). 
In order to investigate whether the unexplained leukemia might be due to gene dosage effects of 
the respective copy number variants, both microduplications harboring a number of genes associated 
with leukemia, the gene expression levels of five genes (DGCR2, CLTCL1, CDC45L, SEPT5 and GP1BB) 
residing in the 22q11.2 region and MLLT4 residing in the 6q27 region were analyzed in cooperation 
with the Institute of Human Genetics, University of Bonn (Classen and Riehmer et al., 2013). DGCR2, 
CLTCL1, CDC45L, SEPT5 and GP1BB have been proposed to be overexpressed in leukemia (Chang et 
al., 2011). MLLT4 has been known to be a fusion partner of MLL in leukemic cells (Marschalek, 2011) 
and might be disrupted by the 6q27 microduplication. It has been found that the expression of 
CDC45L and GP1BB was increased and that the expression of MLLT4 was decreased in comparison 
with age and sex matched controls (data not shown). The detected changes in gene expression levels 
might not only be the cause of the leukemia but a consequence of its therapy, as CDC45L plays a role 
in eukaryotic DNA replication (Pacek et al., 2006) presumably modulated by the used 
chemotherapeutic agents (Classen and Riehmer et al., 2013).  
As the cancer predisposition in patient 2, was not explained by the 22q11.21 microduplication, the 
exomes of the patient as well as of her parents were analyzed by WES in order to find causative single 
nucleotide variants. The initial approach was to perform a trio‐based de novo analysis, as suggested 
by recent studies (Vissers et al., 2010; de Ligt et al., 2012). The parents were also analyzed by WES in 
order to subtract the inherited variants from the detected variants in the patient the remaining 
variants are then de novo. This approach identified the CHEK2 variant in patient 2. Next, other 
filtering strategies were applied based on quality measures, deleteriousness predictions, and the use 
of the mining tool Genome TraxTM, utilizing available databases e.g. HGMD inherited disease 
mutations, COSMIC somatic disease mutations as well as PROTEOME and HGMD disease gene 
associations (Classen and Riehmer et al., 2013). This approach identified three variants related to 
cancer. Two mutations in the BLM gene were detected, which have been described as Bloom 
syndrome founder mutations (German et al., 2007). It was found that patient 2 was compound 
heterozygous for two stop mutations in the BLM gene, one of which was inherited from the mother 
and the other from the father (Figure 27, page 94). Bloom syndrome is a rare autosomal recessive 
hereditary disorder associated with most of the symptoms found in patient 2, including short stature, 
mild craniofacial dysmorphia, hypo‐ and hyper pigmented skin lesions and cancer predisposition 
(German et al., 2007). Bloom syndrome patients are diagnosed with cancer at an early age (German, 
1997), which is in concordance with patient 2, who developed her first malignancy at the age of eight 
DISCUSSION 
 
- 109 - 
years and the second at the age of 19 years. However, the severe mental retardation patient 2 
displayed is usually not a symptom of Bloom syndrome. If patients with Bloom syndrome display 
intellectual disability, it is found to be mild. The data presented here suggests that the severe 
intellectual disability in patient 2 is caused by an additive effect of Bloom syndrome and the 22q11.2 
microduplication syndrome, which can both be linked to developmental delay (Ensenauer et al., 2003, 
German et al., 2007). About 50% of Bloom syndrome patients develop cancer; up to 10% develop a 
secondary malignancy, including acute lymphoblastic leukemias and germ cell tumors (German, 1997, 
Bloom Syndrome Gene ReviewsTM). Presumably, the marked organ sensitivity to chemotherapy in 
patient 2 leading to enhanced toxicity of the treatment for both cancers is also linked to Bloom 
syndrome (Mao et al. 2010). Additionally to the two BLM stop mutations, the patient carried a 
heterozygous missense variant in the CHEK2 gene which occurred de novo. This rare missense variant 
has been described as a “HGMD disease mutation” contributing to breast cancer susceptibility (Le 
Calvez‐Kelm et al., 2011). This missense variant results in a mutant protein with essentially no kinase 
activity (Desrichard et al., 2011) and no response to DNA damage in an in vivo assay (Roeb et al., 
2012). Heterozygous germline mutations in the CHEK2 gene have been reported to cause Li‐Fraumeni 
syndrome (Bell at al., 1999) and multi‐organ cancer susceptibility (Cybulski et al., 2004). Taken 
together, it can be proposed that the cancer predisposition in patient 2 is caused by an additive effect 
of the two BLM founder mutations and the pathogenic CHEK2 variant.  
Had we only followed the initial approach to screen only for de novo variants by the so called trio‐
based analysis, the two BLM founder mutations would have been missed. The exome sequencing 
analysis of patient 2 was the first case in our research laboratory. The findings in patient 2 and the 
experiences made during the analysis made us overthink the filtering strategies and develop a 
workflow for analyzing WES data sets (4.5.1). Therefore a trio‐based analysis is now only applied 
secondarily, when the other approaches have yielded no causative variants explaining the phenotype. 
These results show that a trio‐based analysis is not always necessary with the advantage that the 
analysis is less expensive, because only the patient has to be sequenced. 
Taken together, two genome‐wide screening methods were used to unravel the genetic changes 
causing the highly complex phenotype of patient 2. Employing array‐CGH and WES, two inherited 
microduplications as well as two inherited recessive founder mutations (BLM) and one de novo 
missense variant (CHEK2) were identified. Therefore, it can be concluded, that patient 2 is affected by 
Bloom syndrome in combination with the 22q11.2 microduplication syndrome, and the CHEK2 
associated cancer susceptibility syndrome explaining the severe intellectual disability and the cancer 
predisposition in the patient. WES is a useful tool to detect additional genomic causes of inherited 
syndromes even though a microduplication or microdeletion has been diagnosed. This is especially 
important in those complex phenotypes, in which not all clinical symptoms can be explained by the 
detected microduplication or microdeletion, or in cases in which the healthy unaffected parent 
displays the same microimbalance. This case also demonstrates that complex phenotypes may be 
caused by more than one genetic alteration, rather a combination of copy number variants and point 
mutations may be the cause. 
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4.5.1 Adjustment of WES filter strategy based on findings in patient 2 – future strategy 
The big challenge of WES is the handling of the enormous amounts of generated data as well as 
the interpretation of detected variants (1.3.2, page 13). Various approaches and filtering strategies 
have been developed in order to identify the relevant and disease causing variants (Neveling and 
Hoischen, 2012; Bamshad et al., 2011). The findings in patient 2 showed that a trio‐based de novo 
analysis is not always the best approach. Depending on the obtained results, filter strategies have to 
be adapted. Therefore, a workflow was developed which combines different filtering strategies 
(Figure 30, page 111). 
Depending on the platform used, 20.000 to 40.000 variants are found in the exome from 
peripheral blood of one sample. In order to reduce the number of variants and to eliminate false 
positive calls, a first quality filter step was performed, which retains all variants having a coverage of 
at least 20. Coverage is the number of times one specific base position is sequenced. Secondly, all 
variants that do not have any influence on mRNA or protein structure e.g. synonymous variants are 
removed. Therefore, all remaining variants are so called “serious” variants, i.e. they are non‐
synonymous coding, causing a stop codon or a stop codon is lost, frameshift coding mutations, 
essential splice site or INDELs, these are small insertions or deletions. Thirdly, it is usually advisable to 
filter on the basis of deleteriousness prediction for non‐synonymous variants. Prediction programs, 
e.g. SIFT, PolyPhen2, MutationTaster and Condel, can be employed, which predict, based on the 
detected base substitution, if a variant has a major effect on the gene product. Here, decisions on the 
stringency of filtering can be made. Frequently, a variant is retained if at least one prediction program 
calls the variant “probably damaging” or “disease causing”. After removing all the synonymous and 
the “benign” variants, i.e. the variants predicted to have no damage, a combined analysis of two 
different strategies, which we call candidate and database strategy were used in order to further 
reduce the number of variants. The candidate strategy is based on a gene list, that has been prepared 
according to an own literature search and includes genes, which are known to be associated with the 
analyzed disease or phenotype. The database strategy employs mining tools such as Genome TraxTM 
to find disease related genes. The tool enables selecting variants in genes related to certain clinical 
features. The Genome TraxTM filtering tool is based on databases such as HGMD® (Human Gene 
Mutation Database) mutations. After application of the above mentioned filtering steps, the number 
of variants is reduced dramatically. Next, population based filtering is performed. During population 
based filtering, databases such as the ENSEMBL Genome Browser were employed to search for the 
minor allele and genotype frequencies of the given variant. According to the in‐house internal 
standard we have defined, only variants displaying a minor allele frequency and genotype frequency 
smaller than 3% are retained. Minor allele frequencies are used from the population, e.g. Europeans 
or European Americans that the patients belong to. Further, the inheritance model was taken into 
consideration and variants from in‐house exomes were subtracted. The latter is done to exclude 
variants caused by systematic errors and common variants. Usually a manageable number of variants 
remained, which were then verified by Sanger sequencing. If no appropriate variants resulted from 
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the filter strategy a trio‐based sequencing strategy was employed in addition to detect de novo 
variants in the patients.  
 
 
Figure 30: Scheme of filtering strategy used to reduce the number of variants identified by NGS and to 
identify the causative variants. 
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5 Summary 
Since the development of screening methods that can be used on an exome‐ or genome‐wide 
scale such as array‐based comparative genomic hybridization (array‐CGH) and next generation 
sequencing (NGS), these techniques have been employed to analyze large patient and tumor cohorts 
and are also frequently used for diagnostic purposes. In this study, array‐CGH was used to analyze 
DNA from tumors of the central nervous system to identify somatic copy number changes. 
Approximately 300 tumor samples from the German Glioma Network and an intracranial malignant 
peripheral nerve sheath tumor were analyzed using array‐CGH to identify specific patterns of copy 
number alterations in the different tumor entities. Furthermore, array‐CGH and whole exome 
sequencing (WES) were performed on DNA from peripheral blood from a patient presenting with a 
complex phenotype including cancer predisposition to identify causative germline aberrations.  
The first project addressed molecular aberrations in gliomas classified as grade II and grade III by 
the World Health Organization (WHO) including astrocytomas, oligoastrocytomas and 
oligodendrogliomas as well as anaplastic astrocytomas and anaplastic oligoastrocytomas. Tumor 
samples of the different glioma entities were analyzed using array‐CGH, in order to detect common 
genetic imbalances in the gliomas of WHO grade II and III. Together with the German Glioma Network 
the mutation status in the IDH1 (isocitrate‐dehydrogenase 1) and IDH2 genes was determined. Most 
of the WHO grade II and grade III gliomas harbored an IDH1 or IDH2 mutation. It could be shown that 
WHO grade II gliomas displayed DNA copy number changes less frequently than WHO grade III 
gliomas. Interestingly, a small group of IDH1/2 wild‐type WHO grade II astrocytomas were detected 
which displayed glioblastoma‐like genomic imbalances. Patients with an IDH1/2 wild‐type 
astrocytoma of WHO grade II displaying a glioblastoma‐like genomic profile, i.e. gains on 
chromosomes 7, 19 and 20 as well as losses of chromosomes 9 and 10, possibly would benefit from a 
more intensive therapy strategy. Therefore these analyses have future implications. Furthermore, 
frequent deletions of chromosomal arms 1p and 19q were found in oligodendroglial tumors or in 
mixed astrocytic tumors displaying also an oligodendroglial component. Both alterations were 
significantly less frequent in astrocytic tumors.  
The molecular analysis of primary WHO grade IV glioblastomas was subdivided into two parts. As 
the prognosis of primary glioblastoma is still poor, long‐term survival of more than three years after 
diagnosis is rare in these patients. Thus, the first part of the analysis (project 2 of this work) focused 
on tumors from patients who exhibited long‐term survival. Genomic profiles of glioblastomas from 
long‐term survivors were compared to those from short‐term and intermediate‐term survivors. The 
IDH1/2 mutation and the MGMT promoter methylation status were also determined in these tumors. 
This analysis showed that patients with long‐term survival were younger and corresponding tumors 
more often had an IDH1/2 mutation and a MGMT promoter methylation. Genomic imbalances were 
prominently different between IDH1/2 mutant and IDH1/2 wild‐type tumors, but not between 
survival groups of IDH1/2 wild‐type glioblastoma patients, suggesting that long‐term survival is due to 
other, e.g. host‐related factors.  
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The second part of the analysis (project 3 of this work) focused on tumor recurrence of primary 
WHO grade IV glioblastomas. Glioblastomas have a tendency to recur despite combined surgical 
resection, radiotherapy and temozolomide chemotherapy. When the tumor recurs the WHO grade 
remains the same, therefore, the recurrent tumor is treated similar to the primary tumor. Genomic 
profiles of 27 primary and recurrent IDH1/2 wild‐type glioblastoma from the same patient were 
compared to determine genetic patterns of glioblastoma progression. After comparing the array‐CGH 
profiles of the primary and recurrent tumors, taking the tumor cell content into account, a difference 
profile for each tumor pair was generated. Subsequently, three molecular relapse groups were 
defined (Equal, Sequential and Discrepant). Seven of the 27 (26%) tumor pairs were identified to be 
Equal pairs, showing no DNA copy number differences between primary and recurrent tumor, 
suggesting a monoclonal cell composition of both tumors. In nine of 27 (33%) tumor pairs, the same 
and additional chromosomal imbalances were found in the recurrent tumor as compared to the 
primary tumor (Sequential pairs). These findings suggest a sequential acquisition or selection for 
aberrations during tumor progression. In eleven of 27 (41%) pairs, the difference profiles of primary 
and recurrent tumors were divergent, i.e. the recurrent tumors contained additional chromosomal 
aberrations but had also lost others (Discrepant pairs). These findings suggest a polyclonal 
composition of the primary tumors and considerable clonal evolution. Interestingly, losses on 
chromosomal band 9p21.3, harboring the CDKN2A/B locus, were significantly more common in 
primary tumors of the Sequential and Discrepant tumor pairs, also called non‐Equal pairs. Analyzing 
regions of chromosomal differences between primary and recurrent tumors 46 candidate genes 
associated with tumor recurrence were identified. Frequently, the identified genes for apoptosis 
regulators, possibly explaining why these cells escape therapy induced apoptosis. Taken together 
about 75% of IDH1/2 wild‐type recurrent glioblastomas acquire additional genomic alterations during 
progression. This process is possibly facilitated by the loss of genetic material from chromosomal 
band 9p21.3 in the primary glioblastomas. These tumor recurrence‐associated chromosomal changes 
may contribute to therapy resistance, e.g. by copy number alterations of apoptosis regulatory genes. 
The analysis of the genomic differences between primary and recurrent glioblastomas may identify 
newly acquired genetic properties targetable by salvage therapies for a more effective treatment of 
patients with recurrent glioblastoma.  
In the fourth project of this work, two intracranial tumor samples from a 47‐year old female 
patient were retrospectively analyzed using array‐CGH in order to determine their clonal relationship. 
The histological diagnosis of the first tumor was an unusual pituitary adenoma, but the second tumor 
that had developed 3 months later was diagnosed as a rare malignant peripheral nerve sheath tumor. 
Though the two tumor samples were different in their histopathology, the question arose if the first 
and the second tumor contained the same copy number changes and thus most likely developed 
from the same origin. Array‐CGH of the first tumor revealed a complex pattern of chromosomal 
imbalances affecting all chromosomes but one (chromosome 16). Array‐CGH of the second tumor 
revealed a similarly complex profile. About 80% of the 29 copy number changes detected in the 
second tumor were already present in the first tumor. These findings provide strong evidence for a 
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clonal relationship between the two tumor samples and suggest that the second tumor was a 
recurrent tumor of the first lesion. It also could be shown that the genomic profiles of both tumors 
were highly similar to those of already published MPNST cases, indicating that the analyzed tumor 
indeed is a MPNST. Taken together, it could be shown that array‐CGH can be successfully used to 
identify the clonal relationship between two histologically distinct tumors. 
The fifth project of this work aimed at identifying the germline aberrations underlying a complex 
phenotype including cancer predisposition. Symptoms of the patient included cognitive impairment, 
two neoplastic diseases (a both‐sided mixed malignant germ cell tumor of the ovaries and an acute 
pre‐B‐lymphoblastic leukemia) prior to the age of 20 years, anomalies of skin pigmentation and short 
stature. Using array‐CGH on DNA from peripheral blood from the patient and her mother, two 
maternally inherited microduplications in the chromosomal bands 6q27 and 22q11.21 were detected. 
The microduplication with the size of 0.26 Mb in 6q27 encompassed parts of the MLLT4 gene, a 
known fusion partner of MLL in leukemic cells. The microduplication in chromosomal band 22q11.21 
had a size of 2.5 Mb, harboring approximately 50 genes. This region has been reported to be 
susceptible to chromosomal rearrangements and to cause the 22q11.21 microduplication syndrome 
when duplicated and is associated with a high variability, explaining in part the patient’s intellectual 
disability but not its severity. Particularly the two malignancies of the patient were not explained by 
the detected microduplications. Therefore, DNA from peripheral blood from the patient as well as 
from her patents was screened by WES in order to find further causative germline aberrations. A trio‐
based de novo analysis, subtracting the parental variants from variants detected in the patient, 
revealed a de novo CHEK2 variant (CHEK2,c.1427C>T;p.Thr476Met). This rare missense variant is a 
“HGMD disease mutation” contributing to breast cancer susceptibility. Using a different filter strategy 
for the WES data set of the patient, two known BLM founder mutations (BLM,c.1642C>T;p.Gln548X; 
BLM,c.2695C>T;p.Arg899X) were also detected. Sanger sequencing revealed that the patient was 
compound heterozygous for these two stop mutations in the BLM gene, i.e. that one of the mutations 
was inherited from the mother and the other from the father. Bloom syndrome, caused by mutations 
in the BLM gene is a rare autosomal recessive disorder associated with most of the symptoms found 
in the patient, including short stature, mild craniofacial dysmorphia, hypo‐ and hyper‐pigmented skin 
lesions and cancer predisposition. Taken together, two genome‐wide screening methods have been 
used to unravel the highly complex phenotype of the patient. Employing array‐CGH and WES, two 
inherited microduplications as well as two inherited recessive founder mutations (BLM) and one de 
novo missense variant (CHEK2) were identified. The combination of Bloom syndrome with the 
22q11.2 microduplication syndrome and the CHEK2 associated multi‐cancer susceptibility syndrome, 
are presumed to cause the severe intellectual disability, and explain the cancer predisposition in the 
patient. This case demonstrated that complex phenotypes may be caused by more than one genetic 
alteration, rather a combination of copy number variants and point mutations may be the cause. 
In summary, array‐CGH was used to detect somatic tumor aberrations in WHO grade II to WHO 
grade IV glioma entities as well as a case of a MPNST. Further, employing two genome‐wide screening 
methods, array‐CGH and WES, the complex genotype of a patient with syndromic cancer 
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predisposition was unraveled, indicating that complex phenotypes may be caused by a number of 
different genetic alterations.  
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6 Deutsche Zusammenfassung 
Die Entwicklung von genomweiten Analyseverfahren, wie die Array‐basierte komparative 
genomische Hybridisierung (Array‐CGH) und die Sequenzierung humaner Exome oder Genome 
mittels next generation sequencing, hat in den letzten Jahren dazu geführt, dass große Patienten‐ und 
Tumorkollektive in immer kürzerer Zeit exom‐ oder genomweit analysiert werden konnten. Diese 
Methoden finden mittlerweile auch für diagnostische Zwecke ein großes Anwendungsspektrum. In 
dieser Arbeit wurden beide Methoden verwendet, um sowohl somatische Kopienzahlveränderungen 
in unterschiedlichen Tumoren des Zentralnervensystems, wie auch Veränderungen in der Keimbahn 
einer Patientin mit einer Krebsdisposition zu untersuchen. Dabei wurden annähernd 300 
Tumorproben unterschiedlicher Gliomentitäten im Rahmen des Deutschen Gliomnetzwerkes mittels 
Array‐CGH auf somatische DNA‐Kopienzahlveränderungen hin untersucht. Zu den untersuchten 
Tumoren des Zentralnervensystems gehörten nach der World Health Organization (WHO) 
Klassifizierten Grad II bis Grad IV Gliome, sowie ein Fall eines malignen peripheren 
Nervenscheidentumors. Eine Kombination aus Array‐CGH und Exomsequenzierung wurde in einem 
weiteren Projekt verwendet, um ursachliche Keimbahnveränderungen an DNA aus peripherem Blut 
bei einer Patientin mit einem komplexen Phänotyp einschließlich Krebsdisposition zu identifizieren.  
Im ersten Projekt dieser Arbeit war es das Ziel, die DNA‐Kopienzahlveränderungen von WHO   
Grad II Astrozytomen, Oligoastrozytomen und Oligodendrogliomen sowie die 
Kopienzahlveränderungen von WHO Grad III anaplastischen Astrozytomen und anaplastischen 
Oligoastrozytomen mittels Array‐CGH zu identifizieren, und genomische Profile für die 
unterschiedlichen Tumorentitäten zu erstellen. Weiterhin wurden im Rahmen des Gliomnetzwerkes 
Mutationsanalysen im IDH1 (Isocitrat‐Dehydrogenase 1) und IDH2 Gen durchgeführt. Die meisten 
WHO Grad II und III Gliome zeigten eine Mutation im IDH1 oder IDH2 Gen. Bei den WHO Grad II 
Gliomen waren weniger Kopienzahlveränderungen nachweisbar, als bei den WHO Grad III Gliomen. 
Dennoch gab es eine kleine Gruppe von IDH1/2‐Wildtyp WHO Grad II Astrozytomen, die Glioblastom‐
typische Kopienzahlveränderungen aufwiesen. Die Patienten mit den IDH1/2‐Wildtyp WHO Grad II 
Astrozytomen mit einem Glioblastom‐typischen Array‐CGH Profil, d.h. Gewinne auf den 
Chromosomen 7, 19 und 20 sowie Verlust auf den Chromosomen 9 und 10, würden möglicherweise 
von einer intensiveren Therapie profitieren. Insofern haben die Untersuchungen prospektiv eine 
translationale Bedeutung. Darüber hinaus wurde in oligodendroglialen Tumoren oder 
oligodendroglialen‐astrozytären Mischtumoren häufig einen Verlust der Chromosomenarme 1p und 
19q gefunden. Beide Veränderungen waren in astrozytären Tumoren deutlich seltener.  
Die molekularen Analysen von primären WHO Grad IV Glioblastomen wurden in zwei weitere 
Projekte unterteilt. Der Schwerpunkt des ersten dieser Projekte (Projekt 2 dieser Arbeit) lag in der 
Analyse von WHO Grad IV Glioblastomen von Langzeit‐Überlebern, da die Ursachen für das Langzeit‐
Überleben von der molekularen Seite noch schlecht charakterisiert sind. Unter Langzeit‐Überlebern 
versteht man Patienten, die nach Diagnose länger als drei Jahre überlebt haben. Um spezifische 
genomweite Veränderungen zu identifizieren, die essentiell für das Langzeit‐Überleben sind, wurden 
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genomweite Profile von primären Glioblastomen von Patienten mit kurzem, intermediärem oder 
langem Überleben erstellt und verglichen. Diese Analysen zeigten, dass Langzeit‐Überleber meistens 
jünger als andere Patienten beim Zeitpunkt der Diagnose waren und dass die entsprechenden 
Tumoren oftmals eine IDH1/2 Mutation, sowie eine Methylierung des MGMT Promotors aufwiesen. 
Zwischen Tumoren mit einer IDH1/2 Mutation und Tumoren mit IDH1/2‐Wildtypstatus konnte ein 
klarer Unterschied in den genomischen Profilen entdeckt werden, nicht aber in den Profilen zwischen 
den einzelnen Überlebensgruppen. Das lässt darauf schließen, dass das Langzeit‐Überleben 
vermutlich auf andere, wie z.B. Patienten‐spezifische Faktoren, zurückzuführen ist.  
Im Zweiten Teil der molekularen Analysen von primären WHO Grad IV Glioblastomen (Projekt 3 
dieser Arbeit) stand die Rezidivbildung und deren molekulare Charakterisierung im Vordergrund. 
Glioblastome haben die Tendenz lokal zu rezidivieren, auch nach intensiver und kombinierter 
Behandlung durch operative Maßnahmen, Strahlen‐ und Chemotherapien. In der Regel wird der 
Rezidivtumor ähnlich wie der Primärtumor behandelt. In dieser Studie wurden genomische 
Imbalancen von 27 primären Glioblastomen mit einem IDH1/2‐Wildtypstatus und von den 
dazugehörigen Rezidivtumoren derselben Patienten untersucht. Beim Vergleich der genomischen 
Profile von Primär‐ und Rezidivtumor wurde der unterschiedliche Tumorzellanteil angeglichen und ein 
Differenzprofil für jedes Tumorpaar erstellt. Aufgrund der verschiedenen Differenzprofile wurden drei 
verschiedene Gruppen („Equal“, „Sequential“ und „Discrepant“) identifiziert. Sieben der 27 (26%) 
Tumorpaare wurden als „Equal“‐Tumore bezeichnet, das heißt, dass keine DNA‐
Kopienzahlunterschiede zwischen Primär‐ und Rezidivtumor vorlagen. Das lässt vermuten, dass 
sowohl der Primär‐ als auch der Rezidivtumor eine monoklonale Zellkomposition aufwiesen. Bei neun 
der 27 (33%) Tumorpaare wiesen die Rezidivtumore gleiche Kopienzahlveränderungen sowie neu 
dazugewonnene chromosomale Veränderungen gegenüber dem Primärtumor auf („Sequential“). 
Dieses Ergebnis legt nahe, dass es eine sequentielle Akquisition oder eine Selektion für gewisse 
chromosomale Veränderungen während der Tumorprogression gibt. Elf der 27 (41%) Tumorpaare 
zeigten ein Differenzprofil mit vielen Unterschieden zwischen Primär‐ und Rezidivtumor 
(„Discrepant“). Zum einen zeigte der Rezidivtumor zusätzliche DNA‐Kopienzahlveränderungen, zum 
anderen konnten einige Veränderungen, die im Primärtumor vorhanden waren, im Rezidiv nicht mehr 
detektiert werden. Das lässt vermuten, dass der Primärtumor eine polyklonale Zellkomposition 
aufwies und dass eine ausgeprägte klonale Weiterentwicklung stattgefunden hat. Interessanterweise 
waren die Verluste in der chromosomalen Bande 9p21.3, die das CDKN2A/B Gen beinhaltet, in den 
Primärtumoren von „Sequential“‐ und „Discrepant“‐Paaren stärker ausgeprägt. In den 
chromosomalen Regionen, die unterschiedliche Kopien Zahlen in Primär‐ und Rezidivtumor 
aufwiesen, waren 46 Kandidatengene lokalisiert, die aufgrund der Literaturlage mit der 
Rezidivbildung assoziiert sein könnten. Dabei zeigten sich häufig Kopienzahlunterschiede in 
Apoptoseregulatoren, was erklären könnte, warum diese Tumorzellen der therapieinduzierten 
Apoptose entgehen. Insgesamt konnte gezeigt werden, dass 75% der IDH1/2‐Wildtyp 
Rezidivglioblastome während der Tumorprogression zusätzliche DNA‐Kopienzahlveränderungen 
erwerben. Dieser Prozess könnte mit dem Verlust von genetischem Material aus 9p21.3 
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zusammenhängen. Die hier beschriebenen genomischen Unterschiede zwischen Primär‐ und 
Rezidivtumoren könnten neue Ansatzpunkte für alternative Therapiestrategien in Patienten mit 
einem rezidivierenden Glioblastom bieten.  
Im vierten Projekt wurden zwei histologisch unterschiedliche Tumorproben einer 47‐jährigen 
Patientin mittels Array‐CGH hinsichtlich des klonalen Ursprungs untersucht. Ursprünglich wurde bei 
der Patientin ein benigner Hypophysentumor diagnostiziert, nach kürzester Zeit wurde jedoch ein 
Rezidiv entdeckt, das histologisch eher einem malignen peripheren Nervenscheidentumor glich. Es 
wurde eine Array‐CGH an den DNAs aus beiden Tumorproben durchgeführt. Dabei zeigte sich im 
ersten Tumor ein genomisches Profil, in dem fast alle Chromosomen, außer Chromosom 16, DNA‐
Kopienzahlveränderungen aufwiesen. Das genomische Profil des zweiten Tumors zeigte ähnliche 
Kopienzahlveränderungen, ungefähr 80% der insgesamt 29 im ersten Tumor detektierten 
Veränderungen konnten auch im zweiten Tumor identifiziert werden. Dieses Ergebnis legt nahe, dass 
es einen klonalen Zusammenhang zwischen dem ersten und dem zweiten Tumor gibt, und lässt 
vermuten, dass der zweite Tumor ein Rezidiv des ersten ist. Außerdem konnte festgestellt werden, 
dass nicht nur das Rezidiv sondern auch der zuerst diagnostizierte Tumor chromosomale 
Veränderungen aufwies, die typisch für einen malignen peripheren Nervenscheidentumor sind. 
Daraus lässt sich schließen, dass Array‐CGH eine geeignete Methode ist, um den Ursprung von 
Tumoren zu klären, besonders wenn diese histologisch enorme Unterschiede aufweisen.  
In einem fünften Projekt wurde die Keimbahn einer Patientin mit einem komplexen Phänotyp 
einschließlich einer Krebsdisposition, auf genetische Ursachen hin untersucht. Zu den 
Hauptsymptomen gehörte eine mentale Retardierung, zwei Tumor‐Erkrankungen (ein 
Ovarialkarzinom und eine akute B‐Lymphoblastäre Leukämie) vor dem 20. Lebensjahr, 
Pigmentierungsstörungen der Haut und ein Kleinwuchs. Es wurde zunächst vermutet, dass dieser 
schwere Phänotyp auf ein Mikroduplikations‐ oder Mikrodeletionssyndrom zurückzuführen ist, da 
diese oft mehrere Gene betreffen und so die unterschiedlichen Merkmale des Phänotyps erklären 
könnten. Um den komplexen Phänotyp zu erklären, wurde an der aus peripherem Blut isolierten DNA 
der Patientin und ihrer Eltern zunächst eine Array‐CGH‐Analyse durchgeführt. Mittels Array‐CGH 
wurden zwei Mikroduplikationen in den chromosomalen Banden 6q27 und 22q11.21 identifiziert, die 
beide von der Mutter ererbt waren. Die Mikroduplikation in der chromosomalen Bande 6q27 hatte 
eine Größe von 0,26 Mb und betraf einen Teil des MLLT4 Gens, das bereits als Fusionspartner von 
MLL in Leukämiezellen beschrieben wurde. Die Mikroduplikation in der chromosomalen Bande 
22q11.21 hatte eine Größe von 2.5 Mb und umfasste ungefähr 50 Gene. Diese chromosomale Region 
ist anfällig für chromosomale Umbauten und liegt dem 22q11.21 Mikroduplikationssyndrom 
zugrunde, das durch eine hohe Variabilität ausgezeichnet ist (z.B. Ausprägung der kognitiven Defizite). 
Diese Mikroduplikation erklärt zum Teil die mentale Retardierung der Patientin, aber nicht deren 
starke Ausprägung. Da die beiden Tumorerkrankungen der Patientin durch die beiden identifizierten 
Mikroduplikationen nicht wirklich erklärbar waren, wurde zusätzlich eine Exomsequenzierung 
durchgeführt. Mittels dieser wurde entdeckt, dass die Patientin Compoundheterozygot für zwei Stop‐
Mutationen im BLM‐Gen war. Mutationen in diesem Gen verursachen das autosomal‐rezessiv 
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erbliche Bloom Syndrom, welches u.a. zu Krebsdisposition, Hautanomalien und Kleinwuchs führt. 
Außerdem wurde eine de novo CHEK2‐Variante entdeckt, die mit Krebsdisposition einhergeht. 
Zusammengefasst erklären die hier beschriebenen genomischen Veränderungen den komplexen 
Phänotyp der Patientin.  
Zusammenfassend konnte in dieser Arbeit gezeigt werden, dass sich die beiden Methoden Array‐
CGH und Exomsequenzierung hervorragend dazu eignen, sowohl genomweite somatische 
Kopienzahlveränderungen in unterschiedlichen Tumoren des Zentralnervensystems zu identifizieren, 
als auch Keimbahnveränderungen bei Patienten mit Krebsdisposition durch exomweite Analysen 
aufzudecken.  
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